Processing 00000000.tx.1: Diabetes and Insulin Secretion The ATP-Sensitive K+ Channel (KATP) Connection Joseph C. 

Phrase: "Diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "and"

Phrase: "Insulin Secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "The ATP-Sensitive K+ Channel"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0332324:Sensitive [Functional Concept]
   812   C0439799:Channel [Spatial Concept]
   812   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   812   C1550474:sensitive [Idea or Concept]
   812   C1706095:Channel [Conceptual Entity]
   812   C1708601:K' [Quantitative Concept]

Phrase: "(KATP"

Phrase: ")"

Phrase: "Connection Joseph C."
Processing 00000000.tx.2: Koster, M. 

Phrase: "Koster,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.3: Alan Permutt, and Colin G. 

Phrase: "Alan Permutt,"

Phrase: "and"

Phrase: "Colin G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.4: Nichols Department of Cell Biology and Physiology, Washington University School of Medicine, St. 

Phrase: "Nichols Department of Cell Biology"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1704729:Department [Organization]

Phrase: "and"

Phrase: "Physiology,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0031842:Physiology [Biomedical Occupation or Discipline]
  1000   C0031843:physiology [Physiologic Function]
   928 E C0205463:Physiologic [Functional Concept]

Phrase: "Washington University School of Medicine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0036375:School [Manufactured Object,Organization]

Phrase: "St."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3272372:ST [Intellectual Product]
Processing 00000000.tx.5: Louis, Missouri Address correspondence and reprint requests to Joseph C. 

Phrase: "Louis,"

Phrase: "Missouri Address correspondence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0282413:Correspondence [Intellectual Product]

Phrase: "and"

Phrase: "reprint"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3273171:Reprint [Intellectual Product]

Phrase: "requests to Joseph C."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0686900:request [Functional Concept]
   770   C1272683:Request [Functional Concept]
   770   C1522634:Request [Intellectual Product]
Processing 00000000.tx.6: Koster PhD, Department of Cell Biology and Physiology, Washington University School of Medicine, St. 

Phrase: "Koster PhD,"

Phrase: "Department of Cell Biology"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1704729:Department [Organization]

Phrase: "and"

Phrase: "Physiology,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0031842:Physiology [Biomedical Occupation or Discipline]
  1000   C0031843:physiology [Physiologic Function]
   928 E C0205463:Physiologic [Functional Concept]

Phrase: "Washington University School of Medicine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0036375:School [Manufactured Object,Organization]

Phrase: "St."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3272372:ST [Intellectual Product]
Processing 00000000.tx.7: Louis, MO 63110. 

Phrase: "Louis,"

Phrase: "MO 63110."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538743:MO [Idea or Concept]
Processing 00000000.tx.8: E-mail: jkoster{at}cellbio.wustl.edu CHI, congenital hyperinsulinism; 

Phrase: "E-mail"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]
   861   C0024492:Mail [Manufactured Object]
   861   C1538057:MAIL [Gene or Genome]
   861   C1547565:Mail [Idea or Concept]

Phrase: ":"

Phrase: "jkoster{at}cellbio.wustl.edu"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0059804:EDU [Organic Chemical,Pharmacologic Substance]

Phrase: "CHI,"

Phrase: "congenital hyperinsulinism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2931834:Congenital Hyperinsulinism [Disease or Syndrome]
   861   C0020459:Hyperinsulinism [Disease or Syndrome]

Phrase: ";"
Processing 00000000.tx.9: FOXP3, forkhead box P3; 

Phrase: "FOXP3,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1416467:FORKHEAD BOX P3 [Gene or Genome]
   827   C1412751:P3 [Gene or Genome]
   827   C1427831:P3 [Gene or Genome]
   827   C1539372:p3 [Gene or Genome]
   734   C3273493:Fork Head Box [Amino Acid Sequence]

Phrase: "forkhead box P3"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1416467:FORKHEAD BOX P3 [Gene or Genome]
   827   C1412751:P3 [Gene or Genome]
   827   C1427831:P3 [Gene or Genome]
   827   C1539372:p3 [Gene or Genome]
   734   C3273493:Fork Head Box [Amino Acid Sequence]

Phrase: ";"
Processing 00000000.tx.10: GSIS, glucose-stimulated insulin secretion; 

Phrase: "GSIS,"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "glucose-stimulated insulin secretion"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.11: IPF-1, insulin promoter factor 1; 

Phrase: "IPF-1,"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
  1000   C0248419:insulin promoter factor 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1826562:INSULIN PROMOTER FACTOR 1 [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   812   C1521761:Factor [Functional Concept]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C2827422:Factor [Conceptual Entity]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "insulin promoter factor 1"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
  1000   C0248419:insulin promoter factor 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1826562:INSULIN PROMOTER FACTOR 1 [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   812   C1521761:Factor [Functional Concept]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C2827422:Factor [Conceptual Entity]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.12: KATP channel, ATP-sensitive K+ channel; 

Phrase: "KATP channel,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439799:Channel [Spatial Concept]
   861   C1706095:Channel [Conceptual Entity]

Phrase: "ATP-sensitive K+ channel"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0332324:Sensitive [Functional Concept]
   812   C0439799:Channel [Spatial Concept]
   812   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   812   C1550474:sensitive [Idea or Concept]
   812   C1706095:Channel [Conceptual Entity]
   812   C1708601:K' [Quantitative Concept]

Phrase: ";"
Processing 00000000.tx.13: PIP2, phosphatidylinositol-4,5-bisphosphate; 

Phrase: "PIP2,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0070798:PIP2 [Biologically Active Substance,Lipid,Organophosphorus Compound]
  1000   C3538724:PIP2 [Body Part, Organ, or Organ Component]

Phrase: "phosphatidylinositol-4,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0031621:Phosphatidyl Inositol [Biologically Active Substance,Lipid]
   861   C2348046:Phosphatidylinositol [Lipid]

Phrase: "5-bisphosphate"

Phrase: ";"
Processing 00000000.tx.14: SUR1, sulfonylurea receptor-1  ABSTRACT TOP ABSTRACT Part 1: -cell KATP... 

Phrase: "SUR1,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   827   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   827   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   827   C3536898:Sulfonylurea [Pharmacologic Substance]

Phrase: "sulfonylurea receptor-1  ABSTRACT TOP ABSTRACT Part 1"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   812   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   793   C0000857:Abstract [Occupational Activity]
   793   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   793   C0449719:Part [Spatial Concept]
   793   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   793   C0600678:Abstract [Intellectual Product]
   793   C1552863:Abstract [Idea or Concept]
   793   C1704458:Top [Spatial Concept]
   793   C1709471:Part [Quantitative Concept]
   793   C3536898:Sulfonylurea [Pharmacologic Substance]

Phrase: ": -"

Phrase: "cell KATP..."
Processing 00000000.tx.15: Part 2: KATP channel-dependent... 

Phrase: "Part 2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0449719:Part [Spatial Concept]
   861   C1709471:Part [Quantitative Concept]

Phrase: ":"

Phrase: "KATP channel-dependent..."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0851827:Dependent [Qualitative Concept]
   827   C1701901:Dependent [Qualitative Concept]
   827   C3244310:dependent [Functional Concept]
Processing 00000000.tx.16: REFERENCES  The ATP-sensitive K+ channel (KATP channel) senses metabolic changes in the pancreatic -cell, thereby coupling metabolism to electrical activity and ultimately to insulin secretion. 

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "The ATP-sensitive K+ channel"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0332324:Sensitive [Functional Concept]
   812   C0439799:Channel [Spatial Concept]
   812   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   812   C1550474:sensitive [Idea or Concept]
   812   C1706095:Channel [Conceptual Entity]
   812   C1708601:K' [Quantitative Concept]

Phrase: "(KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439799:Channel [Spatial Concept]
   861   C1706095:Channel [Conceptual Entity]

Phrase: ")"

Phrase: "senses"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0036658:sense [Organ or Tissue Function]

Phrase: "metabolic changes in the pancreatic -cell,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   753   C0392747:changes [Functional Concept]
   753   C0443172:changes [Quantitative Concept]
   719 E C1705241:Change [Quantitative Concept]

Phrase: "thereby"

Phrase: "coupling"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1948027:Coupling [Functional Concept]
   966 E C0010222:couple [Family Group]

Phrase: "metabolism to electrical activity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0025519:Metabolism [Organism Function]
   770   C0025520:metabolism [Functional Concept]

Phrase: "and"

Phrase: "ultimately to insulin secretion."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   833   C1256369:insulin secretion [Cell Function]
   770   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C0036536:secretion [Biologic Function]
   770   C0036537:Secretion [Body Substance]
   770   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1579433:Insulin [Pharmacologic Substance]
   715 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
Processing 00000000.tx.17: When KATP channels open, -cells hyperpolarize and insulin secretion is suppressed. 

Phrase: "When"

Phrase: "KATP channels"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   827   C0439799:Channel [Spatial Concept]
   827   C1706095:Channel [Conceptual Entity]

Phrase: "open"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0175566:Open [Spatial Concept]

Phrase: ", -"

Phrase: "cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "hyperpolarize"

Phrase: "and"

Phrase: "insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "is"

Phrase: "suppressed."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260953:Suppressed [Functional Concept]
Processing 00000000.tx.18: The prediction that KATP channel "overactivity" should cause a diabetic state due to undersecretion of insulin has been dramatically borne out by recent genetic studies implicating "activating" mutations in the Kir6.2 subunit of KATP channel as causal in human diabetes. 

Phrase: "The prediction"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0681842:Prediction [Idea or Concept]

Phrase: "that KATP channel ""overactivity"""
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0474395:overactivity [Finding]
   827   C1536696:Overactivity [Finding]
   755 E C0443272:Overactive [Qualitative Concept]

Phrase: "should"

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "a diabetic state due to undersecretion of insulin"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   767   C0421248:diabetic insulin [Finding]
   744   C0241863:DIABETIC [Finding]
   744   C1301808:State [Geographic Area]
   744   C1442792:State [Functional Concept]
   744   C3148680:State [Geographic Area]

Phrase: "has"

Phrase: "been"

Phrase: "dramatically"

Phrase: "borne"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0004897:Bear [Mammal]

Phrase: "out by recent genetic studies"
Meta Candidates (Total=16; Excluded=9; Pruned=0; Remaining=7)
   790   C2827447:Genetic Study [Research Activity]
   760   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   760   C0314603:Genetic [Functional Concept]
   760   C0332185:Recent [Temporal Concept]
   760   C0439787:Out [Spatial Concept]
   760   C0849355:Out [Qualitative Concept]
   760   C0947630:studies [Laboratory Procedure]
   726 E C0557651:Study [Manufactured Object]
   726 E C2603343:Study [Research Activity]
   704 E C0005615:Birth [Organism Function]
   704 E C0035150:Reproduction [Organism Function]
   704 E C0079946:origin [Classification]
   704 E C0439659:Origin [Temporal Concept]
   704 E C1550512:origin [Intellectual Product]
   704 E C1550722:birth [Idea or Concept]
   704 E C3245487:birth [Intellectual Product]

Phrase: "implicating"

Phrase: """"

Phrase: "activating"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1879547:activating [Activity]
   966 E C1515877:Activate [Functional Concept]

Phrase: """ mutations in the Kir6.2 subunit of KATP channel"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   742   C0026882:Mutations [Genetic Function]
   708 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "as causal"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   928   C0015127:causality [Functional Concept]
   928   C1314792:Causalities [Functional Concept]

Phrase: "in human diabetes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.19: This article summarizes the emerging picture of KATP channel as a major cause of neonatal diabetes and of a polymorphism in KATP channel (E23K) as a type 2 diabetes risk factor. 

Phrase: "This article"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1706852:Article [Intellectual Product]

Phrase: "summarizes"

Phrase: "the emerging picture of KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0441468:picture [Manufactured Object]
   753   C0441469:Picture [Manufactured Object]

Phrase: "as a major cause"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0015127:cause [Functional Concept]
   861   C0205164:Major [Qualitative Concept]
   861   C1524003:Cause [Conceptual Entity]

Phrase: "of neonatal diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0158981:Neonatal diabetes [Disease or Syndrome]
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "and of a polymorphism"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0032529:Polymorphism [Genetic Function]
   770   C1515981:And [Idea or Concept]
   770   C1882417:Polymorphism [Qualitative Concept]

Phrase: "in KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439799:Channel [Spatial Concept]
   861   C1706095:Channel [Conceptual Entity]

Phrase: "(E23K"

Phrase: ")"

Phrase: "as a type 2 diabetes risk factor."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   840   C0035648:Risk factor [Quantitative Concept]
   840   C1171304:diabetes risk [Quantitative Concept]
   804   C0035647:Risk [Qualitative Concept]
   804   C1521761:Factor [Functional Concept]
   804   C2827422:Factor [Conceptual Entity]
   717   C0011860:Type 2 Diabetes [Disease or Syndrome]
Processing 00000000.tx.20: The degree of KATP channel "overactivity" correlates with the severity of the diabetic phenotype. 

Phrase: "The degree of KATP channel ""overactivity"" correlates"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0441889:Degree [Qualitative Concept]
   748   C0449286:Degree [Quantitative Concept]
   748   C0542560:Degree [Intellectual Product]
   748   C1561545:degree [Quantitative Concept]
   748   C2348088:Degree [Quantitative Concept]

Phrase: "with the severity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0439793:Severity [Qualitative Concept]
  1000   C2983285:Severity [Intellectual Product]
   928 E C0205082:Severe [Qualitative Concept]

Phrase: "of the diabetic phenotype."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0031437:Phenotype [Organism Attribute]
   861   C1285572:Phenotype [Laboratory Procedure]
Processing 00000000.tx.21: At one end of the spectrum, polymorphisms that result in a modest increase in KATP channel activity represent a risk factor for development of late-onset diabetes. 

Phrase: "At one end"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0444930:End [Spatial Concept]
   861   C2746065:End [Temporal Concept]
   805 E C0205088:Terminal [Temporal Concept]
   805 E C1705314:Terminal [Manufactured Object]
   805 E C1705315:Terminal [Spatial Concept]

Phrase: "of the spectrum,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1883073:Spectrum [Quantitative Concept]
  1000   C2827424:Spectrum [Conceptual Entity]

Phrase: "polymorphisms"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0032529:polymorphisms [Genetic Function]
   966 E C1882417:Polymorphism [Qualitative Concept]

Phrase: "that"

Phrase: "result in a modest increase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0442805:Increase [Functional Concept]
   760   C1274040:Result [Functional Concept]
   760   C1546471:Result [Idea or Concept]
   760   C2825142:Result [Finding]

Phrase: "in KATP channel activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C1153410:channel activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: "represent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "a risk factor for development of late-onset diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   764   C0035648:Risk factor [Quantitative Concept]
   762   C0050325:A-factor [Biologically Active Substance,Organic Chemical]
   762   C0960756:factor A [Organic Chemical]
   762   C1171304:diabetes risk [Quantitative Concept]
   742   C0035647:Risk [Qualitative Concept]
   742   C1521761:Factor [Functional Concept]
   742   C2827422:Factor [Conceptual Entity]
Processing 00000000.tx.22: At the other end, severe "activating" mutations underlie syndromic neonatal diabetes, with multiple organ involvement and complete failure of glucose-dependent insulin secretion, reflecting KATP channel "overactivity" in both pancreatic and extrapancreatic tissues. 

Phrase: "At the"

Phrase: "other end,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0444930:End [Spatial Concept]
  1000   C2746065:End [Temporal Concept]
   944 E C0205088:Terminal [Temporal Concept]
   944 E C1705314:Terminal [Manufactured Object]
   944 E C1705315:Terminal [Spatial Concept]

Phrase: "severe """
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205082:Severe [Qualitative Concept]

Phrase: "activating"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1879547:activating [Activity]
   966 E C1515877:Activate [Functional Concept]

Phrase: """ mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "underlie"

Phrase: "syndromic neonatal diabetes,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0158981:Neonatal diabetes [Disease or Syndrome]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]

Phrase: "with multiple organ involvement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1314939:Involvement [Functional Concept]

Phrase: "and"

Phrase: "complete failure of glucose-dependent insulin secretion,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0231174:Failure [Functional Concept]
   748   C0680095:failure [Individual Behavior]

Phrase: "reflecting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0558058:Reflecting [Mental Process]

Phrase: "KATP channel ""overactivity"""
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0474395:overactivity [Finding]
   827   C1536696:Overactivity [Finding]
   755 E C0443272:Overactive [Qualitative Concept]

Phrase: "in both pancreatic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030274:Pancreatic [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "extrapancreatic tissues."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0040300:Tissues [Tissue]
   827 E C1547928:Tissue [Intellectual Product]
Processing 00000000.tx.23: In the pancreatic -cell, the ATP-sensitive K+ channel (KATP channel) plays an essential role in coupling membrane excitability with glucose-stimulated insulin secretion (GSIS) (1). 

Phrase: "In the pancreatic -cell,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0007634:Cell [Cell]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]

Phrase: "the ATP-sensitive K+ channel"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0332324:Sensitive [Functional Concept]
   812   C0439799:Channel [Spatial Concept]
   812   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   812   C1550474:sensitive [Idea or Concept]
   812   C1706095:Channel [Conceptual Entity]
   812   C1708601:K' [Quantitative Concept]

Phrase: "(KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439799:Channel [Spatial Concept]
   861   C1706095:Channel [Conceptual Entity]

Phrase: ")"

Phrase: "plays"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:Plays [Finding]

Phrase: "an essential role in coupling membrane excitability"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0035820:Role [Social Behavior]
   748   C1705810:Role [Conceptual Entity]

Phrase: "with glucose-stimulated insulin secretion (GSIS)"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ")."
Processing 00000000.tx.24: An increase in glucose metabolism leads to elevated intracellular [ATP]/[ADP] ratio, closure of KATP channels, and membrane depolarization. 

Phrase: "An increase in glucose metabolism"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0442805:Increase [Functional Concept]

Phrase: "leads to elevated intracellular"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   770   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   770   C0175996:intracellular [Cell Component]
   770   C0178719:Intracellular [Spatial Concept]
   770   C0181586:leads [Medical Device]
   770   C0205250:Elevated [Qualitative Concept]
   770   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   770   C1522538:Lead [Functional Concept]
   770   C2348269:Lead [Element, Ion, or Isotope]
   770   C3163633:Elevated [Qualitative Concept]
   770   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "[ATP"

Phrase: "]/"

Phrase: "[ADP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0523452:ADP [Laboratory Procedure]

Phrase: "] ratio,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0456603:Ratio [Quantitative Concept]
  1000   C1547037:Ratio [Intellectual Product]

Phrase: "closure of KATP channels,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0185003:Closure [Therapeutic or Preventive Procedure]
   770   C1521802:Closure [Research Activity]
   715 E C0447303:Occlusal [Body Location or Region]
   715 E C0591895:occlusal [Organic Chemical,Pharmacologic Substance]
   715 E C1947917:Occlusal [Functional Concept]

Phrase: "and"

Phrase: "membrane depolarization."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1816453:membrane depolarization [Cell Function]
Processing 00000000.tx.25: Consequent activation of voltage-dependent Ca2+ channels causes a rise in [Ca2+]i, which stimulates insulin release (Fig. 1). 

Phrase: "Consequent activation of voltage-dependent Ca2+ channels"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1879547:Activation [Activity]

Phrase: "causes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:cause [Functional Concept]
  1000   C1314792:Causes [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "a rise in [Ca2+"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0596235:Ca2+ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "]i,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "which"

Phrase: "stimulates"

Phrase: "insulin release"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0030685:Release [Health Care Activity]
   861   C0391871:Release [Functional Concept]
   861   C0439180:% release [Quantitative Concept]
   861   C0680255:release [Health Care Activity]
   861   C1283071:Release [Functional Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C1963578:Release [Therapeutic or Preventive Procedure]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(Fig. 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.26: Conversely, a decrease in the metabolic signal is predicted to open KATP channels and suppress the electrical trigger of insulin secretion. 

Phrase: "Conversely,"

Phrase: "a decrease in the metabolic signal"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0392756:Decrease [Qualitative Concept]
   753   C0547047:Decrease [Quantitative Concept]

Phrase: "is"

Phrase: "predicted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0681842:Predicted [Idea or Concept]
  1000   C1882327:%{Predicted} [Quantitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "open"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0175566:Open [Spatial Concept]

Phrase: "KATP channels"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   827   C0439799:Channel [Spatial Concept]
   827   C1706095:Channel [Conceptual Entity]

Phrase: "and"

Phrase: "suppress"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260953:suppress [Functional Concept]

Phrase: "the electrical trigger of insulin secretion."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0032930:Trigger [Clinical Attribute]
   753   C1444748:Trigger [Qualitative Concept]
Processing 00000000.tx.27: Sulfonylurea drugs promote, and diazoxide suppresses, insulin secretion by binding to the regulatory sulfonylurea receptor-1 (SUR1) subunit and inhibiting, or activating, KATP channel current, respectively (2). 

Phrase: "Sulfonylurea drugs"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   861   C0013227:Drugs [Pharmacologic Substance]
   827 E C1254351:Drug [Pharmacologic Substance]
   789 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   789 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   761 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "promote"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033414:Promote [Activity]

Phrase: ","

Phrase: "and"

Phrase: "diazoxide"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0012022:Diazoxide [Organic Chemical,Pharmacologic Substance]
   944 E C0699324:Hyperstat [Organic Chemical,Pharmacologic Substance]

Phrase: "suppresses"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260953:suppress [Functional Concept]

Phrase: ","

Phrase: "insulin secretion by binding"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   833   C1256369:insulin secretion [Cell Function]
   819   C1623517:insulin binding [Molecular Function]
   770   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C0036536:secretion [Biologic Function]
   770   C0036537:Secretion [Body Substance]
   770   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1579433:Insulin [Pharmacologic Substance]
   715 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "to the regulatory sulfonylurea receptor-1 (SUR1) subunit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C1711351:Subunit [Quantitative Concept]

Phrase: "and"

Phrase: "inhibiting,"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C3463820:Inhibiting [Activity]
   928 E C0018790:arrested [Disease or Syndrome]
   928 E C0237477:Arrest [Temporal Concept]
   928 E C0392351:arrest [Governmental or Regulatory Activity]
   928 E C0521111:Retarded [Qualitative Concept]
   907 E C0311403:Inhibited [Qualitative Concept]

Phrase: "or"

Phrase: "activating, KATP channel current,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0521116:Current [Temporal Concept]
   812   C1705970:Current [Natural Phenomenon or Process]

Phrase: "respectively"

Phrase: "(2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ")."
Processing 00000000.tx.28: The electrical pathway is modulated by KATP channelindependent mechanisms; 

Phrase: "The electrical pathway"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1704259:Pathway [Molecular Function]
   861   C1705987:Pathway [Conceptual Entity]

Phrase: "is"

Phrase: "modulated by KATP channelindependent mechanisms"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   760   C0441712:Mechanisms [Functional Concept]
   760   C0443264:Modulated [Spatial Concept]
   726 E C1706376:Mechanism [Manufactured Object]

Phrase: ";"
Processing 00000000.tx.29: nutrient metabolites and incretins affect secretion at various stages downstream of KATP channel (3,4), but the drug effects underscore the central role of KATP channeldependent regulation. 

Phrase: "nutrient metabolites"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0870883:Metabolites [Biologically Active Substance]
   861   C2698672:METABOLITES [Regulation or Law]

Phrase: "and"

Phrase: "incretins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1562292:Incretins [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "secretion at various stages"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0036536:secretion [Biologic Function]
   770   C0036537:Secretion [Body Substance]

Phrase: "downstream of KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439799:Channel [Spatial Concept]
   861   C1706095:Channel [Conceptual Entity]

Phrase: "(3,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "4"

Phrase: ")"

Phrase: ","

Phrase: "but"

Phrase: "the drug effects"
Meta Candidates (Total=10; Excluded=6; Pruned=0; Remaining=4)
  1000   C0728866:drug effects [Functional Concept]
   966 E C0728867:Drug effect [Pathologic Function]
   966 E C1411996:drug effect [Biologic Function]
   861   C0013227:Drug [Pharmacologic Substance]
   861   C1254351:Drug [Pharmacologic Substance]
   861   C1280500:effects [Qualitative Concept]
   827 E C2348382:Effect [Qualitative Concept]
   805 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   805 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   768 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "underscore"

Phrase: "the central role of KATP channeldependent regulation."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0035820:Role [Social Behavior]
   748   C1705810:Role [Conceptual Entity]
Processing 00000000.tx.30: View larger version (54K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(54K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.31: 1. 

Phrase: "1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]
Processing 00000000.tx.32: The role of pancreatic KATP channel in insulin secretion. 

Phrase: "The role of pancreatic KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]

Phrase: "in insulin secretion."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.33: Elevated blood glucose increases glucose metabolism in the -cell and elevates [ATP]/[ADP]i. 

Phrase: "Elevated blood glucose"
Meta Candidates (Total=13; Excluded=7; Pruned=0; Remaining=6)
  1000   C0595877:elevated blood glucose [Finding]
   901   C0005802:Blood Glucose [Carbohydrate]
   827   C0005767:Blood [Tissue]
   827   C0005768:blood [Body Substance]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   827   C0229664:Blood [Body Substance]
   755 E C0333275:Bloody [Qualitative Concept]
   743 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   743 E C0392895:Bloods [Population Group]
   743 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   743 E C1511228:VESSEL, BLOOD [Tissue]
   727 E C1558950:VASCULAR [Finding]
   727 E C1801960:Vascular [Qualitative Concept]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "glucose metabolism in the -cell"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0596620:glucose metabolism [Molecular Function]
   760   C0025519:Metabolism [Organism Function]
   760   C0025520:metabolism [Functional Concept]

Phrase: "and"

Phrase: "elevates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205250:elevate [Qualitative Concept]

Phrase: "[ATP"

Phrase: "]/"

Phrase: "[ADP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0523452:ADP [Laboratory Procedure]

Phrase: "]i."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.34: This metabolic signal closes KATP channels, causing depolarization, activation of voltage-dependent Ca2+ channels, Ca2+ entry, and insulin exocytosis. 

Phrase: "This metabolic signal"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1710082:Signal [Phenomenon or Process]

Phrase: "closes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0587267:Close [Functional Concept]

Phrase: "KATP channels,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   827   C0439799:Channel [Spatial Concept]
   827   C1706095:Channel [Conceptual Entity]

Phrase: "causing"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0678227:Causing [Functional Concept]
   966 E C0015127:cause [Functional Concept]
   966 E C1524003:Cause [Conceptual Entity]

Phrase: "depolarization,"

Phrase: "activation of voltage-dependent Ca2+ channels,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1879547:Activation [Activity]

Phrase: "Ca2+ entry,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1705654:Entry [Intellectual Product]

Phrase: "and"

Phrase: "insulin exocytosis."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0015283:Exocytosis [Cell Function]
Processing 00000000.tx.35: Various additional effectors, including PIP2 and acyl CoAs, act to modulate ATP sensitivity of the channel and can thereby affect the coupling of metabolism to secretion.  

Phrase: "Various additional effectors,"

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "PIP2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0070798:PIP2 [Biologically Active Substance,Lipid,Organophosphorus Compound]
  1000   C3538724:PIP2 [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "acyl CoAs,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0001374:Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "act"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0079613:ACT [Therapeutic or Preventive Procedure]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "modulate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443264:modulate [Spatial Concept]

Phrase: "ATP sensitivity of the channel"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   797   C1547341:Channel sensitivity [Idea or Concept]
   760   C0036667:Sensitivity [Quantitative Concept]
   760   C0312418:Sensitivity [Mental Process]
   760   C0427965:Sensitivity [Finding]
   760   C1511883:Sensitivity [Quantitative Concept]
   760   C1522640:Sensitivity [Qualitative Concept]
   760   C2346484:SENSITIVITY [Phenomenon or Process]
   760   C2349185:Sensitivity [Qualitative Concept]

Phrase: "and"

Phrase: "can"

Phrase: "thereby"

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "the coupling of metabolism"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1948027:Coupling [Functional Concept]

Phrase: "to secretion."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0036536:secretion [Biologic Function]
  1000   C0036537:Secretion [Body Substance]
Processing 00000000.tx.36: Alterations in the metabolic signal, in the sensitivity of KATP channel to metabolites, or in the number of active KATP channels, could each disrupt electrical signaling in the -cell and alter insulin release. 

Phrase: "Alterations in the metabolic signal,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   726   C1515926:Alteration [Idea or Concept]

Phrase: "in the sensitivity"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0036667:Sensitivity [Quantitative Concept]
  1000   C0312418:Sensitivity [Mental Process]
  1000   C0427965:Sensitivity [Finding]
  1000   C1511883:Sensitivity [Quantitative Concept]
  1000   C1522640:Sensitivity [Qualitative Concept]
  1000   C2346484:SENSITIVITY [Phenomenon or Process]
  1000   C2349185:Sensitivity [Qualitative Concept]
   928 E C0332324:Sensitive [Functional Concept]
   928 E C1550474:sensitive [Idea or Concept]

Phrase: "of KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439799:Channel [Spatial Concept]
   861   C1706095:Channel [Conceptual Entity]

Phrase: "to metabolites,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0870883:Metabolites [Biologically Active Substance]
  1000   C2698672:METABOLITES [Regulation or Law]

Phrase: "or in the number of active KATP channels,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   744   C0205177:Active [Functional Concept]
   744   C0237753:*Number [Quantitative Concept]
   744   C0449788:Number [Quantitative Concept]
   711   C0439799:Channel [Spatial Concept]
   711   C1706095:Channel [Conceptual Entity]

Phrase: "could"

Phrase: "each"

Phrase: "disrupt"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332454:disrupt [Qualitative Concept]

Phrase: "electrical signaling in the -cell"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   835   C0678845:electrical cell signaling [Cell Function]
   797   C0037083:Cell Signaling [Cell Function]
           Signaling
   760   C3537152:signaling [Biologic Function]

Phrase: "and"

Phrase: "alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "insulin release."
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0030685:Release [Health Care Activity]
   861   C0391871:Release [Functional Concept]
   861   C0439180:% release [Quantitative Concept]
   861   C0680255:release [Health Care Activity]
   861   C1283071:Release [Functional Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C1963578:Release [Therapeutic or Preventive Procedure]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.37: In support of this prediction, earlier studies implicated reduced or absent KATP channel activity in the -cell as causal in congenital hyperinsulinism (CHI) in humans (5). 

Phrase: "In support"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0183683:Support [Medical Device]
  1000   C1521721:Support [Conceptual Entity]

Phrase: "of this prediction,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0681842:Prediction [Idea or Concept]

Phrase: "earlier studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "implicated"

Phrase: "reduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392756:Reduced [Qualitative Concept]

Phrase: "or"

Phrase: "absent KATP channel activity in the -cell"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   778   C1153410:channel activity [Molecular Function]
   748   C0205177:Activity [Functional Concept]
   748   C0439167:% activity [Quantitative Concept]
   748   C0441655:Activity [Activity]
   748   C1561536:*Activity [Idea or Concept]

Phrase: "as causal in congenital hyperinsulinism (CHI)"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   840   C2931834:Congenital Hyperinsulinism [Disease or Syndrome]
   804   C0009678:congenital [Qualitative Concept]
   804   C0020459:Hyperinsulinism [Disease or Syndrome]
   804   C1744681:Congenital [Qualitative Concept]
   733   C0015127:causality [Functional Concept]
   733   C1314792:Causalities [Functional Concept]

Phrase: "in humans"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086418:Humans [Human]

Phrase: "(5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.38: CHI is a rare, mostly recessive, disorder characterized by constitutive insulin secretion despite low blood glucose. 

Phrase: "CHI"

Phrase: "is"

Phrase: "a rare, mostly recessive, disorder"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   902   C0678236:Rare disorder [Disease or Syndrome]
   812   C0012634:Disorder [Disease or Syndrome]

Phrase: "characterized by constitutive insulin secretion"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   806   C1256369:insulin secretion [Cell Function]
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0036536:secretion [Biologic Function]
   760   C0036537:Secretion [Body Substance]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   760   C1880022:Characterized [Activity]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "despite low blood glucose."
Meta Candidates (Total=14; Excluded=7; Pruned=0; Remaining=7)
  1000   C0020615:LOW BLOOD GLUCOSE [Disease or Syndrome]
   913   C0860801:low glucose [Finding]
   901   C0005802:Blood Glucose [Carbohydrate]
   827   C0005767:Blood [Tissue]
   827   C0005768:blood [Body Substance]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   827   C0229664:Blood [Body Substance]
   755 E C0333275:Bloody [Qualitative Concept]
   743 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   743 E C0392895:Bloods [Population Group]
   743 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   743 E C1511228:VESSEL, BLOOD [Tissue]
   727 E C1558950:VASCULAR [Finding]
   727 E C1801960:Vascular [Qualitative Concept]
Processing 00000000.tx.39: If left untreated, severe mental retardation and death may result. 

Phrase: "If"

Phrase: "left untreated, severe mental retardation"
Meta Candidates (Total=10; Excluded=6; Pruned=0; Remaining=4)
   884   C0036857:Mental retardation, severe [Finding,Mental or Behavioral Dysfunction]
   840   C0025362:Mental Retardation [Mental or Behavioral Dysfunction]
   804   C0205082:Severe [Qualitative Concept]
   804   C0229992:mental [Mental Process]
   768 E C0079822:Mentally Retarded [Patient or Disabled Group]
   721 E C0229993:Psychic [Functional Concept]
   704 E C0011980:Diaphragm [Body Part, Organ, or Organ Component]
   704 E C0042241:DIAPHRAGM [Medical Device]
   704 E C1279038:Diaphragm [Body Part, Organ, or Organ Component]
   704 E C1705367:Diaphragm [Medical Device]

Phrase: "and"

Phrase: "death"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011065:Death [Organism Function]
  1000   C1306577:Death, NOS [Finding]

Phrase: "may"

Phrase: "result."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1274040:Result [Functional Concept]
  1000   C1546471:Result [Idea or Concept]
  1000   C2825142:Result [Finding]
Processing 00000000.tx.40: Mutations in KATP channel that reduce channel expression, decrease stimulation of the channel by MgADP, or abolish channel activity account for a majority of all CHI mutations (6,7,8,9). 

Phrase: "Mutations in KATP channel"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0026882:Mutations [Genetic Function]
   737 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "that"

Phrase: "reduce"

Phrase: "channel expression,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "decrease stimulation of the channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1292856:Stimulation [Therapeutic or Preventive Procedure]
   760   C1948023:Stimulation [Natural Phenomenon or Process]

Phrase: "by MgADP,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024468:MgADP [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "or"

Phrase: "abolish"

Phrase: "channel activity account for a majority of all CHI mutations"
Meta Candidates (Total=17; Excluded=1; Pruned=0; Remaining=16)
   750   C1153410:channel activity [Molecular Function]
   750   C2931834:Congenital Hyperinsulinism [Disease or Syndrome]
   735   C0009678:congenital [Qualitative Concept]
   735   C0020459:Hyperinsulinism [Disease or Syndrome]
   735   C0026882:Mutations [Genetic Function]
   735   C0205177:Activity [Functional Concept]
   735   C0439167:% activity [Quantitative Concept]
   735   C0439799:Channel [Spatial Concept]
   735   C0441655:Activity [Activity]
   735   C0680220:majority [Social Behavior]
   735   C1551359:account [Idea or Concept]
   735   C1561536:*Activity [Idea or Concept]
   735   C1706095:Channel [Conceptual Entity]
   735   C1744681:Congenital [Qualitative Concept]
   735   C2741673:Account # [Clinical Attribute]
   735   C2981730:Account [Classification]
   702 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "(6,"

Phrase: "7,"

Phrase: "8,"

Phrase: "9"

Phrase: ")."
Processing 00000000.tx.41: Conversely, mutations that result in "overactive" channels should decrease membrane excitability and impair glucose sensing by the -cell. 

Phrase: "Conversely,"

Phrase: "mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "that"

Phrase: "result"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1274040:Result [Functional Concept]
  1000   C1546471:Result [Idea or Concept]
  1000   C2825142:Result [Finding]

Phrase: "in ""overactive"" channels"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C0439799:Channel [Spatial Concept]
   793   C1706095:Channel [Conceptual Entity]

Phrase: "should"

Phrase: "decrease"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0392756:Decrease [Qualitative Concept]
  1000   C0547047:Decrease [Quantitative Concept]

Phrase: "membrane excitability"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0235169:Excitability [Sign or Symptom]
   789 E C0857393:excitable [Sign or Symptom]

Phrase: "and"

Phrase: "impair"

Phrase: "glucose sensing by the -cell."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C1658150:glucose sensing [Cell Function]
   726   C0036658:sense [Organ or Tissue Function]
Processing 00000000.tx.42: In this scenario, insulin secretion will be reduced and a diabetic phenotype is predicted. 

Phrase: "In this scenario,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683579:scenario [Functional Concept]

Phrase: "insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "will"

Phrase: "be"

Phrase: "reduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392756:Reduced [Qualitative Concept]

Phrase: "and"

Phrase: "a diabetic phenotype"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0031437:Phenotype [Organism Attribute]
   861   C1285572:Phenotype [Laboratory Procedure]

Phrase: "is"

Phrase: "predicted."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0681842:Predicted [Idea or Concept]
  1000   C1882327:%{Predicted} [Quantitative Concept]
Processing 00000000.tx.43: A clear picture is now emerging from both animal and human studies that such KATP channel mutations can indeed cause diabetes. 

Phrase: "A clear picture"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441468:picture [Manufactured Object]
   861   C0441469:Picture [Manufactured Object]

Phrase: "is"

Phrase: "now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "emerging from both animal"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0003062:Animal [Animal]

Phrase: "and"

Phrase: "human"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086418:Human [Human]

Phrase: "studies"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557651:Study [Manufactured Object]
  1000   C0947630:studies [Laboratory Procedure]
  1000   C2603343:Study [Research Activity]

Phrase: "that"

Phrase: "such KATP channel mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "can"

Phrase: "indeed"

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "diabetes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.44: The first part of this review will detail the rapidly emerging clinical evidence for involvement of KATP channel mutations in neonatal and type 2 diabetes and the cellular basis of the disease. 

Phrase: "The first part of this review"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1292711:Part of [Spatial Concept]
   753   C0449719:Part [Spatial Concept]
   753   C1709471:Part [Quantitative Concept]

Phrase: "will"

Phrase: "detail"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1522508:Detail [Qualitative Concept]
  1000   C1561567:detail [Functional Concept]

Phrase: "the rapidly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1637379:Rapidly [Qualitative Concept]

Phrase: "emerging"

Phrase: "clinical evidence for involvement of KATP channel mutations"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: "in neonatal"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1552240:Neonatal [Professional or Occupational Group]
  1000   C1552264:Neonatal [Professional or Occupational Group]
  1000   C2939425:Neonatal [Temporal Concept]

Phrase: "and"

Phrase: "type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "the cellular basis of the disease."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1527178:Basis [Functional Concept]
   753   C1874451:Basis [Pharmacologic Substance]
Processing 00000000.tx.45: The second part will consider the structure-function relationships of the KATP channel and molecular mechanisms that underlie diabetes in which mutations in KATP are causal.  

Phrase: "The second part"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   861   C0205436:Second [Quantitative Concept]
   861   C0449719:Part [Spatial Concept]
   861   C0457385:Second [Temporal Concept]
   861   C0565930:/second [Quantitative Concept]
   861   C1561503:second [Idea or Concept]
   861   C1705190:Second [Qualitative Concept]
   861   C1709471:Part [Quantitative Concept]
   789 E C0027627:secondary [Neoplastic Process]
   789 E C0175668:Secondary [Temporal Concept]

Phrase: "will"

Phrase: "consider"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:consider [Idea or Concept]

Phrase: "the structure-function relationships of the KATP channel"
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   744   C0031843:function [Physiologic Function]
   744   C0439849:Relationships [Qualitative Concept]
   744   C0542341:Function [Functional Concept]
   744   C0678594:Structure [Spatial Concept]
   744   C0700205:FUNCTION [Classification]
   744   C1705273:Function [Intellectual Product]
   718   C2700217:Functional Relationship [Conceptual Entity]
   714   C0923800:Structural relationship [Conceptual Entity]
   711 E C1705630:Relationship [Idea or Concept]
   711 E C1706279:Relationship [Idea or Concept]
   711 E C3540605:Relationship [Intellectual Product]

Phrase: "and"

Phrase: "molecular mechanisms"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0441712:Mechanisms [Functional Concept]
   827 E C1706376:Mechanism [Manufactured Object]

Phrase: "that"

Phrase: "underlie"

Phrase: "diabetes in which mutations"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0011847:Diabetes [Disease or Syndrome]
   770   C0011849:Diabetes [Disease or Syndrome]

Phrase: "in KATP"

Phrase: "are"

Phrase: "causal."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   928   C0015127:causality [Functional Concept]
   928   C1314792:Causalities [Functional Concept]
Processing 00000000.tx.46: Part 1: -cell KATP channel and diabetes: the emerging genetic and clinical picture TOP ABSTRACT Part 1: -cell KATP... 

Phrase: "Part 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0449719:Part [Spatial Concept]
   861   C1709471:Part [Quantitative Concept]

Phrase: ": -"

Phrase: "cell KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439799:Channel [Spatial Concept]
   827   C1706095:Channel [Conceptual Entity]

Phrase: "and"

Phrase: "diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "the emerging genetic"
Meta Candidates (Total=16; Excluded=14; Pruned=0; Remaining=2)
   861   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   861   C0314603:Genetic [Functional Concept]
   805 E C0005615:Birth [Organism Function]
   805 E C0035150:Reproduction [Organism Function]
   805 E C0079946:origin [Classification]
   805 E C0439659:Origin [Temporal Concept]
   805 E C1550512:origin [Intellectual Product]
   805 E C1550722:birth [Idea or Concept]
   805 E C3245487:birth [Intellectual Product]
   777 E C0454729:Natal [Geographic Area]
   777 E C0559522:Genital [Body System]
   777 E C1546649:Genital [Intellectual Product]
   777 E C1550642:Genital [Body Substance]
   768 E C0205313:Original [Idea or Concept]
   768 E C2347409:Original [Occupational Activity]
   750 E C0598240:originality [Mental Process]

Phrase: "and"

Phrase: "clinical picture TOP ABSTRACT Part 1"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   799   C0000857:Abstract [Occupational Activity]
   799   C0205210:Clinical [Qualitative Concept]
   799   C0441468:picture [Manufactured Object]
   799   C0441469:Picture [Manufactured Object]
   799   C0449719:Part [Spatial Concept]
   799   C0600678:Abstract [Intellectual Product]
   799   C1552863:Abstract [Idea or Concept]
   799   C1704458:Top [Spatial Concept]
   799   C1709471:Part [Quantitative Concept]

Phrase: ": -"

Phrase: "cell KATP..."
Processing 00000000.tx.47: Part 2: KATP channel-dependent... 

Phrase: "Part 2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0449719:Part [Spatial Concept]
   861   C1709471:Part [Quantitative Concept]

Phrase: ":"

Phrase: "KATP channel-dependent..."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0851827:Dependent [Qualitative Concept]
   827   C1701901:Dependent [Qualitative Concept]
   827   C3244310:dependent [Functional Concept]
Processing 00000000.tx.48: REFERENCES  Mutations in Kir6.2 underlie neonatal diabetes. 

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Mutations in Kir6.2"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0026882:Mutations [Genetic Function]
   737 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "underlie"

Phrase: "neonatal diabetes."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0158981:Neonatal diabetes [Disease or Syndrome]
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.49: Given the above paradigm, any gain of KATP channel function is expected to suppress GSIS. 

Phrase: "Given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "the above paradigm,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0681797:paradigm [Research Activity]

Phrase: "any gain of KATP channel function"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1517378:Gain [Quantitative Concept]

Phrase: "is"

Phrase: "expected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1517001:Expected [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "suppress"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260953:suppress [Functional Concept]

Phrase: "GSIS."
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   875   C1719133:Glucose/Insulin [Quantitative Concept]
   861   C1256369:insulin secretion [Cell Function]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0036536:secretion [Biologic Function]
   812   C0036537:Secretion [Body Substance]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.50: This prediction was originally confirmed by the striking neonatal diabetic phenotype of two different genetic models: 1) mice with targeted disruption of the pancreatic -cell glucokinase gene (10) and 2) transgenic mice expressing -cell KATP channels with decreased sensitivity to inhibitory ATP (i.e., "overactive" KATP channel) (11). 

Phrase: "This prediction"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0681842:Prediction [Idea or Concept]

Phrase: "was"

Phrase: "originally"

Phrase: "confirmed by the striking neonatal diabetic phenotype of two different genetic models"
Meta Candidates (Total=17; Excluded=1; Pruned=0; Remaining=16)
   753   C0026343:Models, Genetic [Intellectual Product]
   753   C0521093:Confirmed by [Qualitative Concept]
           confirmed
   736   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   736   C0031437:Phenotype [Organism Attribute]
   736   C0038452:striking [Occupational Activity]
   736   C0205448:Two [Quantitative Concept]
   736   C0241863:DIABETIC [Finding]
   736   C0314603:Genetic [Functional Concept]
   736   C0750484:Confirmed [Idea or Concept]
   736   C1285572:Phenotype [Laboratory Procedure]
   736   C1552240:Neonatal [Professional or Occupational Group]
   736   C1552264:Neonatal [Professional or Occupational Group]
   736   C1705242:Different [Qualitative Concept]
   736   C2939425:Neonatal [Temporal Concept]
   736   C3161035:Models [Intellectual Product]
   703 E C1456348:Confirm [Qualitative Concept]

Phrase: ":"

Phrase: "1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ")"

Phrase: "mice with targeted disruption of the pancreatic -cell glucokinase gene"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   757   C1417166:MICE gene [Gene or Genome]
   739   C0025914:Mice [Mammal]
   739   C0025929:mice [Mammal]
   739   C0026809:Mice [Mammal]

Phrase: "(10"

Phrase: ")"

Phrase: "and"

Phrase: "2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ")"

Phrase: "transgenic mice"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0025936:Mice, Transgenic [Mammal]
   861   C0003069:Transgenic [Animal]
   861   C0025914:Mice [Mammal]
   861   C0025929:mice [Mammal]
   861   C0026809:Mice [Mammal]

Phrase: "expressing -"

Phrase: "cell KATP channels with decreased sensitivity"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   767   C1547341:Channel sensitivity [Idea or Concept]
   719   C0439799:Channel [Spatial Concept]
   719   C1706095:Channel [Conceptual Entity]

Phrase: "to inhibitory ATP"

Phrase: "(i.e., ""overactive"" KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0439799:Channel [Spatial Concept]
   804   C1706095:Channel [Conceptual Entity]

Phrase: ")"

Phrase: "(11"

Phrase: ")."
Processing 00000000.tx.51: In each case, acute neonatal hyperglycemia together with ketoacidosis, leading to death within a few days, was observed. 

Phrase: "In each case,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0868928:Case [Functional Concept]
  1000   C1706255:CASE [Medical Device]
  1000   C1706256:Case [Conceptual Entity]

Phrase: "acute neonatal hyperglycemia together with ketoacidosis,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0475718:Neonatal hyperglycaemia [Disease or Syndrome]
   783   C0342301:Acute hyperglycaemia [Pathologic Function]
   753   C0020456:Hyperglycaemia [Disease or Syndrome]

Phrase: "leading to death"
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   790   C0011065:Death [Organism Function]
   790   C0332152:Leading [Temporal Concept]
   790   C1306577:Death, NOS [Finding]
   790   C1522538:Leading [Functional Concept]
   756 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   756 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   756 E C2348269:Lead [Element, Ion, or Isotope]
   756 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "within a few days,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0439228:days [Temporal Concept]
   827 E C0332173:/day [Temporal Concept]
   827 E C0439505:/day [Temporal Concept]

Phrase: "was"

Phrase: "observed."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441672:Observed [Functional Concept]
Processing 00000000.tx.52: In the latter model (Fig. 2A), blood insulin is at or below the level of detection but insulin is clearly present in the pancreas (11). 

Phrase: "In the latter model"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3161035:Model [Intellectual Product]

Phrase: "(Fig. 2A"

Phrase: ")"

Phrase: ","

Phrase: "blood insulin"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0853230:blood insulin [Laboratory Procedure]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "is at"

Phrase: "or below the level of detection"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0441889:Level [Qualitative Concept]
   753   C0456079:Level [Classification]
   753   C1511790:Detection [Therapeutic or Preventive Procedure]
   753   C1547707:Level [Geographic Area]
   753   C2946261:Level [Pharmacologic Substance]

Phrase: "but"

Phrase: "insulin"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
  1000   C1579433:Insulin [Pharmacologic Substance]
   944 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "is"

Phrase: "clearly"

Phrase: "present in the pancreas"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0030274:Pancreas [Body Part, Organ, or Organ Component]
   770   C0150312:Present [Quantitative Concept]
   770   C0449450:Present [Idea or Concept]
   770   C1278931:Pancreas [Body Part, Organ, or Organ Component]

Phrase: "(11"

Phrase: ")."
Processing 00000000.tx.53: In each case, overactive KATP channel activity, with a failure to switch on insulin secretion, is the logical underlying mechanism; 

Phrase: "In each case,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0868928:Case [Functional Concept]
  1000   C1706255:CASE [Medical Device]
  1000   C1706256:Case [Conceptual Entity]

Phrase: "overactive KATP channel activity,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C1153410:channel activity [Molecular Function]
   812   C0205177:Activity [Functional Concept]
   812   C0439167:% activity [Quantitative Concept]
   812   C0441655:Activity [Activity]
   812   C1561536:*Activity [Idea or Concept]

Phrase: "with a failure to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]

Phrase: "switch on insulin secretion,"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   833   C1256369:insulin secretion [Cell Function]
   770   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C0036536:secretion [Biologic Function]
   770   C0036537:Secretion [Body Substance]
   770   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   770   C1579433:Insulin [Pharmacologic Substance]
   770   C1707719:Switch [Manufactured Object]
   715 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "is"

Phrase: "the logical underlying mechanism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0441712:Mechanism [Functional Concept]
   827   C1706376:Mechanism [Manufactured Object]

Phrase: ";"
Processing 00000000.tx.54: this is due to altered metabolic signal in the former (12) and insensitivity to the normal metabolic signal in the latter (11). 

Phrase: "this"

Phrase: "is due to altered metabolic signal"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C0678226:Due to [Functional Concept]
           due
   753   C0311400:Metabolic [Functional Concept]
   753   C0392747:Altered [Functional Concept]
   753   C1524026:Metabolic [Cell Function]
   753   C1710082:Signal [Phenomenon or Process]
   753   C2707259:Metabolic [Clinical Attribute]
   753   C3146286:Due [Idea or Concept]

Phrase: "in the former"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205156:Former [Temporal Concept]
  1000   C0750523:FORMER [Idea or Concept]

Phrase: "(12"

Phrase: ")"

Phrase: "and"

Phrase: "insensitivity to the normal metabolic signal"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0237677:Insensitivity [Finding]

Phrase: "in the latter"

Phrase: "(11"

Phrase: ")."
Processing 00000000.tx.55: View larger version (36K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(36K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.56: 2. 

Phrase: "2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]
Processing 00000000.tx.57: KATP channeldependent diabetes in mouse and humans. 

Phrase: "KATP channeldependent diabetes in mouse"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]

Phrase: "and"

Phrase: "humans."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086418:Humans [Human]
Processing 00000000.tx.58: A: Upper left: In Kir6.2[N30]-expressing transgenic (TG) mice, only 3 of 150 F1 transgenic mice survived to weaning (11). 

Phrase: "A"

Phrase: ":"

Phrase: "Upper left"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205091:Left [Spatial Concept]
   861   C1552822:left [Functional Concept]

Phrase: ":"

Phrase: "In Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:Kir6.2 [Gene or Genome]

Phrase: "[N30"

Phrase: "]-"

Phrase: "expressing"

Phrase: "transgenic (TG) mice,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0025936:Mice, Transgenic [Mammal]
   861   C0003069:Transgenic [Animal]
   861   C0025914:Mice [Mammal]
   861   C0025929:mice [Mammal]
   861   C0026809:Mice [Mammal]

Phrase: "only 3 of 150 F1 transgenic mice"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C0025936:Mice, Transgenic [Mammal]
   748   C0003069:Transgenic [Animal]
   748   C0025914:Mice [Mammal]
   748   C0025929:mice [Mammal]
   748   C0026809:Mice [Mammal]
   748   C0205171:Only [Quantitative Concept]
   748   C1720467:Only [Intellectual Product]

Phrase: "survived to weaning"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0043084:Weaning [Organism Function]
   756   C0310255:SURVIVE [Pharmacologic Substance]

Phrase: "(11"

Phrase: ")."
Processing 00000000.tx.59: Those that did were approximately two-thirds the body weight of wild-type (WT) littermates. 

Phrase: "Those"

Phrase: "that"

Phrase: "did"

Phrase: "were"

Phrase: "approximately two-thirds"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0205437:Third [Quantitative Concept]
   827   C0205448:Two [Quantitative Concept]

Phrase: "the body weight of wild-type (WT) littermates."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   778   C0005910:Body Weight [Organism Attribute]
           weight
   778   C1305866:body weight [Diagnostic Procedure]
           weight
   774   C0037669:Type, Body [Organism Attribute]
   748   C0043100:Weight [Quantitative Concept]
   748   C0242821:body [Human]
   748   C0460148:Body [Anatomical Structure]
   748   C1268086:Body [Anatomical Structure]
   748   C1705104:Weight [Idea or Concept]
Processing 00000000.tx.60: Upper right: Steady-state dependence of KATP channel current on [ATP] was shifted approximately fivefold to higher [ATP] in membrane patches from transgenic -cells. 

Phrase: "Upper right"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205090:Right [Spatial Concept]

Phrase: ":"

Phrase: "Steady-state dependence of KATP channel current on [ATP"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C0011546:Dependence [Mental Process]
   742   C0439857:Dependence [Mental or Behavioral Dysfunction]
   742   C2698668:DEPENDENCE [Regulation or Law]

Phrase: "]"

Phrase: "was"

Phrase: "shifted"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0333051:shifted [Functional Concept]
   966 E C2347509:Shift [Phenomenon or Process]

Phrase: "approximately fivefold to higher"

Phrase: "[ATP"

Phrase: "]"

Phrase: "in membrane"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025255:Membrane [Tissue]
  1000   C0596901:Membrane [Cell Component]
  1000   C1706182:Membrane [Manufactured Object]
   928 E C0205287:Membranous [Qualitative Concept]

Phrase: "patches from transgenic -cells."
Meta Candidates (Total=14; Excluded=3; Pruned=0; Remaining=11)
   770   C0003069:Transgenic [Animal]
   770   C0007634:Cells [Cell]
   770   C0332461:Patch [Finding]
   770   C0445403:Patch [Biomedical or Dental Material]
   770   C0991556:Patch [Medical Device]
   770   C0994894:Patches [Medical Device]
   770   C1305400:Patch [Medical Device]
   770   C1533128:Patch [Biomedical or Dental Material]
   770   C1706366:{Patch} [Quantitative Concept]
   770   C1707974:Patch [Biomedical or Dental Material]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.61: Lower: Blood glucose (left) and serum insulin (right) levels were at or outside the level of detection in 2- to 4-day neonatal transgenic mice (11). 

Phrase: "Lower"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441994:Lower [Spatial Concept]
  1000   C1548802:Lower [Body Location or Region]
  1000   C2003888:Lower [Activity]

Phrase: ":"

Phrase: "Blood glucose"
Meta Candidates (Total=12; Excluded=7; Pruned=0; Remaining=5)
  1000   C0005802:Blood Glucose [Carbohydrate]
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: "(left"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205091:Left [Spatial Concept]
  1000   C1552822:left [Functional Concept]

Phrase: ")"

Phrase: "and"

Phrase: "serum insulin"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0428357:Serum insulin [Laboratory Procedure]
  1000   C1261415:serum insulin [Laboratory or Test Result]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "(right"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205090:Right [Spatial Concept]

Phrase: ")"

Phrase: "levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0441889:Levels [Qualitative Concept]
   966 E C0456079:Level [Classification]
   966 E C1547707:Level [Geographic Area]
   966 E C2946261:Level [Pharmacologic Substance]

Phrase: "were at"

Phrase: "or"

Phrase: "outside"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205101:Outside [Spatial Concept]

Phrase: "the level of detection"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0441889:Level [Qualitative Concept]
   770   C0456079:Level [Classification]
   770   C1547707:Level [Geographic Area]
   770   C2946261:Level [Pharmacologic Substance]

Phrase: "in 2-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "to 4-day neonatal transgenic mice"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   840   C0025936:Mice, Transgenic [Mammal]
   804   C0003069:Transgenic [Animal]
   804   C0025914:Mice [Mammal]
   804   C0025929:mice [Mammal]
   804   C0026809:Mice [Mammal]

Phrase: "(11"

Phrase: ")."
Processing 00000000.tx.62: B: Peak serum insulin levels compared with baseline in three permanent neonatal diabetes patients carrying R201 mutations in Kir6.2. 

Phrase: "B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: ":"

Phrase: "Peak serum insulin levels"
Meta Candidates (Total=19; Excluded=5; Pruned=0; Remaining=14)
   890   C0428357:Serum insulin level [Laboratory Procedure]
           Serum insulin
   890   C1261415:serum insulin level [Laboratory or Test Result]
           serum insulin
   886   C0444505:Peak level [Quantitative Concept]
   861   C0202098:insulin levels [Laboratory Procedure]
   861   C0428405:insulin levels [Laboratory or Test Result]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0229671:Serum [Body Substance]
   812   C0441889:Levels [Qualitative Concept]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1546774:Serum [Intellectual Product]
   812   C1550100:Serum [Body Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   779 E C0456079:Level [Classification]
   779 E C1547707:Level [Geographic Area]
   779 E C2946261:Level [Pharmacologic Substance]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "compared with baseline"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0168634:baseline [Biomedical or Dental Material]
   790   C1442488:Baseline [Quantitative Concept]
   790   C1707455:Compared [Activity]

Phrase: "in three permanent neonatal diabetes patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0030705:Patients [Patient or Disabled Group]

Phrase: "carrying"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0206243:Carrying [Activity]
   966 E C0699809:carry [Finding]

Phrase: "R201 mutations in Kir6.2."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0026882:Mutations [Genetic Function]
   726 E C1705285:Mutation [Cell or Molecular Dysfunction]
Processing 00000000.tx.63: Glucose, administered intravenously at 0.3 g/kg, failed to elicit an insulin response, but significant insulin was released in response to tolbutamide (at 3 mg/kg). 

Phrase: "Glucose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "administered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521801:Administered [Functional Concept]
   966 E C1621583:Administer [Functional Concept]

Phrase: "intravenously at 0.3 g/kg,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C1300563:g/kg [Quantitative Concept]
   753   C0022718:KG [Geographic Area]
   753   C0439209:kg [Quantitative Concept]
   753   C0439267:g% [Quantitative Concept]

Phrase: "failed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:Failed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "elicit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449265:elicit [Qualitative Concept]

Phrase: "an insulin response,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0871261:Response [Organism Attribute]
   861   C1704632:Response [Finding]
   861   C1706817:Response [Intellectual Product]
   861   C2911692:Response [Mental Process]

Phrase: "but"

Phrase: "significant insulin"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "released in response"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   790   C0391871:Released [Functional Concept]
   790   C0871261:Response [Organism Attribute]
   790   C1283071:Released [Functional Concept]
   790   C1704632:Response [Finding]
   790   C1706817:Response [Intellectual Product]
   790   C2911692:Response [Mental Process]
   756 E C0030685:Release [Health Care Activity]
   756 E C0439180:% release [Quantitative Concept]
   756 E C0680255:release [Health Care Activity]
   756 E C1963578:Release [Therapeutic or Preventive Procedure]

Phrase: "to tolbutamide"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040374:Tolbutamide [Organic Chemical,Pharmacologic Substance]
   944 E C0701229:Orinase [Organic Chemical,Pharmacologic Substance]

Phrase: "("

Phrase: "at 3 mg/kg"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C0439272:mg kg [Quantitative Concept]
   827   C0022718:KG [Geographic Area]
   827   C0439209:kg [Quantitative Concept]
   827   C0439269:mg% [Quantitative Concept]
   827   C1960952:mg % [Quantitative Concept]
   827   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: ")."
Processing 00000000.tx.64: ISPAD, International Society for Pediatric and Adolescent Diabetes. 

Phrase: "ISPAD,"

Phrase: "International Society for Pediatric"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0037455:society [Organization]
   770   C1512888:International [Idea or Concept]

Phrase: "and"

Phrase: "Adolescent Diabetes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.65: Republished from Gloyn et al. 

Phrase: "Republished from Gloyn et al."
Processing 00000000.tx.66: (27) with permission.  

Phrase: "(27"

Phrase: ")"

Phrase: "with permission."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0521104:permission [Qualitative Concept]
  1000   C1524004:Permission [Intellectual Product]
Processing 00000000.tx.67: The obvious prediction of these mouse models is that genetically induced ATP insensitivity of -cell KATP channels could underlie impaired insulin release and neonatal diabetes in humans (13,14). 

Phrase: "The obvious prediction of these mouse models"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0681842:Prediction [Idea or Concept]

Phrase: "is"

Phrase: "that genetically induced ATP insensitivity of -cell KATP channels"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   760   C0439799:Channel [Spatial Concept]
   760   C1706095:Channel [Conceptual Entity]

Phrase: "could"

Phrase: "underlie"

Phrase: "impaired insulin release"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0030685:Release [Health Care Activity]
   827   C0391871:Release [Functional Concept]
   827   C0439180:% release [Quantitative Concept]
   827   C0680255:release [Health Care Activity]
   827   C1283071:Release [Functional Concept]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   827   C1963578:Release [Therapeutic or Preventive Procedure]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   743 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "neonatal diabetes in humans"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C0158981:Neonatal diabetes [Disease or Syndrome]
   770   C0011847:Diabetes [Disease or Syndrome]
   770   C0011849:Diabetes [Disease or Syndrome]

Phrase: "(13,"

Phrase: "14"

Phrase: ")."
Processing 00000000.tx.68: Rare in occurrence (1:400,000 births), neonatal diabetes is usually diagnosed within the first 3 months of life and relies on insulin administration to treat the hyperglycemia (15). 

Phrase: "Rare in occurrence"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0521114:Rare [Temporal Concept]
   790   C0522498:Rare [Qualitative Concept]
   790   C1514917:RARE [Gene or Genome]

Phrase: "(1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ":"

Phrase: "400,000 births"
Meta Candidates (Total=16; Excluded=15; Pruned=0; Remaining=1)
   827   C0005615:Births [Organism Function]
   793 E C1550722:birth [Idea or Concept]
   793 E C3245487:birth [Intellectual Product]
   755 E C0017296:GENETIC [Therapeutic or Preventive Procedure]
   755 E C0314603:Genetic [Functional Concept]
   755 E C0454729:Natal [Geographic Area]
   734 E C0035150:Reproduction [Organism Function]
   734 E C0079946:origin [Classification]
   734 E C0439659:Origin [Temporal Concept]
   734 E C1550512:origin [Intellectual Product]
   721 E C0559522:Genital [Body System]
   721 E C1546649:Genital [Intellectual Product]
   721 E C1550642:Genital [Body Substance]
   716 E C0205313:Original [Idea or Concept]
   716 E C2347409:Original [Occupational Activity]
   704 E C0598240:originality [Mental Process]

Phrase: ")"

Phrase: ","

Phrase: "neonatal diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0158981:Neonatal diabetes [Disease or Syndrome]
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "is"

Phrase: "usually"

Phrase: "diagnosed within the first 3 months of life"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   744   C0011900:Diagnosed [Finding]
   744   C0205435:First [Quantitative Concept]
   744   C0376558:Life [Idea or Concept]
   744   C0439231:months [Temporal Concept]
   744   C1279901:First [Qualitative Concept]
   711 E C0439507:/month [Temporal Concept]

Phrase: "and"

Phrase: "relies on insulin administration to"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   806   C0199782:insulin administration [Therapeutic or Preventive Procedure]
   760   C0001554:Administration [Occupational Activity]
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1533734:Administration [Therapeutic or Preventive Procedure]
   760   C1579433:Insulin [Pharmacologic Substance]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "treat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1292734:TREAT [Functional Concept]
  1000   C1522326:Treat [Functional Concept]

Phrase: "the hyperglycemia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020456:Hyperglycaemia [Disease or Syndrome]

Phrase: "(15"

Phrase: ")."
Processing 00000000.tx.69: In transient neonatal diabetes, which is milder, hyperglycemia usually resolves within 18 months, whereas the permanent form requires insulin treatment for life. 

Phrase: "In transient neonatal diabetes,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   901   C0158981:Neonatal diabetes [Disease or Syndrome]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0040704:Transient [Population Group]
   827   C0205374:Transient [Temporal Concept]
   827   C1552240:Neonatal [Professional or Occupational Group]
   827   C1552264:Neonatal [Professional or Occupational Group]
   827   C2939425:Neonatal [Temporal Concept]

Phrase: "which"

Phrase: "is"

Phrase: "milder, hyperglycemia usually"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0020456:Hyperglycaemia [Disease or Syndrome]

Phrase: "resolves within 18 months,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0439231:months [Temporal Concept]
   770   C2699488:Resolve [Conceptual Entity]
   737 E C0439507:/month [Temporal Concept]

Phrase: "whereas"

Phrase: "the permanent form"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0348078:Form [Qualitative Concept]
   861   C0376315:Form [Manufactured Object]
   861   C1522492:Form [Functional Concept]

Phrase: "requires"

Phrase: "insulin treatment for life."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0745343:insulin treatment [Therapeutic or Preventive Procedure]
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.70: Until recently, the cause of the majority of permanent neonatal diabetes cases has remained unknown. 

Phrase: "Until"

Phrase: "recently,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "the cause of the majority of permanent neonatal diabetes cases"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0015127:cause [Functional Concept]
   739   C1524003:Cause [Conceptual Entity]

Phrase: "has"

Phrase: "remained"

Phrase: "unknown."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439673:Unknown [Qualitative Concept]
Processing 00000000.tx.71: Homozygous and compound heterozygous mutations in glucokinase, the rate-limiting enzyme of glucose metabolism in islet cells, cause isolated permanent neonatal diabetes and account for a minority of cases (at least six families reported to date) (16,17). 

Phrase: "Homozygous"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0019904:Homozygous [Organism Attribute]

Phrase: "and"

Phrase: "compound heterozygous mutations in glucokinase,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0026882:Mutations [Genetic Function]
   726 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "the rate-limiting enzyme of glucose metabolism"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0014442:Enzyme [Enzyme,Organic Chemical]

Phrase: "in islet cells,"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
  1000   C0022131:Islet Cells [Body Part, Organ, or Organ Component]
   966 E C1522529:Islet Cell [Cell]
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "isolated"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0205409:Isolated [Functional Concept]
  1000   C1548221:Isolated [Idea or Concept]
   966 E C0370215:Isolate [Substance]
   966 E C1875400:ISOLATE [Pharmacologic Substance]

Phrase: "permanent neonatal diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0158981:Neonatal diabetes [Disease or Syndrome]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]

Phrase: "and"

Phrase: "account for a minority of cases"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C1551359:account [Idea or Concept]
   753   C2741673:Account # [Clinical Attribute]
   753   C2981730:Account [Classification]

Phrase: "("

Phrase: "at least six families"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0015576:Families [Family Group]
   827   C1704727:Family [Conceptual Entity]
   743 E C0241888:Familial [Functional Concept]

Phrase: "reported to date"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   858   C1302584:Reported Date [Temporal Concept]
   790   C0011008:Date [Temporal Concept]
   790   C0684224:Reported [Intellectual Product]
   790   C0700287:Reported [Health Care Activity]
   790   C2348077:Date [Food]
   790   C3496591:Reported [Clinical Attribute]
   756 E C3273238:Report [Intellectual Product]

Phrase: ")"

Phrase: "(16,"

Phrase: "17"

Phrase: ")."
Processing 00000000.tx.72: Similarly, compound heterozygous or homozygous mutations in insulin promoter factor 1 (IPF-1), an essential transcriptional regulator of pancreatic development, underlie a fewer number of cases (18,19). 

Phrase: "Similarly,"

Phrase: "compound heterozygous"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0019425:Heterozygous [Organism Attribute]

Phrase: "or"

Phrase: "homozygous mutations in insulin promoter factor 1 (IPF-1),"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   748   C0026882:Mutations [Genetic Function]
   714 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "an essential transcriptional regulator of pancreatic development,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0040649:Transcriptional [Genetic Function]
   748   C0182953:REGULATOR [Medical Device]
   748   C1704734:Regulator [Medical Device]
   748   C1704735:Regulator [Conceptual Entity]

Phrase: "underlie"

Phrase: "a fewer number of cases"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0237753:*Number [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]

Phrase: "(18,"

Phrase: "19"

Phrase: ")."
Processing 00000000.tx.73: Other rare forms of permanent neonatal diabetes are associated with multiple deficiencies. 

Phrase: "Other rare forms of permanent neonatal diabetes"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   748   C0348078:forms [Qualitative Concept]
   748   C0376315:Forms [Manufactured Object]
   714 E C1522492:Form [Functional Concept]

Phrase: "are"

Phrase: "associated with multiple deficiencies."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0439064:Multiple [Quantitative Concept]
   737   C0011155:Deficiency [Functional Concept]
   737   C0162429:Deficiency [Disease or Syndrome]
   737 E C0750490:Associate [Idea or Concept]
   737   C1623416:deficiency [Qualitative Concept]
   737 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.74: These include Wolcott-Rallison syndrome, characterized by infancy-onset diabetes along with growth and mental retardation and caused by mutations in EIF2AK3, a regulator of protein synthesis (20,21). 

Phrase: "These"

Phrase: "include"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332257:include [Functional Concept]
  1000   C1552866:include [Idea or Concept]
  1000   C2700399:Include [Activity]

Phrase: "Wolcott-Rallison syndrome,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0432217:Wolcott-Rallison syndrome [Congenital Abnormality,Disease or Syndrome]
   827   C0039082:Syndrome [Disease or Syndrome]

Phrase: "characterized by infancy-onset diabetes"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0231330:Infancy [Temporal Concept]
   760   C0332162:Onset [Qualitative Concept]
   760   C1880022:Characterized [Activity]

Phrase: "along with growth"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0018270:'growth' NOS [Organism Function]
  1000   C0220844:growth [Physiologic Function]
  1000   C1621966:Growth [Organ or Tissue Function]
  1000   C2911660:Growth [Activity]

Phrase: "and"

Phrase: "mental retardation"
Meta Candidates (Total=10; Excluded=8; Pruned=0; Remaining=2)
  1000   C0025362:Mental Retardation [Mental or Behavioral Dysfunction]
   928 E C0079822:Mentally Retarded [Patient or Disabled Group]
   861   C0229992:mental [Mental Process]
   777 E C0229993:Psychic [Functional Concept]
   761 E C0011980:Diaphragm [Body Part, Organ, or Organ Component]
   761 E C0042241:DIAPHRAGM [Medical Device]
   761 E C1279038:Diaphragm [Body Part, Organ, or Organ Component]
   761 E C1705367:Diaphragm [Medical Device]
   750 E C0086045:mindfulness [Mental Process]
   750 E C3542996:Mindfulness [Mental Process]

Phrase: "and"

Phrase: "caused by mutations"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0026882:Mutations [Genetic Function]
   756   C0015127:cause [Functional Concept]
   756   C1524003:Cause [Conceptual Entity]
   756 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "in EIF2AK3,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1414326:EIF2AK3 [Gene or Genome]

Phrase: "a regulator of protein synthesis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0182953:REGULATOR [Medical Device]
   760   C1704734:Regulator [Medical Device]
   760   C1704735:Regulator [Conceptual Entity]

Phrase: "(20,"

Phrase: "21"

Phrase: ")."
Processing 00000000.tx.75: In addition, defects of forkhead box P3 (FOXP3) underlie IPEX (immunodysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome, which also includes neonatal-onset diabetes (22). 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "defects of forkhead box P3 (FOXP3)"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   760   C0243067:defects [Functional Concept]
   726 E C1457869:Defect [Functional Concept]
   726 E C1861101:DEFECT [Disease or Syndrome]

Phrase: "underlie"

Phrase: "IPEX"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0342288:IPEX [Congenital Abnormality]
  1000   C3539774:IPEX [Gene or Genome]

Phrase: "(immunodysregulation,"

Phrase: "polyendocrinopathy,"

Phrase: "enteropathy,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021831:Enteropathy [Disease or Syndrome]

Phrase: "X-linked"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0241764:X-linked [Genetic Function]
   827   C1517892:Link [Intellectual Product]
   827   C1704666:Link [Intellectual Product]

Phrase: ")"

Phrase: "syndrome,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039082:Syndrome [Disease or Syndrome]

Phrase: "which also"

Phrase: "includes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332257:Includes [Functional Concept]
  1000   C1552866:include [Idea or Concept]
  1000   C2700399:Include [Activity]

Phrase: "neonatal-onset diabetes"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C0158981:Neonatal diabetes [Disease or Syndrome]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   734   C1855106:Neonatal onset [Finding]

Phrase: "(22"

Phrase: ")."
Processing 00000000.tx.76: While defects in glucokinase and KATP channel are predicted to impair glucose sensing of the -cell, leading to suppressed insulin release, mutations in IPF-1 and FOXP3 underlie decreased -cell mass; 

Phrase: "While"

Phrase: "defects in glucokinase"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   790   C0243067:defects [Functional Concept]
   756 E C1457869:Defect [Functional Concept]
   756 E C1861101:DEFECT [Disease or Syndrome]

Phrase: "and"

Phrase: "KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439799:Channel [Spatial Concept]
   861   C1706095:Channel [Conceptual Entity]

Phrase: "are"

Phrase: "predicted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0681842:Predicted [Idea or Concept]
  1000   C1882327:%{Predicted} [Quantitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "impair"

Phrase: "glucose sensing of the -cell,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C1658150:glucose sensing [Cell Function]
   726   C0036658:sense [Organ or Tissue Function]

Phrase: "leading to suppressed insulin release,"
Meta Candidates (Total=17; Excluded=5; Pruned=0; Remaining=12)
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0030685:Release [Health Care Activity]
   760   C0332152:Leading [Temporal Concept]
   760   C0391871:Release [Functional Concept]
   760   C0439180:% release [Quantitative Concept]
   760   C0680255:release [Health Care Activity]
   760   C1260953:Suppressed [Functional Concept]
   760   C1283071:Release [Functional Concept]
   760   C1522538:Leading [Functional Concept]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   760   C1963578:Release [Therapeutic or Preventive Procedure]
   726 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   726 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   726 E C2348269:Lead [Element, Ion, or Isotope]
   726 E C3275067:LEAD [Therapeutic or Preventive Procedure]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "mutations in IPF-1"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   753   C0026882:Mutations [Genetic Function]
   719 E C1705285:Mutation [Cell or Molecular Dysfunction]
   716   C0248419:insulin promoter factor 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   716   C1826562:INSULIN PROMOTER FACTOR 1 [Gene or Genome]

Phrase: "and"

Phrase: "FOXP3"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1416467:FORKHEAD BOX P3 [Gene or Genome]
   827   C1412751:P3 [Gene or Genome]
   827   C1427831:P3 [Gene or Genome]
   827   C1539372:p3 [Gene or Genome]
   734   C3273493:Fork Head Box [Amino Acid Sequence]

Phrase: "underlie"

Phrase: "decreased -cell mass"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0577559:Mass [Finding]
   827   C1306372:*Mass [Quantitative Concept]
   827   C3152252:Mass [Quantitative Concept]

Phrase: ";"
Processing 00000000.tx.77: IPF-1 through impaired pancreatic development and FOXP3 through autoimmune destruction of pancreatic islets (23,24). 

Phrase: "IPF-1 through impaired pancreatic development"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   833   C0248419:insulin promoter factor 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   833   C1826562:INSULIN PROMOTER FACTOR 1 [Gene or Genome]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   744   C1521761:Factor [Functional Concept]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]
   744   C2827422:Factor [Conceptual Entity]

Phrase: "and"

Phrase: "FOXP3 through autoimmune destruction of pancreatic islets"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C1416467:FORKHEAD BOX P3 [Gene or Genome]
   742   C1412751:P3 [Gene or Genome]
   742   C1427831:P3 [Gene or Genome]
   742   C1539372:p3 [Gene or Genome]

Phrase: "(23,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: "24"

Phrase: ")."
Processing 00000000.tx.78: In contrast to permanent neonatal diabetes, a majority of transient neonatal diabetes cases are attributable to paternal imprinting at chromosome 6q24 (25). 

Phrase: "In contrast to permanent neonatal diabetes,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0158981:Neonatal diabetes [Disease or Syndrome]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]

Phrase: "a majority of transient neonatal diabetes cases"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0680220:majority [Social Behavior]

Phrase: "are"

Phrase: "attributable to paternal imprinting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0596130:Attributable [Mental Process]

Phrase: "at chromosome 6q24"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1521572:6q24 [Cell Component]

Phrase: "(25"

Phrase: ")."
Processing 00000000.tx.79: Two candidate genes have been identified: ZAC (zinc finger protein that regulates apoptosis and cell-cycle arrest) and HYAMI (hydatidiform mole-associated and imprinted transcript), an untranslated mRNA of unknown function. 

Phrase: "Two candidate genes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C1332838:Candidate Genes [Gene or Genome]
   827   C0017337:Genes [Gene or Genome]

Phrase: "have"

Phrase: "been"

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: ":"

Phrase: "ZAC"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1335223:ZAC [Gene or Genome]
  1000   C1709407:ZAC [Gene or Genome]
  1000   C1825810:ZAC [Gene or Genome]

Phrase: "(zinc finger protein"
Meta Candidates (Total=12; Excluded=6; Pruned=0; Remaining=6)
   901   C0080347:Zinc Finger [Amino Acid Sequence]
   827   C0016129:Finger [Body Location or Region]
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0043481:Zinc [Biologically Active Substance,Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1281584:Finger [Body Part, Organ, or Organ Component]
   827   C2348288:Zinc [Element, Ion, or Isotope]
   771 E C0442015:Digital [Intellectual Product]
   771 E C1883674:Digital [Qualitative Concept]
   743 E C0549188:fingers [Quantitative Concept]
   734 E C0582802:Digit [Body Part, Organ, or Organ Component]
   734 E C1283912:Digit [Body Part, Organ, or Organ Component]
   734 E C3241971:Digit [Quantitative Concept]

Phrase: "that"

Phrase: "regulates"

Phrase: "apoptosis"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0162638:Apoptosis [Cell Function]
   928 E C1516044:Apoptotic [Qualitative Concept]

Phrase: "and"

Phrase: "cell-cycle arrest"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C1155873:Cell Cycle Arrest [Cell Function]
  1000   C1516332:Cell Cycle Arrest [Cell Function]
   827   C0237477:Arrest [Temporal Concept]
   827   C0392351:arrest [Governmental or Regulatory Activity]
   734   C0007586:Cell Cycle [Cell Function]
   734   C1155839:Cell Cycle [Cell Function]

Phrase: ")"

Phrase: "and"

Phrase: "HYAMI"

Phrase: "(hydatidiform mole-associated"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   827   C0332281:Associated [Qualitative Concept]
   793 E C0750490:Associate [Idea or Concept]
   793 E C1706221:Associate [Professional or Occupational Group]
   734   C0020217:Hydatidiform Mole [Neoplastic Process]
   734   C3463897:HYDATIDIFORM MOLE [Disease or Syndrome]

Phrase: "and"

Phrase: "imprinted transcript"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1519595:Transcript [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: ")"

Phrase: ","

Phrase: "an untranslated mRNA of unknown function."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.80: Recent genetic studies demonstrate that heterozygous mutations in KCNJ11, encoding the Kir6.2 subunit of the KATP channel, underlie neonatal diabetes in humans, accounting for both permanent neonatal diabetes (2631), in which type 1 autoantibodies are absent, and relapsing transient neonatal diabetes, in which chromosome 6 abnormalities were excluded (32,33). 

Phrase: "Recent genetic studies"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   884   C2827447:Genetic Study [Research Activity]
   827   C0947630:studies [Laboratory Procedure]
   793 E C0557651:Study [Manufactured Object]
   793 E C2603343:Study [Research Activity]

Phrase: "demonstrate"

Phrase: "that heterozygous mutations in KCNJ11,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0026882:Mutations [Genetic Function]
   726 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "encoding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1547699:Encoding [Idea or Concept]
  1000   C2700640:Encoding [Activity]

Phrase: "the Kir6.2 subunit of the KATP channel,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1711351:Subunit [Quantitative Concept]

Phrase: "underlie"

Phrase: "neonatal diabetes in humans,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C0158981:Neonatal diabetes [Disease or Syndrome]
   770   C0011847:Diabetes [Disease or Syndrome]
   770   C0011849:Diabetes [Disease or Syndrome]

Phrase: "accounting for both permanent neonatal diabetes"
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   790   C0158981:Neonatal diabetes [Disease or Syndrome]
   753   C0000938:Accounting [Occupational Activity]
   753   C0011847:Diabetes [Disease or Syndrome]
   753   C0011849:Diabetes [Disease or Syndrome]
   753   C0205355:Permanent [Temporal Concept]
   753   C1552240:Neonatal [Professional or Occupational Group]
   753   C1552264:Neonatal [Professional or Occupational Group]
   753   C2939425:Neonatal [Temporal Concept]
   719 E C1551359:account [Idea or Concept]
   719 E C2741673:Account # [Clinical Attribute]
   719 E C2981730:Account [Classification]

Phrase: "(2631"

Phrase: ")"

Phrase: ","

Phrase: "in which type 1 autoantibodies"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0004358:Autoantibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   734   C0441729:Type 1 [Classification]

Phrase: "are"

Phrase: "absent,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0332197:Absent [Quantitative Concept]
  1000   C2699517:ABSENT [Finding]
   928 E C0424530:Absences [Finding]
   928 E C1689985:Absence [Anatomical Abnormality]

Phrase: "and"

Phrase: "relapsing transient neonatal diabetes,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   861   C0158981:Neonatal diabetes [Disease or Syndrome]
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0011849:Diabetes [Disease or Syndrome]
   812   C0040704:Transient [Population Group]
   812   C0205374:Transient [Temporal Concept]
   812   C1552240:Neonatal [Professional or Occupational Group]
   812   C1552264:Neonatal [Professional or Occupational Group]
   812   C2939425:Neonatal [Temporal Concept]

Phrase: "in which chromosome 6 abnormalities"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   913   C0008625:Chromosome Abnormalities [Cell or Molecular Dysfunction]
   913   C0008626:Chromosome Abnormalities [Disease or Syndrome]
   827   C0000768:Abnormalities [Congenital Abnormality]
   827   C0000769:abnormalities [Functional Concept]
   793 E C1704258:Abnormality [Finding]
   743 E C0205161:Abnormal [Qualitative Concept]
   743 E C2347472:% Abnormal [Quantitative Concept]
   743 E C2699333:ABNORMAL [Intellectual Product]
   734   C0008669:Chromosome 6 [Cell Component]

Phrase: "were"

Phrase: "excluded"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1554077:Excluded [Idea or Concept]
  1000   C2828389:Excluded [Activity]
   966 E C0332196:Exclude [Functional Concept]

Phrase: "(32,"

Phrase: "33"

Phrase: ")."
Processing 00000000.tx.81: Both de novo appearance of Kir6.2 mutations and familial transmission have been reported (2631). 

Phrase: "Both de novo appearance of Kir6.2 mutations"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0233426:Appearance [Organism Attribute]
   744   C0700364:Appearance [Qualitative Concept]

Phrase: "and"

Phrase: "familial transmission"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0040722:transmission [Idea or Concept]
   861   C0242781:Transmission [Pathologic Function]
   861   C1521797:Transmission [Natural Phenomenon or Process]

Phrase: "have"

Phrase: "been"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "(2631"

Phrase: ")."
Processing 00000000.tx.82: Significantly, in all examined families, neonatal diabetes was observed only in individuals carrying the Kir6.2 mutations and not in other family members. 

Phrase: "Significantly,"

Phrase: "in all examined families,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0015576:Families [Family Group]
   861   C1704727:Family [Conceptual Entity]
   777 E C0241888:Familial [Functional Concept]

Phrase: "neonatal diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0158981:Neonatal diabetes [Disease or Syndrome]
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "was"

Phrase: "observed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441672:Observed [Functional Concept]

Phrase: "only in individuals"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0205171:Only [Quantitative Concept]
   790   C1720467:Only [Intellectual Product]
   756   C0027361:Individual [Population Group]
   756   C0237401:Individual [Human]

Phrase: "carrying"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0206243:Carrying [Activity]
   966 E C0699809:carry [Finding]

Phrase: "the Kir6.2 mutations"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]
   734   C1416578:Kir6.2 [Gene or Genome]

Phrase: "and"

Phrase: "not in other family members."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   806   C0086282:Family Members [Family Group]
   773 E C1611821:Family Member [Intellectual Product]
   760   C0015576:Family [Family Group]
   760   C0680022:members [Population Group]
   760   C1518422:Not [Functional Concept]
   760   C1704727:Family [Conceptual Entity]
   726 E C2698041:Member [Professional or Occupational Group]
Processing 00000000.tx.83: Interestingly, in a subgroup of patients carrying Kir6.2 mutations, permanent neonatal diabetes is part of a larger syndrome that often includes marked developmental delay in motor intellectual and social skills, muscle weakness, dysmorphic features, and epilepsy (27,29,30). 

Phrase: "Interestingly,"

Phrase: "in a subgroup"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1079230:subgroup [Virus]
  1000   C1515021:Subgroup [Classification]

Phrase: "of patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "carrying"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0206243:Carrying [Activity]
   966 E C0699809:carry [Finding]

Phrase: "Kir6.2 mutations,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]
   734   C1416578:Kir6.2 [Gene or Genome]

Phrase: "permanent neonatal diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0158981:Neonatal diabetes [Disease or Syndrome]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]

Phrase: "is"

Phrase: "part of a larger syndrome"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C1292711:Part of [Spatial Concept]
   760   C0449719:Part [Spatial Concept]
   760   C1709471:Part [Quantitative Concept]

Phrase: "that often"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332183:Often [Temporal Concept]

Phrase: "includes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332257:Includes [Functional Concept]
  1000   C1552866:include [Idea or Concept]
  1000   C2700399:Include [Activity]

Phrase: "marked developmental delay in motor"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   882   C1864913:Delay in motor development [Finding]
   844   C1852607:Motor developmental delay [Finding]
   806   C0424605:Developmental delay [Mental or Behavioral Dysfunction]
   797   C0520947:Motor delay [Disease or Syndrome]
   797   C1854301:Motor delay [Finding]
   762   C0870919:Motor Development [Organism Function]
   760   C0205421:Delay [Temporal Concept]
   760   C0458003:Developmental [Qualitative Concept]
   760   C0678723:Developmental [Organism Function]

Phrase: "intellectual"

Phrase: "and"

Phrase: "social skills,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0683256:social skills [Social Behavior]
   861   C0678856:skills [Individual Behavior]

Phrase: "muscle weakness,"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0030552:muscle weakness [Sign or Symptom]
  1000   C0151786:Muscle Weakness [Sign or Symptom]
   861   C0004093:Weakness [Sign or Symptom]
   861   C0026845:Muscle [Tissue]
   789 E C0442025:Muscular [Spatial Concept]
   789 E C1762617:Weak [Qualitative Concept]

Phrase: "dysmorphic features,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0432072:Dysmorphic features [Congenital Abnormality]
   827   C1521970:Feature [Qualitative Concept]
   827   C1706388:Feature [Conceptual Entity]
   827   C2346469:Feature [Qualitative Concept]
   827   C2348519:Feature [Qualitative Concept]

Phrase: "and"

Phrase: "epilepsy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0014544:Epilepsy [Disease or Syndrome]

Phrase: "(27,"

Phrase: "29,"

Phrase: "30"

Phrase: ")."
Processing 00000000.tx.84: Despite normal-sized cortex and cerebellum, a majority of patients with syndromic permanent neonatal diabetes also display language and social development that is delayed from 5 to 48 months (27). 

Phrase: "Despite normal-sized cortex"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0007776:Cortex [Body Part, Organ, or Organ Component]
   827   C1176472:Cortex [Body Part, Organ, or Organ Component]
   827   C2700441:Cortex [Plant]
   717   C0332506:Normal size [Quantitative Concept]

Phrase: "and"

Phrase: "cerebellum,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0007765:Cerebellum [Body Part, Organ, or Organ Component]
  1000   C1268981:Cerebellum [Body Part, Organ, or Organ Component]
  1000   C1707522:Cerebellum [Tissue]

Phrase: "a majority of patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0680220:majority [Social Behavior]

Phrase: "with syndromic permanent neonatal diabetes also"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   840   C0158981:Neonatal diabetes [Disease or Syndrome]
   804   C0011847:Diabetes [Disease or Syndrome]
   804   C0011849:Diabetes [Disease or Syndrome]

Phrase: "display"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705417:Display [Manufactured Object]

Phrase: "language"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023008:Language [Language]

Phrase: "and"

Phrase: "social development"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0037409:Social Development [Social Behavior]
   861   C0243107:development [Physiologic Function]
   861   C0678723:Development [Organism Function]
   861   C1527148:Development [Functional Concept]
   789 E C0458003:Developmental [Qualitative Concept]

Phrase: "that"

Phrase: "is"

Phrase: "delayed from 5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0205421:Delayed [Temporal Concept]
   790   C3272602:Delayed [Qualitative Concept]

Phrase: "to 48 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "(27"

Phrase: ")."
Processing 00000000.tx.85: There appears to be no correlation between the age of diagnosis and the severity of the permanent neonatal diabetes (syndromic versus nonsyndromic). 

Phrase: "There"

Phrase: "appears"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700364:APPEAR [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "no correlation between the age of diagnosis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1707520:Correlation [Qualitative Concept]

Phrase: "and"

Phrase: "the severity of the permanent neonatal diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0439793:Severity [Qualitative Concept]
   748   C2983285:Severity [Intellectual Product]

Phrase: "(syndromic"

Phrase: "versus"

Phrase: "nonsyndromic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2677304:Nonsyndromic [Finding]

Phrase: ")."
Processing 00000000.tx.86: As Kir6.2 represents the pore-forming subunit of KATP channels in skeletal muscle and in neurons throughout the brain (34,35), differentially overactive KATP channels in extrapancreatic tissue can potentially account for neurological disorders associated with this subgroup of patients through as-yet-to-be-defined mechanisms. 

Phrase: "As Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:Kir6.2 [Gene or Genome]

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "the pore-forming subunit of KATP channels"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1711351:Subunit [Quantitative Concept]

Phrase: "in skeletal muscle"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0242692:Muscle, Skeletal [Tissue]
  1000   C1280260:Skeletal muscle [Body Part, Organ, or Organ Component]
   861   C0026845:Muscle [Tissue]
   861   C0037253:skeletal [Body System]
   861   C0521324:Skeletal [Spatial Concept]
   789 E C0442025:Muscular [Spatial Concept]

Phrase: "and in neurons"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0027882:Neurons [Cell]
   790   C1515981:And [Idea or Concept]
   706 E C0521390:Neuronal [Immunologic Factor]

Phrase: "throughout the brain"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0006104:Brain [Body Part, Organ, or Organ Component]
  1000   C1269537:Brain [Body Part, Organ, or Organ Component]

Phrase: "(34,"

Phrase: "35"

Phrase: ")"

Phrase: ","

Phrase: "differentially overactive KATP channels in extrapancreatic tissue"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   714   C0439799:Channel [Spatial Concept]
   714   C1706095:Channel [Conceptual Entity]

Phrase: "can"

Phrase: "potentially"

Phrase: "account for neurological disorders"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0027765:Neurological Disorders [Disease or Syndrome]
   770   C0012634:Disorders [Disease or Syndrome]
   770   C0205494:Neurological [Qualitative Concept]
   770   C1551359:account [Idea or Concept]
   770   C2707261:Neurological [Clinical Attribute]
   770   C2741673:Account # [Clinical Attribute]
   770   C2981730:Account [Classification]

Phrase: "associated with this subgroup of patients"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   790   C0332281:Associated with [Qualitative Concept]
           Associated
   753   C0030705:Patients [Patient or Disabled Group]
   753   C1079230:subgroup [Virus]
   753   C1515021:Subgroup [Classification]
   719 E C0750490:Associate [Idea or Concept]
   719 E C1706221:Associate [Professional or Occupational Group]

Phrase: "through as-yet-to-"

Phrase: "be-"

Phrase: "defined mechanisms."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0441712:Mechanisms [Functional Concept]
   827 E C1706376:Mechanism [Manufactured Object]
Processing 00000000.tx.87: Neonatal diabetic subjects with Kir6.2 mutations demonstrate varying levels of C-peptide (27,3133,36) consistent with a varying degree of -cell dysfunction and likely accounting for the variable hyperglycemia often observed with neonatal diabetes. 

Phrase: "Neonatal diabetic subjects with Kir6.2 mutations"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   714   C0681850:Subject [Group]
   714   C1550501:{Subject} [Idea or Concept]
   714   C1706203:Subject [Idea or Concept]
   714   C2349001:Subject [Human]
   714   C2697811:Subject [Functional Concept]

Phrase: "demonstrate"

Phrase: "varying levels of C-peptide"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   844   C0202100:c peptide levels [Laboratory Procedure]
   760   C0441889:Levels [Qualitative Concept]
   726 E C0456079:Level [Classification]
   726 E C1547707:Level [Geographic Area]
   726 E C2946261:Level [Pharmacologic Substance]

Phrase: "(27,"

Phrase: "3133,"

Phrase: "36"

Phrase: ")"

Phrase: "consistent with a varying degree of -cell dysfunction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0332290:Consistent with [Idea or Concept]
           Consistent

Phrase: "and"

Phrase: "likely accounting for the variable hyperglycemia often"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0000938:Accounting [Occupational Activity]

Phrase: "observed with neonatal diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0158981:Neonatal diabetes [Disease or Syndrome]
   770   C0011847:Diabetes [Disease or Syndrome]
   770   C0011849:Diabetes [Disease or Syndrome]
   770   C1441672:Observed [Functional Concept]
   770   C1552240:Neonatal [Professional or Occupational Group]
   770   C1552264:Neonatal [Professional or Occupational Group]
   770   C2939425:Neonatal [Temporal Concept]
Processing 00000000.tx.88: Consistent with a defect at the level of KATP channel, affected patients carrying R201 mutations did not secrete insulin in response to glucose or glucagon but did in response to sulfonylurea (tolbutamide), albeit at subnormal levels (Fig. 2B) (27,30). 

Phrase: "Consistent with a defect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0332290:Consistent with [Idea or Concept]
           Consistent

Phrase: "at the level"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0441889:Level [Qualitative Concept]
  1000   C0456079:Level [Classification]
  1000   C1547707:Level [Geographic Area]
  1000   C2946261:Level [Pharmacologic Substance]

Phrase: "of KATP channel,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439799:Channel [Spatial Concept]
   861   C1706095:Channel [Conceptual Entity]

Phrase: "affected patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0522476:affected patients [Qualitative Concept]
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "carrying"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0206243:Carrying [Activity]
   966 E C0699809:carry [Finding]

Phrase: "R201 mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0026882:Mutations [Genetic Function]
   827 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "secrete"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1327616:secrete [Cell Function]

Phrase: "insulin in response"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   790   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   790   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   790   C1579433:Insulin [Pharmacologic Substance]
   734 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   706 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "to glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "or"

Phrase: "glucagon"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017687:Glucagon [Amino Acid, Peptide, or Protein,Hormone,Neuroreactive Substance or Biogenic Amine,Pharmacologic Substance]
  1000   C0876232:Glucagon [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "but"

Phrase: "did in response"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0871261:Response [Organism Attribute]
   790   C1704632:Response [Finding]
   790   C1706817:Response [Intellectual Product]
   790   C1707660:DID [Machine Activity]
   790   C2828361:Did [Activity]
   790   C2911692:Response [Mental Process]

Phrase: "to sulfonylurea"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
  1000   C3536898:Sulfonylurea [Pharmacologic Substance]

Phrase: "(tolbutamide"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040374:Tolbutamide [Organic Chemical,Pharmacologic Substance]
   944 E C0701229:Orinase [Organic Chemical,Pharmacologic Substance]

Phrase: ")"

Phrase: ","

Phrase: "albeit at subnormal levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   770   C0441889:Levels [Qualitative Concept]
   737 E C0456079:Level [Classification]
   737 E C1547707:Level [Geographic Area]
   737 E C2946261:Level [Pharmacologic Substance]

Phrase: "(Fig. 2B"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450354:2b [Intellectual Product]
   861   C1706096:2B [Research Activity]

Phrase: ")"

Phrase: "(27,"

Phrase: "30"

Phrase: ")."
Processing 00000000.tx.89: Importantly, several patients have now been weaned from insulin onto glibenclamide therapy, and at 1- to 6-month follow-ups, blood glucose has been well controlled without insulin supplement (31,36). 

Phrase: "Importantly,"

Phrase: "several patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "have"

Phrase: "now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "been"

Phrase: "weaned from insulin"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   790   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   790   C0043084:weaned [Organism Function]
   790   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   790   C1579433:Insulin [Pharmacologic Substance]
   734 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   706 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "onto glibenclamide therapy,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]

Phrase: "and"

Phrase: "at 1-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1412113:AT-1 [Gene or Genome]
   861   C1516077:At [Spatial Concept]

Phrase: "to 6-month follow-ups,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0332283:follow [Temporal Concept]
   812   C1719822:Follow [Intellectual Product]
   812   C3542434:UPS [Intellectual Product]

Phrase: "blood glucose"
Meta Candidates (Total=12; Excluded=7; Pruned=0; Remaining=5)
  1000   C0005802:Blood Glucose [Carbohydrate]
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: "has"

Phrase: "been"

Phrase: "well controlled without insulin supplement"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   760   C0205170:Well [Qualitative Concept]
   760   C2587213:Controlled [Functional Concept]
   760   C3146287:Well [Manufactured Object]
   726 E C0243148:control [Qualitative Concept]
   726 E C1550141:Control [Substance]
   726 E C1882979:Control [Conceptual Entity]
   726 E C3274648:Control [Qualitative Concept]

Phrase: "(31,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: "36"

Phrase: ")."
Processing 00000000.tx.90: In many cases, however, the oral dosage of sulfonylureas significantly exceeds (by several-fold) the doses commonly used to treat type 2 diabetes (36,37). 

Phrase: "In many cases,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0868928:Cases [Functional Concept]
  1000   C1533148:Cases [Quantitative Concept]
   966 E C1706255:CASE [Medical Device]
   966 E C1706256:Case [Conceptual Entity]

Phrase: "however,"

Phrase: "the oral dosage of sulfonylureas significantly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0178602:Dosage [Quantitative Concept]

Phrase: "exceeds"

Phrase: "("

Phrase: "by several-fold"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0332462:Fold [Spatial Concept]
   861   C0439064:Several [Quantitative Concept]
   861   C0443302:Several [Quantitative Concept]
   861   C1880834:FOLD [Phenomenon or Process]

Phrase: ")"

Phrase: "the doses commonly"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0178602:Doses [Quantitative Concept]
   827 E C0869039:Dose [Quantitative Concept]
   827 E C1114758:Dose # [Clinical Attribute]
   827 E C1428722:DOS [Gene or Genome]

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "treat"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1292734:TREAT [Functional Concept]
  1000   C1522326:Treat [Functional Concept]

Phrase: "type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "(36,"

Phrase: "37"

Phrase: ")."
Processing 00000000.tx.91: Consistent with this clinical observation, the neonatal diabetescausing mutations in Kir6.2 are frequently associated with a concomitant decrease in sensitivity of the KATP channel to sulfonylureas (27,38,39), which may underlie the increased therapeutic dosages. 

Phrase: "Consistent with this clinical observation,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C0332290:Consistent with [Idea or Concept]
           Consistent

Phrase: "the neonatal diabetescausing mutations in Kir6.2"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   748   C0026882:Mutations [Genetic Function]
   714 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "are"

Phrase: "frequently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332183:Frequently [Temporal Concept]

Phrase: "associated with a concomitant decrease"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   760   C0392756:Decrease [Qualitative Concept]
   760   C0521115:Concomitant [Temporal Concept]
   760   C0547047:Decrease [Quantitative Concept]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]

Phrase: "in sensitivity"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0036667:Sensitivity [Quantitative Concept]
  1000   C0312418:Sensitivity [Mental Process]
  1000   C0427965:Sensitivity [Finding]
  1000   C1511883:Sensitivity [Quantitative Concept]
  1000   C1522640:Sensitivity [Qualitative Concept]
  1000   C2346484:SENSITIVITY [Phenomenon or Process]
  1000   C2349185:Sensitivity [Qualitative Concept]
   928 E C0332324:Sensitive [Functional Concept]
   928 E C1550474:sensitive [Idea or Concept]

Phrase: "of the KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439799:Channel [Spatial Concept]
   861   C1706095:Channel [Conceptual Entity]

Phrase: "to sulfonylureas"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0038766:SULFONYLUREAS [Organic Chemical,Pharmacologic Substance]
   966 E C3536898:Sulfonylurea [Pharmacologic Substance]

Phrase: "(27,"

Phrase: "38,"

Phrase: "39"

Phrase: ")"

Phrase: ","

Phrase: "which"

Phrase: "may"

Phrase: "underlie"

Phrase: "the increased therapeutic dosages."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0178602:Dosages [Quantitative Concept]
Processing 00000000.tx.92: As additional mutations are uncovered, it is becoming clear that the temporal presentation of the disease can be quite variable. 

Phrase: "As additional mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0026882:Mutations [Genetic Function]
   827 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "are"

Phrase: "uncovered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439845:Uncovered [Functional Concept]

Phrase: ","

Phrase: "it"

Phrase: "is"

Phrase: "becoming"

Phrase: "clear"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2963144:Clear [Qualitative Concept]

Phrase: "that"

Phrase: "the temporal presentation of the disease"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   783   C3274800:Disease Presentation [Clinical Attribute]
   753   C0449450:Presentation [Idea or Concept]

Phrase: "can"

Phrase: "be"

Phrase: "quite variable."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439828:Variable [Qualitative Concept]
Processing 00000000.tx.93: One patient was diagnosed at only 26 weeks of age (27) and another at 5 years (32). 

Phrase: "One patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "was"

Phrase: "diagnosed at only 26 weeks of age (27"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   744   C0001779:Age [Organism Attribute]
   744   C0011900:Diagnosed [Finding]
   744   C0205171:Only [Quantitative Concept]
   744   C0439230:weeks [Temporal Concept]
   744   C1720467:Only [Intellectual Product]
   711 E C0332174:/week [Temporal Concept]

Phrase: ")"

Phrase: "and"

Phrase: "another at 5 years"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0439234:years [Temporal Concept]
   737 E C0439508:/year [Temporal Concept]

Phrase: "(32"

Phrase: ")."
Processing 00000000.tx.94: Within a single pedigree, one Kir6.2 mutation (C42R) is shown to underlie transient neonatal diabetes, childhood-onset diabetes, as well an apparently type 2 diabetes, all in different carriers (33). 

Phrase: "Within a single pedigree,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030761:Pedigree [Intellectual Product]

Phrase: "one Kir6.2 mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0026882:Mutation [Genetic Function]
   812   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "(C42R"

Phrase: ")"

Phrase: "is"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "underlie"

Phrase: "transient neonatal diabetes,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   901   C0158981:Neonatal diabetes [Disease or Syndrome]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0040704:Transient [Population Group]
   827   C0205374:Transient [Temporal Concept]
   827   C1552240:Neonatal [Professional or Occupational Group]
   827   C1552264:Neonatal [Professional or Occupational Group]
   827   C2939425:Neonatal [Temporal Concept]

Phrase: "childhood-onset diabetes,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   734   C1837352:Childhood onset [Finding]

Phrase: "as well"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205170:Well [Qualitative Concept]
  1000   C3146287:Well [Manufactured Object]

Phrase: "an apparently type 2 diabetes,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0011860:Type 2 Diabetes [Disease or Syndrome]
   875   C1320657:type diabetes [Finding]
   861   C0441730:Type 2 [Classification]
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0011849:Diabetes [Disease or Syndrome]
   812   C0332307:Type [Qualitative Concept]
   812   C1547052:*Type [Quantitative Concept]

Phrase: "all in different carriers"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   770   C0007294:carriers [Finding]
   770   C0444868:All [Quantitative Concept]
   770   C1705242:Different [Qualitative Concept]
   770   C3539085:All [Idea or Concept]
   737 E C0560175:Carrier [Finding]
   737 E C1706209:Carrier [Medical Device]
   737 E C3273162:Carrier [Intellectual Product]

Phrase: "(33"

Phrase: ")."
Processing 00000000.tx.95: Such late presentation suggests that the disease may become apparent at much later ages than typically ascribed, consistent with the notion that the mildest forms of the disease may not manifest until adulthood. 

Phrase: "Such late presentation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0449450:Presentation [Idea or Concept]

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "the disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]

Phrase: "may"

Phrase: "become"

Phrase: "apparent at much later ages"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   797   C0521994:Apparent age [Organism Attribute]
   760   C0750489:apparent [Idea or Concept]

Phrase: "than typically"

Phrase: "ascribed"

Phrase: ","

Phrase: "consistent with the notion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0332290:Consistent with [Idea or Concept]
           Consistent

Phrase: "that"

Phrase: "the mildest forms of the disease"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   753   C0348078:forms [Qualitative Concept]
   753   C0376315:Forms [Manufactured Object]
   719 E C1522492:Form [Functional Concept]

Phrase: "may"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "manifest until adulthood."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0205319:Manifest [Functional Concept]
   790   C0700597:Adulthood [Temporal Concept]
Processing 00000000.tx.96: This raises the additional possibility that if the disease manifests postnatally, it may be misdiagnosed as type 1 diabetes. 

Phrase: "This"

Phrase: "raises"

Phrase: "the additional possibility"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   789   C0332149:Possible [Qualitative Concept]
   789   C1705910:Possible [Qualitative Concept]
   789   C2362652:Possible [Qualitative Concept]

Phrase: "that"

Phrase: "if"

Phrase: "the disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]

Phrase: "manifests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205319:Manifest [Functional Concept]

Phrase: "postnatally,"

Phrase: "it"

Phrase: "may"

Phrase: "be"

Phrase: "misdiagnosed as type 1 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   862   C0011854:Type 1 diabetes [Disease or Syndrome]
   806   C0441729:Type 1 [Classification]
   797   C1320657:Diabetes type [Finding]
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0332307:Type [Qualitative Concept]
   760   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.97: So far, however, screening of children diagnosed with type 1 diabetes before 2 years of age, and lacking predisposing HLA genotypes, has failed to demonstrate a significant number of KCNJ11 mutations (28). 

Phrase: "So"

Phrase: "far,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205108:far [Spatial Concept]

Phrase: "however,"

Phrase: "screening of children"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   790   C0008059:Children [Age Group]
   790   C0220908:Screening [Health Care Activity]
   790   C0220909:screening [Functional Concept]
   790   C0680063:Children [Family Group]
   790   C1698960:screening [Intellectual Product]
   790   C1710031:Screening [Diagnostic Procedure]
   790   C1710477:SCREENING [Research Activity]
   756 E C1305399:screen [Functional Concept]
   756 E C1705053:Screen [Medical Device]

Phrase: "diagnosed with type 1 diabetes"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   862   C0011854:Type 1 diabetes [Disease or Syndrome]
   806   C0441729:Type 1 [Classification]
   797   C1320657:Diabetes type [Finding]
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0011900:Diagnosed [Finding]
   760   C0332307:Type [Qualitative Concept]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "before 2 years"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439234:years [Temporal Concept]
   827 E C0439508:/year [Temporal Concept]

Phrase: "of age,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001779:Age [Organism Attribute]

Phrase: "and"

Phrase: "lacking predisposing HLA genotypes,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0017431:Genotypes [Organism Attribute]

Phrase: "has"

Phrase: "failed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:Failed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "demonstrate"

Phrase: "a significant number of KCNJ11 mutations"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0237753:*Number [Quantitative Concept]
   753   C0449788:Number [Quantitative Concept]

Phrase: "(28"

Phrase: ")."
Processing 00000000.tx.98: Polymorphisms of Kir6.2 predispose to adult-onset diabetes. 

Phrase: "Polymorphisms of Kir6.2"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0032529:polymorphisms [Genetic Function]
   737 E C1882417:Polymorphism [Qualitative Concept]

Phrase: "predispose to adult-onset diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   862   C0011860:Adult-Onset Diabetes [Disease or Syndrome]
   806   C1836537:Adult onset [Finding]
   760   C0001675:Adult [Age Group]
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0332162:Onset [Qualitative Concept]
   760   C1706450:Adult [Human]
Processing 00000000.tx.99: Numerous studies have now examined the association of KATP channel polymorphisms with late-onset type 2 diabetes (4044). 

Phrase: "Numerous studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "have"

Phrase: "now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "examined"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332128:Examined [Finding]

Phrase: "the association of KATP channel polymorphisms"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0004083:Association [Mental Process]
   753   C0439849:Association [Qualitative Concept]
   753   C0596306:Association [Phenomenon or Process]
   753   C0699792:association [Social Behavior]

Phrase: "with late-onset type 2 diabetes"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   911   C0011860:late onset diabetes [Disease or Syndrome]
           Type 2 Diabetes
   853   C1320657:type diabetes [Finding]
   840   C0441730:Type 2 [Classification]
   804   C0011847:Diabetes [Disease or Syndrome]
   804   C0011849:Diabetes [Disease or Syndrome]
   804   C0332307:Type [Qualitative Concept]
   804   C1547052:*Type [Quantitative Concept]

Phrase: "(4044"

Phrase: ")."
Processing 00000000.tx.100: By suppressing excitability, KATP channel polymorphisms that increase channel activity could, in combination with other environmental and genetic factors, contribute to chronically impaired -cell function. 

Phrase: "By suppressing excitability,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0235169:Excitability [Sign or Symptom]
   789 E C0857393:excitable [Sign or Symptom]

Phrase: "KATP channel polymorphisms"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0032529:polymorphisms [Genetic Function]
   793 E C1882417:Polymorphism [Qualitative Concept]

Phrase: "that"

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "channel activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1153410:channel activity [Molecular Function]
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "could"

Phrase: ","

Phrase: "in combination"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205195:Combination [Qualitative Concept]
  1000   C1947911:Combination [Physical Object]

Phrase: "with other environmental"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0014406:Environmental [Spatial Concept]

Phrase: "and"

Phrase: "genetic factors,"
Meta Candidates (Total=18; Excluded=14; Pruned=0; Remaining=4)
   861   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   861   C0314603:Genetic [Functional Concept]
   827   C1521761:Factor [Functional Concept]
   827   C2827422:Factor [Conceptual Entity]
   805 E C0005615:Birth [Organism Function]
   805 E C0035150:Reproduction [Organism Function]
   805 E C0079946:origin [Classification]
   805 E C0439659:Origin [Temporal Concept]
   805 E C1550512:origin [Intellectual Product]
   805 E C1550722:birth [Idea or Concept]
   805 E C3245487:birth [Intellectual Product]
   777 E C0454729:Natal [Geographic Area]
   777 E C0559522:Genital [Body System]
   777 E C1546649:Genital [Intellectual Product]
   777 E C1550642:Genital [Body Substance]
   768 E C0205313:Original [Idea or Concept]
   768 E C2347409:Original [Occupational Activity]
   750 E C0598240:originality [Mental Process]

Phrase: "contribute"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1880177:Contribute [Activity]

Phrase: "to chronically"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1883351:To [Qualitative Concept]

Phrase: "impaired -"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0221099:Impaired [Functional Concept]
  1000   C0684336:Impaired [Pathologic Function]

Phrase: "cell function."
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
  1000   C0007613:Cell Function [Cell Function]
   861   C0007634:Cell [Cell]
   861   C0031843:function [Physiologic Function]
   861   C0542341:Function [Functional Concept]
   861   C0700205:FUNCTION [Classification]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1705273:Function [Intellectual Product]
   861   C1948049:Cell [Spatial Concept]
   789 E C0205245:Functional [Functional Concept]
   789 E C2700217:Functional [Conceptual Entity]
Processing 00000000.tx.101: In the face of insulin resistance, this is expected to exacerbate the hyperglycemic state. 

Phrase: "In the face"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015450:Face [Body Location or Region]
  1000   C1281591:Face [Body Part, Organ, or Organ Component]

Phrase: "of insulin resistance,"
Meta Candidates (Total=12; Excluded=5; Pruned=0; Remaining=7)
  1000   C0021655:Insulin Resistance [Pathologic Function]
  1000   C2700570:INSULIN RESISTANCE [Gene or Genome]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0237834:Resistance [Mental Process]
   861   C1514892:Resistance [Physiologic Function]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   789 E C0332325:Resistant [Functional Concept]
   789 E C1550464:resistent [Idea or Concept]
   789 E C2827757:RESISTANT [Laboratory or Test Result]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "this"

Phrase: "is"

Phrase: "expected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1517001:Expected [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "exacerbate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0436331:exacerbate [Finding]

Phrase: "the hyperglycemic state."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1301808:State [Geographic Area]
   861   C1442792:State [Functional Concept]
   861   C3148680:State [Geographic Area]
Processing 00000000.tx.102: Although results from initial studies are conflicting (45,46), large-scale association studies and meta-analyses have now identified the E23K polymorphism in KCNJ11 as a slight, but significant, risk factor in the complex development of type 2 diabetes (42,44,4750). 

Phrase: "Although"

Phrase: "results from initial studies"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   819   C0683954:results studies [Finding]
   737   C1274040:Result [Functional Concept]
   737   C1546471:Result [Idea or Concept]
   737   C2825142:Result [Finding]

Phrase: "are"

Phrase: "conflicting"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0009671:conflicting [Individual Behavior]
   966 E C1705242:Conflict [Qualitative Concept]

Phrase: "(45,"

Phrase: "46"

Phrase: ")"

Phrase: ","

Phrase: "large-scale association studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   812   C0947630:studies [Laboratory Procedure]
   779 E C0557651:Study [Manufactured Object]
   779 E C2603343:Study [Research Activity]

Phrase: "and"

Phrase: "meta-analyses"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0920317:meta-analyses [Research Activity]
   966 E C0282458:Meta-Analysis [Intellectual Product]
   861   C1042496:Meta [Eukaryote]
   827   C0002778:Analysis [Laboratory Procedure]
   827   C0936012:Analysis [Research Activity]
   827   C1524024:analysis [Functional Concept]

Phrase: "have"

Phrase: "now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: "the E23K polymorphism in KCNJ11"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0032529:Polymorphism [Genetic Function]
   760   C1882417:Polymorphism [Qualitative Concept]

Phrase: "as a slight,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2937276:Slight [Qualitative Concept]
  1000   C2945599:Slight [Qualitative Concept]

Phrase: "but"

Phrase: "significant, risk factor in the complex development of type 2 diabetes"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   756   C0035648:Risk factor [Quantitative Concept]
   754   C1171304:diabetes risk [Quantitative Concept]
   738   C0035647:Risk [Qualitative Concept]
   738   C1521761:Factor [Functional Concept]
   738   C2827422:Factor [Conceptual Entity]

Phrase: "(42,"

Phrase: "44,"

Phrase: "4750"

Phrase: ")."
Processing 00000000.tx.103: However, given the high allelic frequency of E23K in the general population (frequency of heterozygous EK genotype = 47%; homozygous KK genotype = 12%), the polymorphism is likely to represent a large population-attributable risk (41,48,51,52). 

Phrase: "However,"

Phrase: "given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "the high allelic frequency of E23K"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C0017270:allelic frequency [Quantitative Concept]
   783   C0205212:High frequency [Temporal Concept]
   753   C0376249:frequency [Quantitative Concept]
   753   C0439603:Frequency [Temporal Concept]
   753   C0871396:Frequency [Quantitative Concept]
   753   C1561548:Frequency [Qualitative Concept]
   753   C1705502:Frequency [Quantitative Concept]

Phrase: "in the general population"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0683971:General Population [Population Group]
   861   C0032659:Population [Quantitative Concept]
   861   C1257890:Population [Population Group]

Phrase: "(frequency of heterozygous EK genotype"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0376249:frequency [Quantitative Concept]
   760   C0439603:Frequency [Temporal Concept]
   760   C0871396:Frequency [Quantitative Concept]
   760   C1561548:Frequency [Qualitative Concept]
   760   C1705502:Frequency [Quantitative Concept]

Phrase: "= 47%"

Phrase: "; homozygous KK genotype"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   913   C0019904:homozygous genotype [Organism Attribute]
   827   C0017431:Genotype [Organism Attribute]

Phrase: "= 12%"

Phrase: ")"

Phrase: ","

Phrase: "the polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032529:Polymorphism [Genetic Function]
  1000   C1882417:Polymorphism [Qualitative Concept]

Phrase: "is"

Phrase: "likely to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332148:Likely [Qualitative Concept]
   861   C0750492:Likely [Idea or Concept]

Phrase: "represent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "a large population-attributable risk"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   923   C1514229:Population Attributable Risk [Quantitative Concept]
   875   C0242444:population risk [Population Group]
   875   C2987720:Population risk [Quantitative Concept]
   861   C0814766:Attributable Risk [Qualitative Concept]
   812   C0032659:Population [Quantitative Concept]
   812   C0035647:Risk [Qualitative Concept]
   812   C0596130:Attributable [Mental Process]
   812   C1257890:Population [Population Group]

Phrase: "(41,"

Phrase: "48,"

Phrase: "51,"

Phrase: "52"

Phrase: ")."
Processing 00000000.tx.104: Importantly, a recent haplotype analysis of the Kir6.2/SUR1 gene region has demonstrated a strong allelic association of E23K in Kir6.2 with a polymorphism in SUR1 (A1369S), raising the possibility that E23K alone may not entirely account for the reported association with type 2 diabetes (49). 

Phrase: "Importantly,"

Phrase: "a recent haplotype analysis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0002778:Analysis [Laboratory Procedure]
   827   C0936012:Analysis [Research Activity]
   827   C1524024:analysis [Functional Concept]

Phrase: "of the Kir6.2/SUR1 gene region"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   795   C0017446:Region [Geographic Area]
   795   C0205147:Region [Spatial Concept]
   724 E C0205276:Regional [Spatial Concept]
   724 E C1947913:Regional [Spatial Concept]

Phrase: "has"

Phrase: "demonstrated"

Phrase: "a strong allelic association of E23K"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0004083:Association [Mental Process]
   753   C0439849:Association [Qualitative Concept]
   753   C0596306:Association [Phenomenon or Process]
   753   C0699792:association [Social Behavior]

Phrase: "in Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:Kir6.2 [Gene or Genome]

Phrase: "with a polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032529:Polymorphism [Genetic Function]
  1000   C1882417:Polymorphism [Qualitative Concept]

Phrase: "in SUR1"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   827   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   827   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   827   C3536898:Sulfonylurea [Pharmacologic Substance]

Phrase: "(A1369S"

Phrase: ")"

Phrase: ","

Phrase: "raising"

Phrase: "the possibility"

Phrase: "that E23K"

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "may"

Phrase: "not entirely"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "account for the reported association"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   760   C0004083:Association [Mental Process]
   760   C0439849:Association [Qualitative Concept]
   760   C0596306:Association [Phenomenon or Process]
   760   C0684224:Reported [Intellectual Product]
   760   C0699792:association [Social Behavior]
   760   C0700287:Reported [Health Care Activity]
   760   C1551359:account [Idea or Concept]
   760   C2741673:Account # [Clinical Attribute]
   760   C2981730:Account [Classification]
   760   C3496591:Reported [Clinical Attribute]
   726 E C3273238:Report [Intellectual Product]

Phrase: "with type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "(49"

Phrase: ")."
Processing 00000000.tx.105: Cellular basis of KATP channel diabetes. 

Phrase: "Cellular basis of KATP channel diabetes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1527178:Basis [Functional Concept]
   753   C1874451:Basis [Pharmacologic Substance]
Processing 00000000.tx.106: Recombinant expression of mutant channels indicates that both the type 2associated polymorphism (E23K) and neonatal diabetesassociated Kir6.2 mutations result in reduced sensitivity to intracellular ATP, either by reducing ATP affinity per se or indirectly via an increase in the intrinsic open-state stability (27,38,39,51,53) (see below). 

Phrase: "Recombinant expression of mutant channels"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "indicates"

Phrase: "that"

Phrase: "both the type 2associated polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0032529:Polymorphism [Genetic Function]
   827   C1882417:Polymorphism [Qualitative Concept]

Phrase: "(E23K"

Phrase: ")"

Phrase: "and"

Phrase: "neonatal diabetesassociated Kir6.2 mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   804   C0026882:Mutations [Genetic Function]
   771 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "result in reduced sensitivity"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   770   C0036667:Sensitivity [Quantitative Concept]
   770   C0312418:Sensitivity [Mental Process]
   770   C0392756:Reduced [Qualitative Concept]
   770   C0427965:Sensitivity [Finding]
   770   C1274040:Result [Functional Concept]
   770   C1511883:Sensitivity [Quantitative Concept]
   770   C1522640:Sensitivity [Qualitative Concept]
   770   C1546471:Result [Idea or Concept]
   770   C2346484:SENSITIVITY [Phenomenon or Process]
   770   C2349185:Sensitivity [Qualitative Concept]
   770   C2825142:Result [Finding]

Phrase: "to intracellular ATP,"

Phrase: "either by reducing ATP affinity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0392756:Reducing [Qualitative Concept]
   760   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "per se"

Phrase: "or"

Phrase: "indirectly via an increase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0442805:Increase [Functional Concept]

Phrase: "in the intrinsic open-state stability"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   812   C0175566:Open [Spatial Concept]
   812   C0205360:Stability [Qualitative Concept]
   812   C1301808:State [Geographic Area]
   812   C1442792:State [Functional Concept]
   812   C2347098:Stability [Qualitative Concept]
   812   C3148680:State [Geographic Area]
   741 E C0547049:Openness [Spatial Concept]
   741 E C1547311:Stable [Intellectual Product]

Phrase: "(27,"

Phrase: "38,"

Phrase: "39,"

Phrase: "51,"

Phrase: "53"

Phrase: ")"

Phrase: "("

Phrase: "see below"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0042789:see [Organism Function]
   833   C1947903:See [Activity]

Phrase: ")."
Processing 00000000.tx.107: At the cellular level, an important question is: Just how much change in ATP sensitivity is necessary to cause significant impairment of insulin secretion? 

Phrase: "At the cellular level,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0441889:Level [Qualitative Concept]
   861   C0456079:Level [Classification]
   861   C1547707:Level [Geographic Area]
   861   C2946261:Level [Pharmacologic Substance]

Phrase: "an important question"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1522634:Question [Intellectual Product]

Phrase: "is"

Phrase: ":"

Phrase: "Just how"

Phrase: "much change in ATP sensitivity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0392747:Change [Functional Concept]
   760   C0443172:change [Quantitative Concept]
   760   C1705241:Change [Quantitative Concept]

Phrase: "is"

Phrase: "necessary to"

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "significant impairment of insulin secretion?"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0684336:Impairment [Pathologic Function]
Processing 00000000.tx.108: The diabetic phenotype of transgenic mice expressing "overactive" KATP channels in -cells predicted the correlate disease in humans and is a potentially relevant model (11). 

Phrase: "The diabetic phenotype of transgenic mice"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0031437:Phenotype [Organism Attribute]
   753   C1285572:Phenotype [Laboratory Procedure]

Phrase: "expressing"

Phrase: """overactive"" KATP channels in -cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   804   C0007634:Cells [Cell]
   804   C3282337:Cells [Cell]
   771 E C1269647:Cell [Cell]
   771 E C1704653:Cell [Medical Device]
   771 E C1948049:Cell [Spatial Concept]

Phrase: "predicted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0681842:Predicted [Idea or Concept]
  1000   C1882327:%{Predicted} [Quantitative Concept]

Phrase: "the"

Phrase: "correlate"

Phrase: "disease in humans"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   790   C0012634:Disease [Disease or Syndrome]
   734 E C1836721:MALS [Finding]
   734 E C3538764:MALS [Gene or Genome]
   734 E C3540595:MAL [Gene or Genome]

Phrase: "and"

Phrase: "is"

Phrase: "a potentially relevant model"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C3161035:Model [Intellectual Product]

Phrase: "(11"

Phrase: ")."
Processing 00000000.tx.109: These mice express Kir6.2 subunits with truncated NH2-termini, which causes a 10-fold reduction of ATP sensitivity in heterologously expressed channels. 

Phrase: "These mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025914:Mice [Mammal]
  1000   C0025929:mice [Mammal]
  1000   C0026809:Mice [Mammal]

Phrase: "express"

Phrase: "Kir6.2 subunits with truncated NH2-termini,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   714   C1711351:Subunit [Quantitative Concept]

Phrase: "which"

Phrase: "causes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0015127:cause [Functional Concept]
  1000   C1314792:Causes [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "a 10-fold reduction of ATP sensitivity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0301630:Reduction [Natural Phenomenon or Process]
   748   C0392756:Reduction [Qualitative Concept]
   748   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "in heterologously expressed channels."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C0439799:Channel [Spatial Concept]
   793   C1706095:Channel [Conceptual Entity]
Processing 00000000.tx.110: Transgenic F1 mice from four of five founder lines expressing the truncated channels were severely hyperglycemic, and hypoinsulinemic, and died as neonates by day 5, most likely from acute ketoacidosis (Fig. 2A). 

Phrase: "Transgenic F1 mice from four of five founder lines"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   781   C1450009:Founder Mice, Transgenic [Mammal]
   762   C0025936:Mice, Transgenic [Mammal]
   742   C0025914:Mice [Mammal]
   742   C0025929:mice [Mammal]
   742   C0026809:Mice [Mammal]

Phrase: "expressing"

Phrase: "the truncated channels"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439799:Channel [Spatial Concept]
   827   C1706095:Channel [Conceptual Entity]

Phrase: "were"

Phrase: "severely hyperglycemic,"

Phrase: "and"

Phrase: "hypoinsulinemic,"

Phrase: "and"

Phrase: "died as neonates"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   790   C0011065:Died [Organism Function]
   790   C0021289:Neonates [Age Group]
   790   C1546956:Died [Finding]
   756 E C2239178:Neonate [Finding]
   756 E C2939425:Neonate, NOS [Temporal Concept]
   718 E C0231800:Expired [Organ or Tissue Function]
   718 E C1704631:Expire [Idea or Concept]

Phrase: "by day 5,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0332173:/day [Temporal Concept]
   861   C0439228:day [Temporal Concept]
   861   C0439505:/day [Temporal Concept]

Phrase: "most likely from acute ketoacidosis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0750501:most likely [Idea or Concept]
   760   C0332148:Likely [Qualitative Concept]
   760   C0750492:Likely [Idea or Concept]

Phrase: "(Fig. 2A"

Phrase: ")."
Processing 00000000.tx.111: Electrophysiology confirmed functional expression of KATP channels with reduced ATP sensitivity, but only approximately fourfold relative to wild type. 

Phrase: "Electrophysiology"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0013865:Electrophysiology [Biomedical Occupation or Discipline]
  1000   C1446476:Electrophysiology [Diagnostic Procedure]

Phrase: "confirmed"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0521093:confirmed [Qualitative Concept]
  1000   C0750484:Confirmed [Idea or Concept]
   966 E C1456348:Confirm [Qualitative Concept]

Phrase: "functional expression of KATP channels"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "with reduced ATP sensitivity,"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   827   C0036667:Sensitivity [Quantitative Concept]
   827   C0312418:Sensitivity [Mental Process]
   827   C0427965:Sensitivity [Finding]
   827   C1511883:Sensitivity [Quantitative Concept]
   827   C1522640:Sensitivity [Qualitative Concept]
   827   C2346484:SENSITIVITY [Phenomenon or Process]
   827   C2349185:Sensitivity [Qualitative Concept]
   755 E C0332324:Sensitive [Functional Concept]
   755 E C1550474:sensitive [Idea or Concept]

Phrase: "but"

Phrase: "only approximately fourfold relative to wild type."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0080103:Relative [Family Group]
   748   C0205345:Relative [Qualitative Concept]
   748   C1547039:*Relative [Quantitative Concept]
Processing 00000000.tx.112: Heterologously expressed Kir.2[E23K]-SUR1 channels exhibit even more modest 2- and 1.5-fold reductions in ATP sensitivity for homozygous (Kir6.2[E23K]) and heterozygous (Kir6.2[E23K] + Kir6.2wt) channels, respectively (51 and J.C.K., unpublished observations: K1/2 [ATP] for Kir6.2wt = 10.7  1.9 mol/l, Kir6.2[E23K] = 17.6  0.9 mol/l [expressed in COSm6 cells]), as well as enhanced MgADP stimulation (51,52,53,54). 

Phrase: "Heterologously expressed Kir.2"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0017550:KIR [Geographic Area]
   812   C0665952:KIR [Amino Acid, Peptide, or Protein,Receptor]
   812   C1415041:KIR [Gene or Genome]
   812   C3540490:KIR [Gene or Genome]

Phrase: "[E23K"

Phrase: "]-SUR1 channels"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   779   C0439799:Channel [Spatial Concept]
   779   C1706095:Channel [Conceptual Entity]

Phrase: "exhibit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0015272:Exhibit [Intellectual Product]

Phrase: "even more modest 2-"

Phrase: "and"

Phrase: "1.5-fold reductions in ATP sensitivity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   748   C0301630:reductions [Natural Phenomenon or Process]
   748   C0441610:reductions [Therapeutic or Preventive Procedure]
   714 E C0392756:Reduction [Qualitative Concept]

Phrase: "for homozygous"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0019904:Homozygous [Organism Attribute]

Phrase: "(Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:Kir6.2 [Gene or Genome]

Phrase: "[E23K"

Phrase: "]"

Phrase: ")"

Phrase: "and"

Phrase: "heterozygous"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0019425:Heterozygous [Organism Attribute]

Phrase: "(Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:Kir6.2 [Gene or Genome]

Phrase: "[E23K"

Phrase: "] + Kir6.2wt"

Phrase: ")"

Phrase: "channels,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0439799:Channel [Spatial Concept]
   966   C1706095:Channel [Conceptual Entity]

Phrase: "respectively"

Phrase: "(51"

Phrase: "and"

Phrase: "J.C.K.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C2346601:J/K [Quantitative Concept]
   827   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1708601:K' [Quantitative Concept]

Phrase: "unpublished observations"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   861   C0302523:observations [Research Activity]
   861   C0700325:observations [Health Care Activity]
   861   C3244290:observations [Functional Concept]
   827 E C1964257:Observation [Diagnostic Procedure]
   777 E C1518527:OBSERVATIONAL [Research Activity]

Phrase: ":"

Phrase: "K1/2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1721009:K1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C3272787:K1 [Gene or Genome]

Phrase: "[ATP"

Phrase: "]"

Phrase: "for Kir6.2wt"

Phrase: "= 10.7  1.9 mol/l,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   904   C3274443:10^7/L [Quantitative Concept]
   898   C0456615:10*9/L [Quantitative Concept]
   827   C0347982:mol/L [Quantitative Concept]

Phrase: "Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:Kir6.2 [Gene or Genome]

Phrase: "[E23K"

Phrase: "]"

Phrase: "= 17.6  0.9 mol/l ["
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0347982:mol/L [Quantitative Concept]

Phrase: "expressed in COSm6 cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0007634:Cells [Cell]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]

Phrase: "]"

Phrase: ")"

Phrase: ","

Phrase: "as well as"

Phrase: "enhanced MgADP stimulation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1292856:Stimulation [Therapeutic or Preventive Procedure]
   827   C1948023:Stimulation [Natural Phenomenon or Process]

Phrase: "(51,"

Phrase: "52,"

Phrase: "53,"

Phrase: "54"

Phrase: ")."
Processing 00000000.tx.113: E23K is in linkage disequilibrium with another Kir6.2 polymorphism, I337V, which itself has no reported effect on channel activity (51,53). 

Phrase: "E23K"

Phrase: "is in linkage disequilibrium"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0023746:Linkage Disequilibrium [Quantitative Concept]
   770   C0023745:linkage [Molecular Function]
   770   C0281825:Disequilibrium [Finding]
   770   C0394006:Disequilibrium [Disease or Syndrome]

Phrase: "with another Kir6.2 polymorphism,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0032529:Polymorphism [Genetic Function]
   827   C1882417:Polymorphism [Qualitative Concept]
   734   C1416578:Kir6.2 [Gene or Genome]

Phrase: "I337V,"

Phrase: "which"

Phrase: "itself"

Phrase: "has"

Phrase: "no reported effect on channel activity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C1301751:No effect [Qualitative Concept]
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "(51,"

Phrase: "53"

Phrase: ")."
Processing 00000000.tx.114: Another study reported no reduction of ATP sensitivity of E23K/I337V channels, but instead showed enhanced stimulatory effects of palmitoyl-CoA on E23K/I337V mutant Kir6.2 channels (55). 

Phrase: "Another study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "no reduction of ATP sensitivity of E23K/I337V channels,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C0301630:Reduction [Natural Phenomenon or Process]
   742   C0392756:Reduction [Qualitative Concept]
   742   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "but"

Phrase: "instead"

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "enhanced stimulatory effects of palmitoyl-CoA"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "on E23K/I337V mutant Kir6.2 channels"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   850   C0379878:Kir6.2 channel [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   766   C0439799:Channel [Spatial Concept]
   766   C1706095:Channel [Conceptual Entity]

Phrase: "(55"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450382:55 [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.115: As discussed below, a small increase in intrinsic open-state stability can underlie a decrease in apparent ATP sensitivity, as well as an increase in sensitivity to activator molecules (5154,56). 

Phrase: "As"

Phrase: "discussed below,"

Phrase: "a small increase in intrinsic open-state stability"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0442805:Increase [Functional Concept]

Phrase: "can"

Phrase: "underlie"

Phrase: "a decrease in apparent ATP sensitivity,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0392756:Decrease [Qualitative Concept]
   753   C0547047:Decrease [Quantitative Concept]

Phrase: "as well as"

Phrase: "an increase in sensitivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0442805:Increase [Functional Concept]

Phrase: "to activator molecules"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0567416:molecules [Substance]
   777 E C1521991:Molecular [Qualitative Concept]

Phrase: "(5154,"

Phrase: "56"

Phrase: ")."
Processing 00000000.tx.116: It seems likely that increased palmitoyl-CoA sensitivity in the latter study, as well as increased MgADP sensitivity and reduced ATP sensitivity in the previous study, all reflect just such an increase. 

Phrase: "It"

Phrase: "seems"

Phrase: "likely"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332148:Likely [Qualitative Concept]
  1000   C0750492:Likely [Idea or Concept]

Phrase: "that increased palmitoyl-CoA sensitivity in the latter study,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   762   C1881189:INCREASED SENSITIVITY [Phenomenon or Process]
   762   C2346484:INCREASED SENSITIVITY [Phenomenon or Process]
           SENSITIVITY
   742   C0036667:Sensitivity [Quantitative Concept]
   742   C0312418:Sensitivity [Mental Process]
   742   C0427965:Sensitivity [Finding]
   742   C1511883:Sensitivity [Quantitative Concept]
   742   C1522640:Sensitivity [Qualitative Concept]
   742   C2349185:Sensitivity [Qualitative Concept]

Phrase: "as well as"

Phrase: "increased MgADP sensitivity"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   913   C1881189:INCREASED SENSITIVITY [Phenomenon or Process]
   913   C2346484:INCREASED SENSITIVITY [Phenomenon or Process]
           SENSITIVITY
   827   C0036667:Sensitivity [Quantitative Concept]
   827   C0312418:Sensitivity [Mental Process]
   827   C0427965:Sensitivity [Finding]
   827   C1511883:Sensitivity [Quantitative Concept]
   827   C1522640:Sensitivity [Qualitative Concept]
   827   C2349185:Sensitivity [Qualitative Concept]
   755 E C0332324:Sensitive [Functional Concept]
   755 E C1550474:sensitive [Idea or Concept]

Phrase: "and"

Phrase: "reduced ATP sensitivity in the previous study,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   748   C0036667:Sensitivity [Quantitative Concept]
   748   C0312418:Sensitivity [Mental Process]
   748   C0427965:Sensitivity [Finding]
   748   C1511883:Sensitivity [Quantitative Concept]
   748   C1522640:Sensitivity [Qualitative Concept]
   748   C2346484:SENSITIVITY [Phenomenon or Process]
   748   C2349185:Sensitivity [Qualitative Concept]

Phrase: "all"

Phrase: "reflect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0558058:reflect [Mental Process]

Phrase: "just"

Phrase: "such an increase."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
Processing 00000000.tx.117: In all cases, the net effect will be reduced glucose sensing by the -cell, and, in support, a small effect of the E23K variant on insulin release was observed during intravenous and oral glucose tolerance tests (43,57,58). 

Phrase: "In all cases,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0868928:Cases [Functional Concept]
  1000   C1533148:Cases [Quantitative Concept]
   966 E C1706255:CASE [Medical Device]
   966 E C1706256:Case [Conceptual Entity]

Phrase: "the net effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1280500:Effect [Qualitative Concept]
   861   C2348382:Effect [Qualitative Concept]

Phrase: "will"

Phrase: "be"

Phrase: "reduced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392756:Reduced [Qualitative Concept]

Phrase: "glucose sensing by the -cell,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C1658150:glucose sensing [Cell Function]
   726   C0036658:sense [Organ or Tissue Function]

Phrase: "and"

Phrase: ","

Phrase: "in support,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0183683:Support [Medical Device]
  1000   C1521721:Support [Conceptual Entity]

Phrase: "a small effect of the E23K variant"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1280500:Effect [Qualitative Concept]
   748   C2348382:Effect [Qualitative Concept]

Phrase: "on insulin release"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0030685:Release [Health Care Activity]
   861   C0391871:Release [Functional Concept]
   861   C0439180:% release [Quantitative Concept]
   861   C0680255:release [Health Care Activity]
   861   C1283071:Release [Functional Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C1963578:Release [Therapeutic or Preventive Procedure]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "was"

Phrase: "observed during intravenous"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0348016:Intravenous [Spatial Concept]
   790   C1441672:Observed [Functional Concept]

Phrase: "and"

Phrase: "oral glucose tolerance tests"
Meta Candidates (Total=21; Excluded=4; Pruned=0; Remaining=17)
   966   C0029161:Oral Glucose Tolerance Test [Diagnostic Procedure]
           Oral Glucose Tolerance
   923   C0017741:Glucose tolerance tests [Diagnostic Procedure]
   906   C0201778:Tolerance test, oral [Laboratory Procedure]
   875   C0595310:glucose tests [Medical Device]
   875   C0597140:oral tolerance [Organism Attribute]
   861   C0178665:Glucose tolerance [Physiologic Function]
   858 E C0337438:glucose test [Laboratory Procedure]
   827   C0201777:Tolerance test [Laboratory Procedure]
   812   C0013220:Tolerance [Finding]
   812   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   812   C0020963:Tolerance [Pathologic Function]
   812   C0022885:Tests [Laboratory Procedure]
   812   C0220929:tolerance [Mental Process]
   812   C0231197:Tolerance [Physiologic Function]
   812   C0392366:Tests [Intellectual Product]
   812   C0442027:Oral [Spatial Concept]
   812   C1704410:Tolerance [Qualitative Concept]
   779 E C0039593:Test [Functional Concept]
   756 E C0680282:toleration [Social Behavior]
   741 E C0231198:Tolerant [Functional Concept]

Phrase: "(43,"

Phrase: "57,"

Phrase: "58"

Phrase: ")."
Processing 00000000.tx.118: E23K also has a strong allelic association with a SUR1 polymorphism (A1369S), raising the possibility that the SUR1 variant may influence, or account for, altered channel activity (49). 

Phrase: "E23K also"

Phrase: "has"

Phrase: "a strong allelic association with a SUR1 polymorphism"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   739   C0004083:Association [Mental Process]
   739   C0439849:Association [Qualitative Concept]
   739   C0596306:Association [Phenomenon or Process]
   739   C0699792:association [Social Behavior]

Phrase: "(A1369S"

Phrase: ")"

Phrase: ","

Phrase: "raising"

Phrase: "the possibility"

Phrase: "that"

Phrase: "the SUR1 variant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0205419:Variant [Qualitative Concept]

Phrase: "may"

Phrase: "influence"

Phrase: ","

Phrase: "or"

Phrase: "account for,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C1551359:account [Idea or Concept]
   833   C2741673:Account # [Clinical Attribute]
   833   C2981730:Account [Classification]

Phrase: "altered channel activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C1153410:channel activity [Molecular Function]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]

Phrase: "(49"

Phrase: ")."
Processing 00000000.tx.119: The effect of the A1369S polymorphism on channel activity is not known (51,55), but the possibility should be acknowledged that alone or in combination with E23K, it contributes to altered ATP sensitivity. 

Phrase: "The effect of the A1369S polymorphism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "on channel activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1153410:channel activity [Molecular Function]
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "is"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "known"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205309:Known [Qualitative Concept]

Phrase: "(51,"

Phrase: "55"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450382:55 [Intellectual Product]

Phrase: ")"

Phrase: ","

Phrase: "but"

Phrase: "the possibility"

Phrase: "should"

Phrase: "be"

Phrase: "acknowledged"

Phrase: "that alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "or in combination"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0205195:Combination [Qualitative Concept]
   790   C1947911:Combination [Physical Object]

Phrase: "with E23K,"

Phrase: "it"

Phrase: "contributes to altered ATP sensitivity."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   762   C0332324:Sensitive to [Functional Concept]
   760   C0036667:Sensitivity [Quantitative Concept]
   760   C0312418:Sensitivity [Mental Process]
   760   C0392747:Altered [Functional Concept]
   760   C0427965:Sensitivity [Finding]
   760   C1511883:Sensitivity [Quantitative Concept]
   760   C1522640:Sensitivity [Qualitative Concept]
   760   C1880177:Contribute [Activity]
   760   C2346484:SENSITIVITY [Phenomenon or Process]
   760   C2349185:Sensitivity [Qualitative Concept]
Processing 00000000.tx.120: (In our unpublished studies of E23K, reconstituted KATP channels carried both the I337V and A1369S polymorphisms.) 

Phrase: "("

Phrase: "In our unpublished studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "of E23K,"

Phrase: "reconstituted KATP channels"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   793   C0439799:Channel [Spatial Concept]
   793   C1706095:Channel [Conceptual Entity]

Phrase: "carried"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0206243:carried [Activity]
  1000   C0699809:carried [Finding]

Phrase: "both the I337V"

Phrase: "and"

Phrase: "A1369S polymorphisms."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0032529:polymorphisms [Genetic Function]
   827 E C1882417:Polymorphism [Qualitative Concept]

Phrase: ")"
Processing 00000000.tx.121: What of the ATP sensitivity of different neonatal diabetes mutants? 

Phrase: "What of the ATP sensitivity of different neonatal diabetes mutants?"
Meta Candidates (Total=15; Excluded=0; Pruned=0; Remaining=15)
   760   C0158981:Neonatal diabetes [Disease or Syndrome]
   739   C0011847:Diabetes [Disease or Syndrome]
   739   C0011849:Diabetes [Disease or Syndrome]
   739   C0036667:Sensitivity [Quantitative Concept]
   739   C0312418:Sensitivity [Mental Process]
   739   C0427965:Sensitivity [Finding]
   739   C0596988:mutants [Cell or Molecular Dysfunction]
   739   C1511883:Sensitivity [Quantitative Concept]
   739   C1522640:Sensitivity [Qualitative Concept]
   739   C1552240:Neonatal [Professional or Occupational Group]
   739   C1552264:Neonatal [Professional or Occupational Group]
   739   C1705242:Different [Qualitative Concept]
   739   C2346484:SENSITIVITY [Phenomenon or Process]
   739   C2349185:Sensitivity [Qualitative Concept]
   739   C2939425:Neonatal [Temporal Concept]
Processing 00000000.tx.122: Gloyn et al. 

Phrase: "Gloyn et al."
Processing 00000000.tx.123: (27) initially showed an 35-fold loss of ATP sensitivity for homozygous R201H mutant channels, but almost no shift in a 1:1 mixture of wild-type and R201H mutant subunits, expected to recapitulate the heterozygous state of the disease. 

Phrase: "(27"

Phrase: ")"

Phrase: "initially"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205265:Initially [Temporal Concept]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "an 35-fold loss of ATP sensitivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1517945:Loss [Quantitative Concept]

Phrase: "for homozygous R201H mutant channels,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   779   C0439799:Channel [Spatial Concept]
   779   C1706095:Channel [Conceptual Entity]

Phrase: "but"

Phrase: "almost"

Phrase: "no shift in a 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0333051:Shift [Functional Concept]
   760   C2347509:Shift [Phenomenon or Process]

Phrase: ":"

Phrase: "1 mixture of wild-type"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0439962:Mixture [Substance]

Phrase: "and"

Phrase: "R201H mutant subunits,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C1711351:Subunit [Quantitative Concept]

Phrase: "expected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1517001:Expected [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "recapitulate"

Phrase: "the heterozygous state of the disease."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C1301808:State [Geographic Area]
   753   C1442792:State [Functional Concept]
   753   C3148680:State [Geographic Area]
Processing 00000000.tx.124: Assuming a 1:1 expression and random assembly, 16 different subunit arrangements are formally possible, making the analysis of mixed expression very complex (51,53,59,60). 

Phrase: "Assuming"

Phrase: "a 1"

Phrase: ":"

Phrase: "1 expression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "random assembly,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1706853:Assembly [Activity]
   861   C1879748:Assembly [Manufactured Object]

Phrase: "16 different subunit arrangements"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   779   C0449830:Arrangement [Spatial Concept]

Phrase: "are"

Phrase: "formally possible,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0332149:Possible [Qualitative Concept]
   861   C1705910:Possible [Qualitative Concept]
   861   C2362652:Possible [Qualitative Concept]

Phrase: "making"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1881534:Make [Functional Concept]

Phrase: "the analysis of mixed expression"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0002778:Analysis [Laboratory Procedure]
   760   C0936012:Analysis [Research Activity]
   760   C1524024:analysis [Functional Concept]

Phrase: "very complex"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439855:Complex [Qualitative Concept]
   861   C1704241:Complex [Chemical Viewed Structurally]

Phrase: "(51,"

Phrase: "53,"

Phrase: "59,"

Phrase: "60"

Phrase: ")."
Processing 00000000.tx.125: However, as acknowledged, 1 of 16 of the expressed channels are expected to be pure mutant, and this alone could give rise to significant currents at physiological [ATP]/[ADP] ratios. 

Phrase: "However,"

Phrase: "as"

Phrase: "acknowledged"

Phrase: ","

Phrase: "1 of 16 of the expressed channels"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C2827734:1+ [Quantitative Concept]
   748   C2981698:1+ [Classification]
   714   C0439799:Channel [Spatial Concept]
   714   C1706095:Channel [Conceptual Entity]

Phrase: "are"

Phrase: "expected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1517001:Expected [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "pure mutant,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596988:Mutant [Cell or Molecular Dysfunction]

Phrase: "and"

Phrase: "this alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "could"

Phrase: "give"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1947971:Give [Functional Concept]

Phrase: "rise to significant currents"

Phrase: "at physiological"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0205463:Physiological [Functional Concept]
   928 E C0031842:Physiology [Biomedical Occupation or Discipline]
   928 E C0031843:physiology [Physiologic Function]

Phrase: "[ATP"

Phrase: "]/"

Phrase: "[ADP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0523452:ADP [Laboratory Procedure]

Phrase: "] ratios."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0456603:Ratios [Quantitative Concept]
  1000   C1610540:*Ratios [Quantitative Concept]
   966 E C1547037:Ratio [Intellectual Product]
Processing 00000000.tx.126: Other mutations (Q52R, I296L I182V, V59G, V59M, Y330C, and F333I) have now been analyzed, demonstrating shifts in ATP sensitivity of up to 1,000-fold for homozygous V59G and I296L mutant channels (38,39). 

Phrase: "Other mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "(Q52R,"

Phrase: "I296L I182V,"

Phrase: "V59G,"

Phrase: "V59M,"

Phrase: "Y330C,"

Phrase: "and"

Phrase: "F333I"

Phrase: ")"

Phrase: "have"

Phrase: "now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "been"

Phrase: "analyzed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]

Phrase: ","

Phrase: "demonstrating"

Phrase: "shifts in ATP sensitivity of"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0333051:shifts [Functional Concept]
   726 E C2347509:Shift [Phenomenon or Process]

Phrase: "up to 1,000-fold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0332462:Fold [Spatial Concept]
   827   C1880834:FOLD [Phenomenon or Process]

Phrase: "for homozygous V59G"

Phrase: "and"

Phrase: "I296L mutant channels"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C0439799:Channel [Spatial Concept]
   793   C1706095:Channel [Conceptual Entity]

Phrase: "(38,"

Phrase: "39"

Phrase: ")."
Processing 00000000.tx.127: Again, much lesser shifts were observed in heterozygous expression, but, without analyzing each subunit combination separately, it remains speculative as to exactly what channel activity can be expected in vivo. 

Phrase: "Again,"

Phrase: "much lesser shifts"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0333051:shifts [Functional Concept]
   793 E C2347509:Shift [Phenomenon or Process]

Phrase: "were"

Phrase: "observed in heterozygous expression,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0019425:Heterozygous [Organism Attribute]
   770   C0185117:Expression [Therapeutic or Preventive Procedure]
   770   C1441672:Observed [Functional Concept]

Phrase: "but"

Phrase: ","

Phrase: "without analyzing"

Phrase: "each subunit combination separately,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0205195:Combination [Qualitative Concept]
   827   C1947911:Combination [Physical Object]

Phrase: "it"

Phrase: "remains"

Phrase: "speculative as to exactly"

Phrase: "what"

Phrase: "channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439799:Channel [Spatial Concept]
  1000   C1706095:Channel [Conceptual Entity]

Phrase: "activity"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0205177:Activity [Functional Concept]
  1000   C0439167:% activity [Quantitative Concept]
  1000   C0441655:Activity [Activity]
  1000   C1561536:*Activity [Idea or Concept]

Phrase: "can"

Phrase: "be"

Phrase: "expected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1517001:Expected [Idea or Concept]

Phrase: "in vivo."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo
Processing 00000000.tx.128: Nonelectrical consequences of altered KATP channel activity. 

Phrase: "Nonelectrical consequences of altered KATP channel activity."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   762   C0686907:Consequence of [Functional Concept]
           consequences
Processing 00000000.tx.129: At this juncture, we cannot preclude nonelectrical secondary mechanisms underlying KATP channelinduced diabetes. 

Phrase: "At this juncture,"

Phrase: "we"

Phrase: "cannot"

Phrase: "preclude"

Phrase: "nonelectrical secondary mechanisms"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0441712:Mechanisms [Functional Concept]
   793 E C1706376:Mechanism [Manufactured Object]

Phrase: "underlying"

Phrase: "KATP channelinduced diabetes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.130: Mice with overactive -cell KATP channels are profoundly diabetic within a few days of birth (11). 

Phrase: "Mice with overactive -cell KATP channels"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0025914:Mice [Mammal]
   753   C0025929:mice [Mammal]
   753   C0026809:Mice [Mammal]

Phrase: "are"

Phrase: "profoundly diabetic within a few days of birth"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0241863:DIABETIC [Finding]

Phrase: "(11"

Phrase: ")."
Processing 00000000.tx.131: Morphologically, the size, distribution, and architecture of the islets are unperturbed at the earliest stages of diabetes (days 13), but collapse of islet architecture, with diffuse distribution of the - and -cells throughout the pancreas, was observed at later stages (after day 3). 

Phrase: "Morphologically,"

Phrase: "the size,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0456389:size [Spatial Concept]

Phrase: "distribution,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0520511:distribution [Idea or Concept]
  1000   C1704711:Distribution [Functional Concept]

Phrase: "and"

Phrase: "architecture of the islets"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0003737:Architecture [Occupation or Discipline]

Phrase: "are"

Phrase: "unperturbed at the earliest stages of diabetes"

Phrase: "(days 13"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0439228:days [Temporal Concept]
   827 E C0332173:/day [Temporal Concept]
   827 E C0439505:/day [Temporal Concept]

Phrase: ")"

Phrase: ","

Phrase: "but"

Phrase: "collapse of islet architecture,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0036974:collapse [Pathologic Function]
   770   C0332521:Collapse [Phenomenon or Process]
   770   C0344329:Collapse [Finding]
   770   C1880118:COLLAPSE [Phenomenon or Process]

Phrase: "with diffuse distribution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0520511:distribution [Idea or Concept]
   861   C1704711:Distribution [Functional Concept]

Phrase: "of the -"

Phrase: "and -"

Phrase: "cells throughout the pancreas,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0007634:Cells [Cell]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]

Phrase: "was"

Phrase: "observed at later stages"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   816   C1279941:late stages [Temporal Concept]
   770   C1306673:Stages [Qualitative Concept]
   770   C1441672:Observed [Functional Concept]
   737   C0205087:Late [Temporal Concept]
   737 E C0205390:Stage [Temporal Concept]
   737 E C1300072:Stage [Clinical Attribute]

Phrase: "("

Phrase: "after day 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0332173:/day [Temporal Concept]
   861   C0439228:day [Temporal Concept]
   861   C0439505:/day [Temporal Concept]

Phrase: ")."
Processing 00000000.tx.132: A similar mechanistic progression may occur in KATP channelinduced permanent neonatal diabetes and may underlie some of the reduced sulfonylurea-sensitive insulin release (27). 

Phrase: "A similar mechanistic progression"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0242656:progression [Pathologic Function]
   827   C0449258:Progression [Functional Concept]

Phrase: "may"

Phrase: "occur in KATP channelinduced permanent neonatal diabetes"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   778   C0158981:Neonatal diabetes [Disease or Syndrome]
   748   C0011847:Diabetes [Disease or Syndrome]
   748   C0011849:Diabetes [Disease or Syndrome]
   748   C0205355:Permanent [Temporal Concept]
   748   C1552240:Neonatal [Professional or Occupational Group]
   748   C1552264:Neonatal [Professional or Occupational Group]
   748   C1709305:Occur [Activity]
   748   C2745955:OCCUR [Temporal Concept]
   748   C2939425:Neonatal [Temporal Concept]

Phrase: "and"

Phrase: "may"

Phrase: "underlie"

Phrase: "some of the reduced sulfonylurea-sensitive insulin release"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0030685:Release [Health Care Activity]
   744   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   744   C0205392:Some [Quantitative Concept]
   744   C0332324:Sensitive [Functional Concept]
   744   C0391871:Release [Functional Concept]
   744   C0392756:Reduced [Qualitative Concept]
   744   C0439180:% release [Quantitative Concept]
   744   C0680255:release [Health Care Activity]
   744   C1283071:Release [Functional Concept]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1550474:sensitive [Idea or Concept]
   744   C1579433:Insulin [Pharmacologic Substance]
   744   C1963578:Release [Therapeutic or Preventive Procedure]
   744   C3536898:Sulfonylurea [Pharmacologic Substance]
   744   C3540770:Some [Intellectual Product]

Phrase: "(27"

Phrase: ")."
Processing 00000000.tx.133: Moreover, a recent transgenic study overexpressing the transient neonatal diabetes locus (6q24) implicated fluctuations in -cell mass and insulin content in the progression of transient neonatal diabetes from the neonatal diabetic phase into remission and ultimately to late-onset diabetes (61). 

Phrase: "Moreover,"

Phrase: "a recent transgenic study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557651:Study [Manufactured Object]
   827   C2603343:Study [Research Activity]

Phrase: "overexpressing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514559:overexpress [Genetic Function]

Phrase: "the transient neonatal diabetes locus"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1708726:Locus [Gene or Genome]

Phrase: "(6q24"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1521572:6q24 [Cell Component]

Phrase: ")"

Phrase: "implicated fluctuations in -cell mass"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C0577559:Mass [Finding]
   804   C1306372:*Mass [Quantitative Concept]
   804   C3152252:Mass [Quantitative Concept]

Phrase: "and"

Phrase: "insulin content in the progression of transient neonatal diabetes"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   742   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C0423896:Content [Mental Process]
   742   C0456205:Content [Conceptual Entity]
   742   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   742   C1579433:Insulin [Pharmacologic Substance]

Phrase: "from the neonatal diabetic phase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0205390:Phase [Temporal Concept]

Phrase: "into remission"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0544452:Remission [Finding]
  1000   C0687702:remission [Neoplastic Process]

Phrase: "and"

Phrase: "ultimately to late-onset diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   884   C0011860:late onset diabetes [Disease or Syndrome]
   804   C0011847:Diabetes [Disease or Syndrome]
   804   C0011849:Diabetes [Disease or Syndrome]

Phrase: "(61"

Phrase: ")."
Processing 00000000.tx.134: If a similar pathophysiology occurs in transient neonatal diabetes patients carrying Kir6.2 mutations, this would be consistent with secondary, nonelectrical consequences of altered -cell KATP channel activity. 

Phrase: "If"

Phrase: "a similar pathophysiology"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0031847:pathophysiology [Functional Concept]
   861   C0277785:Pathophysiology [Qualitative Concept]

Phrase: "occurs in transient neonatal diabetes patients"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   790   C0158981:Neonatal diabetes [Disease or Syndrome]
   753   C0011847:Diabetes [Disease or Syndrome]
   753   C0011849:Diabetes [Disease or Syndrome]
   753   C0030705:Patients [Patient or Disabled Group]
   753   C0040704:Transient [Population Group]
   753   C0205374:Transient [Temporal Concept]
   753   C1552240:Neonatal [Professional or Occupational Group]
   753   C1552264:Neonatal [Professional or Occupational Group]
   753   C1709305:Occur [Activity]
   753   C2745955:OCCUR [Temporal Concept]
   753   C2939425:Neonatal [Temporal Concept]

Phrase: "carrying"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0206243:Carrying [Activity]
   966 E C0699809:carry [Finding]

Phrase: "Kir6.2 mutations,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]
   734   C1416578:Kir6.2 [Gene or Genome]

Phrase: "this"

Phrase: "would"

Phrase: "be"

Phrase: "consistent with secondary, nonelectrical consequences of altered -cell KATP channel activity."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   756   C0332290:Consistent with [Idea or Concept]
           Consistent
Processing 00000000.tx.135: Secondary complications do occur in the converse disease progression resulting from reduced KATP channel density. 

Phrase: "Secondary complications"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0009566:Complications [Pathologic Function]
   861   C1171258:complications [Pathologic Function]
   827 E C2362589:Complication [Idea or Concept]
   777 E C0231242:Complicated [Functional Concept]

Phrase: "do"

Phrase: "occur in the converse disease progression"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C0242656:Disease Progression [Pathologic Function]
           progression
   790   C1947900:Disease progression NOS [Finding]
   753   C0012634:Disease [Disease or Syndrome]
   753   C0449258:Progression [Functional Concept]
   753   C1709305:Occur [Activity]
   753   C2745955:OCCUR [Temporal Concept]

Phrase: "resulting from reduced KATP channel density."
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   753   C0178587:density [Quantitative Concept]
   753   C0392756:Reduced [Qualitative Concept]
   753   C0439799:Channel [Spatial Concept]
   753   C0678226:resulting [Functional Concept]
   753   C1706095:Channel [Conceptual Entity]
   719 E C1274040:Result [Functional Concept]
   719 E C1546471:Result [Idea or Concept]
   719 E C2825142:Result [Finding]
Processing 00000000.tx.136: Transgenic mice lacking KATP channels in 70% of -cells, due to -cell expression of dominant-negative Kir6.2 transgene, hypersecrete throughout as adults (14), but mice completely lacking KATP channels are reportedly hyperinsulinemic as neonates and then progress to reduced GSIS and glucose intolerance as adults (6264). 

Phrase: "Transgenic mice"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0025936:Mice, Transgenic [Mammal]
   861   C0003069:Transgenic [Animal]
   861   C0025914:Mice [Mammal]
   861   C0025929:mice [Mammal]
   861   C0026809:Mice [Mammal]

Phrase: "lacking"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332268:Lacking [Qualitative Concept]

Phrase: "KATP channels in 70% of -cells,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   719   C0439799:Channel [Spatial Concept]
   719   C1706095:Channel [Conceptual Entity]

Phrase: "due to -cell expression"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "of dominant-negative Kir6.2 transgene,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0282641:Transgene [Gene or Genome]

Phrase: "hypersecrete"

Phrase: "throughout as adults"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0001675:Adults [Age Group]
   756 E C1706450:Adult [Human]

Phrase: "(14"

Phrase: ")"

Phrase: ","

Phrase: "but"

Phrase: "mice completely"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0025914:Mice [Mammal]
   861   C0025929:mice [Mammal]
   861   C0026809:Mice [Mammal]

Phrase: "lacking"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332268:Lacking [Qualitative Concept]

Phrase: "KATP channels"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   827   C0439799:Channel [Spatial Concept]
   827   C1706095:Channel [Conceptual Entity]

Phrase: "are"

Phrase: "reportedly hyperinsulinemic as neonates"

Phrase: "and"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "progress to reduced GSIS"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   778   C1256369:insulin secretion [Cell Function]
   774   C1719133:Glucose/Insulin [Quantitative Concept]
   748   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   748   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C0036536:secretion [Biologic Function]
   748   C0036537:Secretion [Body Substance]
   748   C0392756:Reduced [Qualitative Concept]
   748   C1272688:progress [Functional Concept]
   748   C1280477:Progress [Functional Concept]
   748   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   748   C1579433:Insulin [Pharmacologic Substance]
   748   C1948023:Stimulated [Natural Phenomenon or Process]

Phrase: "and"

Phrase: "glucose intolerance as adults"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0271650:Glucose Intolerance [Disease or Syndrome]
   770   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   770   C0231199:Intolerance [Organism Function]
   770   C1744706:intolerance [Intellectual Product]
   770   C2355652:Intolerance [Organism Attribute]

Phrase: "(6264"

Phrase: ")."
Processing 00000000.tx.137: Importantly, when exposed to a high-fat diet, both Kir6.2/ mice and Kir6.2[AAA] transgenic mice progress rapidly to severely undersecreting diabetes (65). 

Phrase: "Importantly,"

Phrase: "when"

Phrase: "exposed to a high-fat diet,"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
   833   C0521974:Diet, High-Fat [Therapeutic or Preventive Procedure]
   790   C0301585:Fat diet [Therapeutic or Preventive Procedure]
   790   C0332157:Exposed to [Clinical Attribute]
           Exposed
   753   C0012155:Diet [Food]
   753   C0205250:High [Qualitative Concept]
   753   C0424612:FAT [Organism Attribute]
   753   C1299351:High [Qualitative Concept]
   753   C1442959:Diet [Organism Function]
   753   C1519433:DIET [Therapeutic or Preventive Procedure]
   753   C2700149:HIGH [Intellectual Product]
   753   C2983588:DIET [Food]
   748 E C0012171:Dietary Fat [Food]
   748 E C1527016:Dietary Fat [Research Activity]

Phrase: "both Kir6.2/ mice"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]
   734   C1416578:Kir6.2 [Gene or Genome]

Phrase: "and"

Phrase: "Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:Kir6.2 [Gene or Genome]

Phrase: "[AAA] transgenic mice"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0025936:Mice, Transgenic [Mammal]
   827   C0003069:Transgenic [Animal]
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]

Phrase: "progress"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1272688:progress [Functional Concept]
  1000   C1280477:Progress [Functional Concept]

Phrase: "rapidly to severely undersecreting diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0011847:Diabetes [Disease or Syndrome]
   804   C0011849:Diabetes [Disease or Syndrome]

Phrase: "(65"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450385:65 [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.138: While these hyperexcitable mice, with reduced KATP channel activity, thus have a very different response to those with overactive KATP channels, they do suggest that profound nonelectrical consequences can follow an initial electrical disturbance. 

Phrase: "While"

Phrase: "these hyperexcitable mice,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0025914:Mice [Mammal]
   861   C0025929:mice [Mammal]
   861   C0026809:Mice [Mammal]

Phrase: "with reduced KATP channel activity,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   902   C0086439:Reduced Activity [Sign or Symptom]
   861   C1153410:channel activity [Molecular Function]
   812   C0205177:Activity [Functional Concept]
   812   C0439167:% activity [Quantitative Concept]
   812   C0441655:Activity [Activity]
   812   C1561536:*Activity [Idea or Concept]

Phrase: "thus"

Phrase: "have"

Phrase: "a very different response to those with overactive KATP channels,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   739   C0871261:Response [Organism Attribute]
   739   C1704632:Response [Finding]
   739   C1706817:Response [Intellectual Product]
   739   C2911692:Response [Mental Process]

Phrase: "they"

Phrase: "do"

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that profound nonelectrical consequences"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0686907:consequences [Functional Concept]

Phrase: "can"

Phrase: "follow"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332283:follow [Temporal Concept]
  1000   C1719822:Follow [Intellectual Product]

Phrase: "an initial electrical disturbance."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C2699787:Disturbance [Qualitative Concept]
Processing 00000000.tx.139: In addition to Kir6.2 defects, loss or reduction of KATP channel activity can also occur due to loss-of-function mutations of the regulatory SUR1 subunit; 

Phrase: "In addition to Kir6.2 defects,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0243067:defects [Functional Concept]
   793 E C1457869:Defect [Functional Concept]
   793 E C1861101:DEFECT [Disease or Syndrome]
   734   C1416578:Kir6.2 [Gene or Genome]

Phrase: "loss"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1517945:Loss [Quantitative Concept]

Phrase: "or"

Phrase: "reduction of KATP channel activity"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   797   C2267000:Reduction Activity [Molecular Function]
   760   C0301630:Reduction [Natural Phenomenon or Process]
   760   C0392756:Reduction [Qualitative Concept]
   760   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "can"

Phrase: "also"

Phrase: "occur due to loss-of-function mutations"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   778   C0678226:Due to [Functional Concept]
           due
   748   C0026882:Mutations [Genetic Function]
   748   C0031843:function [Physiologic Function]
   748   C0542341:Function [Functional Concept]
   748   C0700205:FUNCTION [Classification]
   748   C1517945:Loss [Quantitative Concept]
   748   C1705273:Function [Intellectual Product]
   748   C1709305:Occur [Activity]
   748   C2745955:OCCUR [Temporal Concept]
   748   C3146286:Due [Idea or Concept]
   714 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "of the regulatory SUR1 subunit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C1711351:Subunit [Quantitative Concept]

Phrase: ";"
Processing 00000000.tx.140: such mutations are the most frequent cause of CHI (5). 

Phrase: "such mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "are"

Phrase: "the most frequent cause of CHI"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   764   C2931834:Congenital Hyperinsulinism [Disease or Syndrome]
   742   C0009678:congenital [Qualitative Concept]
   742   C0015127:cause [Functional Concept]
   742   C0020459:Hyperinsulinism [Disease or Syndrome]
   742   C0332183:Frequent [Temporal Concept]
   742   C1524003:Cause [Conceptual Entity]
   742   C1744681:Congenital [Qualitative Concept]

Phrase: "(5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.141: Clinical data indicate that CHI patients carrying SUR1 mutations can also progress to glucose intolerance and, in some cases, overt diabetes (66). 

Phrase: "Clinical data"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1516606:Clinical Data [Intellectual Product]
   861   C1511726:Data [Idea or Concept]
   861   C3245479:data [Medical Device]

Phrase: "indicate"

Phrase: "that CHI patients"

Phrase: "carrying"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0206243:Carrying [Activity]
   966 E C0699809:carry [Finding]

Phrase: "SUR1 mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0026882:Mutations [Genetic Function]
   779 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "can"

Phrase: "also"

Phrase: "progress to glucose intolerance"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0271650:Glucose Intolerance [Disease or Syndrome]
   770   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   770   C0231199:Intolerance [Organism Function]
   770   C1272688:progress [Functional Concept]
   770   C1280477:Progress [Functional Concept]
   770   C1744706:intolerance [Intellectual Product]
   770   C2355652:Intolerance [Organism Attribute]

Phrase: "and"

Phrase: ","

Phrase: "in some cases,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0868928:Cases [Functional Concept]
  1000   C1533148:Cases [Quantitative Concept]
   966 E C1706255:CASE [Medical Device]
   966 E C1706256:Case [Conceptual Entity]

Phrase: "overt diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "(66"

Phrase: ")."
Processing 00000000.tx.142: Finally, non-cell mechanisms must be considered. 

Phrase: "Finally,"

Phrase: "non-cell mechanisms"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0441712:Mechanisms [Functional Concept]
   793 E C1706376:Mechanism [Manufactured Object]

Phrase: "must"

Phrase: "be"

Phrase: "considered."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]
Processing 00000000.tx.143: Kir6.2 is the pore-forming subunit of -cell, muscular, and neuronal KATP channels (34). 

Phrase: "Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:Kir6.2 [Gene or Genome]

Phrase: "is"

Phrase: "the pore-forming subunit of -cell,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0007634:Cell [Cell]
   804   C1269647:Cell [Cell]
   804   C1704653:Cell [Medical Device]
   804   C1948049:Cell [Spatial Concept]

Phrase: "muscular,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0026845:Muscular [Tissue]
  1000   C0442025:Muscular [Spatial Concept]
   928 E C1995013:Muscles [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "neuronal KATP channels"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   793   C0439799:Channel [Spatial Concept]
   793   C1706095:Channel [Conceptual Entity]

Phrase: "(34"

Phrase: ")."
Processing 00000000.tx.144: In skeletal muscle, or in neurons, overactive KATP channel could potentially underlie the muscle weakness reported in syndromic permanent neonatal diabetes (27,29). 

Phrase: "In skeletal muscle,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0242692:Muscle, Skeletal [Tissue]
  1000   C1280260:Skeletal muscle [Body Part, Organ, or Organ Component]
   861   C0026845:Muscle [Tissue]
   861   C0037253:skeletal [Body System]
   861   C0521324:Skeletal [Spatial Concept]
   789 E C0442025:Muscular [Spatial Concept]

Phrase: "or in neurons,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0027882:Neurons [Cell]
   706 E C0521390:Neuronal [Immunologic Factor]

Phrase: "overactive KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439799:Channel [Spatial Concept]
   827   C1706095:Channel [Conceptual Entity]

Phrase: "could"

Phrase: "potentially"

Phrase: "underlie"

Phrase: "the muscle weakness"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0030552:muscle weakness [Sign or Symptom]
  1000   C0151786:Muscle Weakness [Sign or Symptom]
   861   C0004093:Weakness [Sign or Symptom]
   861   C0026845:Muscle [Tissue]
   789 E C0442025:Muscular [Spatial Concept]
   789 E C1762617:Weak [Qualitative Concept]

Phrase: "reported in syndromic permanent neonatal diabetes"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   790   C0158981:Neonatal diabetes [Disease or Syndrome]
   753   C0011847:Diabetes [Disease or Syndrome]
   753   C0011849:Diabetes [Disease or Syndrome]
   753   C0205355:Permanent [Temporal Concept]
   753   C0684224:Reported [Intellectual Product]
   753   C0700287:Reported [Health Care Activity]
   753   C1552240:Neonatal [Professional or Occupational Group]
   753   C1552264:Neonatal [Professional or Occupational Group]
   753   C2939425:Neonatal [Temporal Concept]
   753   C3496591:Reported [Clinical Attribute]
   719 E C3273238:Report [Intellectual Product]

Phrase: "(27,"

Phrase: "29"

Phrase: ")."
Processing 00000000.tx.145: Glucose uptake by skeletal muscle and adipose may also be dependent on KATP channel activity (67), and overactivity in syndromic permanent neonatal diabetes could compromise this function. 

Phrase: "Glucose uptake by skeletal muscle"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C1159527:glucose uptake [Cell Function]
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C0243144:Uptake [Physiologic Function]
   760   C0347980:% uptake [Quantitative Concept]

Phrase: "and"

Phrase: "adipose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   928   C0028754:Adiposity [Disease or Syndrome]
   928   C1563743:adiposity [Organism Attribute]

Phrase: "may"

Phrase: "also"

Phrase: "be"

Phrase: "dependent on KATP channel activity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0851827:Dependent [Qualitative Concept]
   760   C1701901:Dependent [Qualitative Concept]
   760   C3244310:dependent [Functional Concept]

Phrase: "(67"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "overactivity in syndromic permanent neonatal diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0474395:overactivity [Finding]
   753   C1536696:Overactivity [Finding]

Phrase: "could"

Phrase: "compromise"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2945640:compromise [Finding]

Phrase: "this function."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0031843:function [Physiologic Function]
  1000   C0542341:Function [Functional Concept]
  1000   C0700205:FUNCTION [Classification]
  1000   C1705273:Function [Intellectual Product]
   928 E C0205245:Functional [Functional Concept]
   928 E C2700217:Functional [Conceptual Entity]
Processing 00000000.tx.146: In neurons, metabolic sensing is altered with loss of KATP channels (35,68). 

Phrase: "In neurons,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0027882:Neurons [Cell]
   916 E C0521390:Neuronal [Immunologic Factor]

Phrase: "metabolic sensing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0036658:sense [Organ or Tissue Function]

Phrase: "is"

Phrase: "altered with loss of KATP channels"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   753   C0392747:Altered [Functional Concept]
   753   C1517945:Loss [Quantitative Concept]
   719   C0439799:Channel [Spatial Concept]
   719   C1706095:Channel [Conceptual Entity]

Phrase: "(35,"

Phrase: "68"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450387:68 [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.147: Again, the unknown consequences of KATP channel overactivity could underlie developmental defects that are also observed in syndromic permanent neonatal diabetes (27,29). 

Phrase: "Again,"

Phrase: "the unknown consequences of KATP channel overactivity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   762   C0686907:Consequence of [Functional Concept]
           consequences

Phrase: "could"

Phrase: "underlie"

Phrase: "developmental defects"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   983   C0000768:Developmental defect [Congenital Abnormality]
   861   C0243067:defects [Functional Concept]
   827 E C1457869:Defect [Functional Concept]
   827 E C1861101:DEFECT [Disease or Syndrome]

Phrase: "that"

Phrase: "are"

Phrase: "also"

Phrase: "observed in syndromic permanent neonatal diabetes"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C0158981:Neonatal diabetes [Disease or Syndrome]
   753   C0011847:Diabetes [Disease or Syndrome]
   753   C0011849:Diabetes [Disease or Syndrome]
   753   C0205355:Permanent [Temporal Concept]
   753   C1441672:Observed [Functional Concept]
   753   C1552240:Neonatal [Professional or Occupational Group]
   753   C1552264:Neonatal [Professional or Occupational Group]
   753   C2939425:Neonatal [Temporal Concept]

Phrase: "(27,"

Phrase: "29"

Phrase: ")."
Processing 00000000.tx.148: Complete understanding of the mechanisms by which Kir6.2 mutations cause neonatal diabetes will require mechanistic molecular analysis of disease-causing mutations (32,33,38,39), generation of transgenic mouse models of neonatal diabetes (11), and analysis of virally infected -cells or insulinoma cell lines expressing altered KATP channel.  

Phrase: "Complete understanding of the mechanisms"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0162340:Understanding [Mental Process]

Phrase: "by which Kir6.2 mutations"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]
   734   C1416578:Kir6.2 [Gene or Genome]

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "neonatal diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0158981:Neonatal diabetes [Disease or Syndrome]
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "will"

Phrase: "require"

Phrase: "mechanistic molecular analysis of disease-causing mutations"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   778   C1513380:Molecular Analysis [Molecular Biology Research Technique]
   757   C0796357:mutation analysis [Laboratory Procedure]
   748   C0002778:Analysis [Laboratory Procedure]
   748   C0936012:Analysis [Research Activity]
   748   C1524024:analysis [Functional Concept]

Phrase: "(32,"

Phrase: "33,"

Phrase: "38,"

Phrase: "39"

Phrase: ")"

Phrase: ","

Phrase: "generation of transgenic mouse"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0079411:Generation [Temporal Concept]
   770   C3146294:Generation [Activity]

Phrase: "models of neonatal diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0158981:Neonatal diabetes [Disease or Syndrome]
   770   C0011847:Diabetes [Disease or Syndrome]
   770   C0011849:Diabetes [Disease or Syndrome]
   770   C1552240:Neonatal [Professional or Occupational Group]
   770   C1552264:Neonatal [Professional or Occupational Group]
   770   C2939425:Neonatal [Temporal Concept]
   770   C3161035:Model [Intellectual Product]

Phrase: "(11"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "analysis of virally"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0002778:Analysis [Laboratory Procedure]
   790   C0936012:Analysis [Research Activity]
   790   C1524024:analysis [Functional Concept]

Phrase: "infected -"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439663:Infected [Functional Concept]

Phrase: "cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "or"

Phrase: "insulinoma cell lines"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   901   C0007600:Cell lines [Cell]
   827   C0007634:Cell [Cell]
   827   C0205132:lines [Spatial Concept]
   827   C1269647:Cell [Cell]
   827   C1704653:Cell [Medical Device]
   827   C1948049:Cell [Spatial Concept]
   793 E C1550648:Line [Substance]
   793 E C1552960:Line [Quantitative Concept]

Phrase: "expressing"

Phrase: "altered KATP channel."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439799:Channel [Spatial Concept]
   827   C1706095:Channel [Conceptual Entity]
Processing 00000000.tx.149: Part 2: KATP channeldependent diabetes: the molecular defects TOP ABSTRACT Part 1: -cell KATP... 

Phrase: "Part 2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0449719:Part [Spatial Concept]
   861   C1709471:Part [Quantitative Concept]

Phrase: ":"

Phrase: "KATP channeldependent diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "the molecular defects TOP ABSTRACT Part 1"
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   799   C0000857:Abstract [Occupational Activity]
   799   C0243067:defects [Functional Concept]
   799   C0449719:Part [Spatial Concept]
   799   C0600678:Abstract [Intellectual Product]
   799   C1521991:Molecular [Qualitative Concept]
   799   C1552863:Abstract [Idea or Concept]
   799   C1704458:Top [Spatial Concept]
   799   C1709471:Part [Quantitative Concept]
   766 E C1457869:Defect [Functional Concept]
   766 E C1861101:DEFECT [Disease or Syndrome]
   727 E C0567416:Molecule [Substance]

Phrase: ": -"

Phrase: "cell KATP..."
Processing 00000000.tx.150: Part 2: KATP channel-dependent... 

Phrase: "Part 2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0449719:Part [Spatial Concept]
   861   C1709471:Part [Quantitative Concept]

Phrase: ":"

Phrase: "KATP channel-dependent..."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0851827:Dependent [Qualitative Concept]
   827   C1701901:Dependent [Qualitative Concept]
   827   C3244310:dependent [Functional Concept]
Processing 00000000.tx.151: REFERENCES  The KATP channel: structure and function. 

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "The KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439799:Channel [Spatial Concept]
   861   C1706095:Channel [Conceptual Entity]

Phrase: ":"

Phrase: "structure"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678594:Structure [Spatial Concept]

Phrase: "and"

Phrase: "function."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0031843:function [Physiologic Function]
  1000   C0542341:Function [Functional Concept]
  1000   C0700205:FUNCTION [Classification]
  1000   C1705273:Function [Intellectual Product]
   928 E C0205245:Functional [Functional Concept]
   928 E C2700217:Functional [Conceptual Entity]
Processing 00000000.tx.152: Structurally, the pancreatic KATP channel consists of two unrelated subunits: a sulfonylurea receptor (the SUR1 isoform) that is a member of the ABC transporter family and a potassium channel subunit (Kir6.2) that forms the central ion-conducting pathway (Fig. 3A). 

Phrase: "Structurally,"

Phrase: "the pancreatic KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439799:Channel [Spatial Concept]
   827   C1706095:Channel [Conceptual Entity]

Phrase: "consists of two unrelated subunits"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0205448:Two [Quantitative Concept]
   760   C0332529:CONSIST [Qualitative Concept]
   760   C0445356:Unrelated [Finding]
   760   C1704623:Unrelated [Qualitative Concept]
   726   C1711351:Subunit [Quantitative Concept]

Phrase: ":"

Phrase: "a sulfonylurea receptor"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   861   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   861   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   861   C3536898:Sulfonylurea [Pharmacologic Substance]

Phrase: "("

Phrase: "the SUR1 isoform"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0597298:Isoform [Amino Acid, Peptide, or Protein]

Phrase: ")"

Phrase: "that"

Phrase: "is"

Phrase: "a member of the ABC transporter family"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   774   C0086282:Family member [Family Group]
   774   C1611821:Family Member [Intellectual Product]
   748   C0680022:member [Population Group]
   748   C2698041:Member [Professional or Occupational Group]

Phrase: "and"

Phrase: "a potassium channel subunit"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1711351:Subunit [Quantitative Concept]
   734   C0032824:Potassium Channel [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:Kir6.2 [Gene or Genome]

Phrase: ")"

Phrase: "that"

Phrase: "forms"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0348078:Form [Qualitative Concept]
  1000   C0376315:Form [Manufactured Object]
  1000   C1522492:Form [Functional Concept]

Phrase: "the central ion-conducting pathway"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0457123:Conducting pathway [Body Part, Organ, or Organ Component]
   812   C1704259:Pathway [Molecular Function]
   812   C1705987:Pathway [Conceptual Entity]

Phrase: "(Fig. 3A"

Phrase: ")."
Processing 00000000.tx.153: The mature KATP channel exists as an octamer of Kir6.2 and SUR1 subunits in a 4:4 stoichiometry (Fig. 3B) (59,69,70). 

Phrase: "The mature KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439799:Channel [Spatial Concept]
   827   C1706095:Channel [Conceptual Entity]

Phrase: "exists as an octamer of Kir6.2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   778   C1416578:Kir6.2 [Gene or Genome]
   748   C2987476:Exist [Conceptual Entity]

Phrase: "and"

Phrase: "SUR1 subunits in a 4"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   714   C1711351:Subunit [Quantitative Concept]

Phrase: ":"

Phrase: "4 stoichiometry"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597526:Stoichiometry [Quantitative Concept]

Phrase: "(Fig. 3B"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450365:3b [Intellectual Product]
   861   C1706097:3B [Research Activity]

Phrase: ")"

Phrase: "(59,"

Phrase: "69,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450388:69 [Intellectual Product]

Phrase: "70"

Phrase: ")."
Processing 00000000.tx.154: The signature ATP inhibition of the channel results from binding to the pore-forming Kir6.2 subunit (71,72,73,74,75,76). 

Phrase: "The signature ATP inhibition of the channel"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0021467:Inhibition [Mental Process]
   748   C0021469:Inhibition [Molecular Function]
   748   C1628982:% inhibition [Quantitative Concept]
   748   C3463820:Inhibition [Activity]

Phrase: "results from binding"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0243122:binding [Functional Concept]
   790   C1145667:Binding [Activity]
   790   C1167622:Binding [Molecular Function]
   790   C1274040:Result [Functional Concept]
   790   C1546471:Result [Idea or Concept]
   790   C2825142:Result [Finding]

Phrase: "to the pore-forming Kir6.2 subunit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C1711351:Subunit [Quantitative Concept]

Phrase: "(71,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450389:71 [Intellectual Product]

Phrase: "72,"

Phrase: "73,"

Phrase: "74,"

Phrase: "75,"

Phrase: "76"

Phrase: ")."
Processing 00000000.tx.155: Importantly, the inhibitory concentration of ATP causing half-maximal channel inhibition is in the micromolar range (K1/2[ATP] 10 mol/l for native KATP channel) (77), yet cytosolic [ATP] is in the millimolar range (15 mmol/l) and changes little in the presence of high glucose (78). 

Phrase: "Importantly,"

Phrase: "the inhibitory concentration of ATP causing half-maximal channel inhibition"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   739   C0086045:Concentration [Mental Process]
   739   C1446561:Concentration [Quantitative Concept]
   739   C3463820:Inhibitory [Activity]
   722   C2347813:Concentration Maximum [Quantitative Concept]

Phrase: "is in the micromolar range"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0439300:micromolar [Quantitative Concept]
   760   C1514721:Range [Quantitative Concept]
   760   C2348147:Range [Quantitative Concept]
   760   C3542016:Range [Intellectual Product]

Phrase: "(K1/2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1721009:K1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C3272787:K1 [Gene or Genome]

Phrase: "[ATP"

Phrase: "] 10 mol/l for native KATP channel"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   778   C0347982:mol/L [Quantitative Concept]

Phrase: ")"

Phrase: "(77"

Phrase: ")"

Phrase: ","

Phrase: "yet cytosolic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1383501:Cytosolic [Cell Component]

Phrase: "[ATP"

Phrase: "]"

Phrase: "is in the millimolar range"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C1514721:Range [Quantitative Concept]
   760   C1532563:millimolar [Quantitative Concept]
   760   C2348147:Range [Quantitative Concept]
   760   C3542016:Range [Intellectual Product]

Phrase: "(15 mmol/"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439190:MMOLE [Quantitative Concept]

Phrase: "l)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "and"

Phrase: "changes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0392747:Change [Functional Concept]
  1000   C0443172:change [Quantitative Concept]
  1000   C1705241:Change [Quantitative Concept]

Phrase: "little in the presence of high glucose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0023882:Little NOS [Congenital Abnormality,Disease or Syndrome]
   748   C0700321:Little [Quantitative Concept]
   748   C2700395:Little [Quantitative Concept]

Phrase: "(78"

Phrase: ")."
Processing 00000000.tx.156: This observation implicates MgADP, rather than ATP, as the primary physiological regulator of channel activity. 

Phrase: "This observation"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0302523:Observation [Research Activity]
  1000   C0700325:observation [Health Care Activity]
  1000   C1964257:Observation [Diagnostic Procedure]
   928 E C1518527:OBSERVATIONAL [Research Activity]

Phrase: "implicates"

Phrase: "MgADP,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024468:MgADP [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "rather than"

Phrase: "ATP,"

Phrase: "as"

Phrase: "the primary physiological regulator of channel activity."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   800   C1153078:channel regulator activity [Molecular Function]
   748   C0182953:REGULATOR [Medical Device]
   748   C1704734:Regulator [Medical Device]
   748   C1704735:Regulator [Conceptual Entity]
Processing 00000000.tx.157: Through interaction with SUR1, MgADP "stimulates" channel activity by countering ATP inhibition (8,7983). 

Phrase: "Through interaction"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1704675:Interaction [Functional Concept]

Phrase: "with SUR1,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   827   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   827   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   827   C3536898:Sulfonylurea [Pharmacologic Substance]

Phrase: "MgADP """
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024468:MgADP [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "stimulates"

Phrase: """ channel activity by countering ATP inhibition"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C1153410:channel activity [Molecular Function]
   753   C0205177:Activity [Functional Concept]
   753   C0439167:% activity [Quantitative Concept]
   753   C0441655:Activity [Activity]
   753   C1561536:*Activity [Idea or Concept]

Phrase: "(8,"

Phrase: "7983"

Phrase: ")."
Processing 00000000.tx.158: SUR1 mutations that abolish MgADP action, but do not alter ATP sensitivity, also abolish channel activity in vivo and underlie CHI (8,84). 

Phrase: "SUR1 mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0026882:Mutations [Genetic Function]
   779 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "that"

Phrase: "abolish"

Phrase: "MgADP action,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441472:Action [Functional Concept]
   861   C3266814:Action [Activity]

Phrase: "but"

Phrase: "do"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "ATP sensitivity,"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]

Phrase: "also"

Phrase: "abolish"

Phrase: "channel activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1153410:channel activity [Molecular Function]
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "in vivo"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo

Phrase: "and"

Phrase: "underlie"

Phrase: "CHI"

Phrase: "(8,"

Phrase: "84"

Phrase: ")."
Processing 00000000.tx.159: It should be pointed out, however, that despite the essential regulatory role of MgADP, ATP sensitivity of the channel will still be critical in determining the magnitude of KATP channel current. 

Phrase: "It"

Phrase: "should"

Phrase: "be"

Phrase: "pointed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1552961:Point [Quantitative Concept]
   966   C2347617:point [Quantitative Concept]

Phrase: "out,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439787:Out [Spatial Concept]
  1000   C0849355:Out [Qualitative Concept]

Phrase: "however,"

Phrase: "that despite the essential regulatory role of MgADP,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   744   C0024468:MgADP [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   744   C0035820:Role [Social Behavior]
   744   C0205224:Essential [Qualitative Concept]
   744   C0220905:regulatory [Regulation or Law]
   744   C1704735:Regulatory [Conceptual Entity]
   744   C1705810:Role [Conceptual Entity]

Phrase: "ATP sensitivity of the channel"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   797   C1547341:Channel sensitivity [Idea or Concept]
   760   C0036667:Sensitivity [Quantitative Concept]
   760   C0312418:Sensitivity [Mental Process]
   760   C0427965:Sensitivity [Finding]
   760   C1511883:Sensitivity [Quantitative Concept]
   760   C1522640:Sensitivity [Qualitative Concept]
   760   C2346484:SENSITIVITY [Phenomenon or Process]
   760   C2349185:Sensitivity [Qualitative Concept]

Phrase: "will"

Phrase: "still"

Phrase: "be"

Phrase: "critical in determining"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1511545:Critical [Qualitative Concept]

Phrase: "the magnitude of KATP channel current."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0449286:magnitude [Quantitative Concept]
   753   C1704240:Magnitude [Quantitative Concept]
Processing 00000000.tx.160: For a given [MgADP], KATP channel mutations that decrease ATP sensitivity will enhance absolute currents in the physiologic range of ATP, and the net effect of enhanced KATP channel current is a decrease in -cell excitability. 

Phrase: "For a given"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]

Phrase: "[MgADP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024468:MgADP [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "],"

Phrase: "KATP channel mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "that"

Phrase: "decrease"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0392756:Decrease [Qualitative Concept]
  1000   C0547047:Decrease [Quantitative Concept]

Phrase: "ATP sensitivity"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]

Phrase: "will"

Phrase: "enhance"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349975:Enhance [Activity]

Phrase: "absolute currents in the physiologic range of ATP,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   744   C0521116:currents [Temporal Concept]
   711 E C1705970:Current [Natural Phenomenon or Process]

Phrase: "and"

Phrase: "the net effect of enhanced KATP channel current"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "is"

Phrase: "a decrease in -cell excitability."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0235169:Excitability [Sign or Symptom]
   741 E C0857393:excitable [Sign or Symptom]
Processing 00000000.tx.161: View larger version (35K): [in this window] [in a new window]  FIG. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(35K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  FIG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0349966:Fig [Food]
  1000   C1337208:FIG [Food]
Processing 00000000.tx.162: 3. 

Phrase: "3."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]
Processing 00000000.tx.163: Molecular basis of KATP channelinduced diabetes. 

Phrase: "Molecular basis of KATP channelinduced diabetes."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1853126:MOLECULAR BASIS [Idea or Concept]
   753   C1527178:Basis [Functional Concept]
   753   C1874451:Basis [Pharmacologic Substance]
Processing 00000000.tx.164: A: Membrane topology of SUR1x and Kir6.2 subunits of the KATP channel. 

Phrase: "A"

Phrase: ":"

Phrase: "Membrane topology of SUR1x"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0002812:Topology [Biomedical Occupation or Discipline]

Phrase: "and"

Phrase: "Kir6.2 subunits of the KATP channel."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   714   C1711351:Subunit [Quantitative Concept]
Processing 00000000.tx.165: ATP inhibits KATP channels by binding to the Kir6.2 subunit. 

Phrase: "ATP"

Phrase: "inhibits"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "KATP channels by binding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   737   C0439799:Channel [Spatial Concept]
   737   C1706095:Channel [Conceptual Entity]

Phrase: "to the Kir6.2 subunit."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1711351:Subunit [Quantitative Concept]
   734   C1416578:Kir6.2 [Gene or Genome]
Processing 00000000.tx.166: Nucleotide hydrolysis at the SUR1 nucleotide-binding folds (NBFs), or MgADP binding, is thought to counteract the inhibitory effect of ATP. 

Phrase: "Nucleotide hydrolysis at the SUR1 nucleotide-binding folds (NBFs),"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C0020291:Hydrolysis [Natural Phenomenon or Process]

Phrase: "or"

Phrase: "MgADP binding,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0243122:binding [Functional Concept]
   861   C1145667:Binding [Activity]
   861   C1167622:Binding [Molecular Function]

Phrase: "is"

Phrase: "thought"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039869:Thought [Mental Process]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "counteract"

Phrase: "the inhibitory effect of ATP."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.167: B: Predicted octameric structure of KATP channel. 

Phrase: "B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: ":"

Phrase: "Predicted octameric structure of KATP channel."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0678594:Structure [Spatial Concept]
Processing 00000000.tx.168: The functional channel consists of SUR1 or SUR2A and Kir6.2 subunits in a 1:1 stoichiometry. 

Phrase: "The functional channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439799:Channel [Spatial Concept]
   861   C1706095:Channel [Conceptual Entity]

Phrase: "consists of SUR1"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
   806   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   760   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   760   C0332529:CONSIST [Qualitative Concept]
   760   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   760   C3536898:Sulfonylurea [Pharmacologic Substance]

Phrase: "or"

Phrase: "SUR2A"

Phrase: "and"

Phrase: "Kir6.2 subunits in a 1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   719   C1711351:Subunit [Quantitative Concept]

Phrase: ":"

Phrase: "1 stoichiometry."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597526:Stoichiometry [Quantitative Concept]
Processing 00000000.tx.169: As shown from the top view, four Kir6.2 subunits surround and form a central pore. 

Phrase: "As"

Phrase: "shown from the top view,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0449911:View [Spatial Concept]
   760   C1704458:Top [Spatial Concept]
   726   C1547282:Show [Intellectual Product]

Phrase: "four Kir6.2 subunits"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   779   C1711351:Subunit [Quantitative Concept]

Phrase: "surround"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1282914:Surround [Spatial Concept]

Phrase: "and"

Phrase: "form"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0348078:Form [Qualitative Concept]
  1000   C0376315:Form [Manufactured Object]
  1000   C1522492:Form [Functional Concept]

Phrase: "a central pore."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1325742:Pore [Cell Component]
Processing 00000000.tx.170: C: Ribbon diagram of two opposing cytoplasmic domains and two opposing transmembrane domains of Kir6.2, modeled on the crystal structure of KirBac1.1 (86). 

Phrase: "C"

Phrase: ":"

Phrase: "Ribbon diagram of two"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0681494:Diagram [Intellectual Product]

Phrase: "opposing"

Phrase: "cytoplasmic domains"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   983   C1511625:Cytoplasmic Domain [Cell Component]
   827   C1880389:Domain [Functional Concept]
   827   C1883221:Domain [Conceptual Entity]
   827   C3541951:Domain [Intellectual Product]

Phrase: "and"

Phrase: "two"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205448:Two [Quantitative Concept]

Phrase: "opposing"

Phrase: "transmembrane domains of Kir6.2,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   773   C1519623:Transmembrane Domain [Amino Acid Sequence]
   760   C1167322:transmembrane [Cell Component]
   760   C2752508:transmembrane [Cell Component]
   726   C1880389:Domain [Functional Concept]
   726   C1883221:Domain [Conceptual Entity]
   726   C3541951:Domain [Intellectual Product]

Phrase: "modeled on the crystal structure of KirBac1.1"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   770   C0444626:Crystal Structure [Chemical Viewed Structurally]
           Crystal
   744   C0427896:Crystal [Body Substance]
   744   C0678594:Structure [Spatial Concept]
   744   C1533132:Crystal [Body Substance]
   744   C1704641:Crystal [Manufactured Object]
   714   C0026349:Structural Model [Manufactured Object]
   711   C3161035:Model [Intellectual Product]

Phrase: "(86"

Phrase: ")."
Processing 00000000.tx.171: Many Kir6.2 residues mutated in human neonatal diabetes are indicated, together with K185, which is an additional residue that is predicted to line the ATP-binding cavity (see text for complete list of Kir6.2 residues mutated in neonatal diabetes). 

Phrase: "Many Kir6.2 residues"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   793   C1709915:Residue [Conceptual Entity]
   793   C1882936:RESIDUE [Phenomenon or Process]
   743 E C1609982:Residual [Qualitative Concept]
   734   C1416578:Kir6.2 [Gene or Genome]

Phrase: "mutated in human neonatal diabetes"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   806   C0158981:Neonatal diabetes [Disease or Syndrome]
   797   C0598967:neonatal human [Age Group]
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0086418:Human [Human]
   760   C1552240:Neonatal [Professional or Occupational Group]
   760   C1552264:Neonatal [Professional or Occupational Group]
   760   C1705285:Mutated [Cell or Molecular Dysfunction]
   760   C2939425:Neonatal [Temporal Concept]
   726 E C1513776:Mutate [Genetic Function]

Phrase: "are"

Phrase: "indicated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1444656:Indicated [Finding]

Phrase: ","

Phrase: "together with K185,"

Phrase: "which"

Phrase: "is"

Phrase: "an additional residue"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C1709915:Residue [Conceptual Entity]
   861   C1882936:RESIDUE [Phenomenon or Process]
   789 E C1609982:Residual [Qualitative Concept]

Phrase: "that"

Phrase: "is"

Phrase: "predicted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0681842:Predicted [Idea or Concept]
  1000   C1882327:%{Predicted} [Quantitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "line"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205132:Line [Spatial Concept]
  1000   C1550648:Line [Substance]
  1000   C1552960:Line [Quantitative Concept]

Phrase: "the ATP-binding cavity"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0011334:cavity [Disease or Syndrome]
   827   C0333343:Cavity [Body Space or Junction]
   827   C1510420:Cavity [Anatomical Abnormality]
   734   C1148923:ATP binding [Molecular Function]

Phrase: "("

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "text for complete list of Kir6.2 residues"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C1527021:Text [Intellectual Product]
   744   C1554111:Text [Idea or Concept]
   744   C1705606:Text [Intellectual Product]
   744   C3541382:Text [Intellectual Product]

Phrase: "mutated in neonatal diabetes"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   833   C0158981:Neonatal diabetes [Disease or Syndrome]
   770   C0011847:Diabetes [Disease or Syndrome]
   770   C0011849:Diabetes [Disease or Syndrome]
   770   C1552240:Neonatal [Professional or Occupational Group]
   770   C1552264:Neonatal [Professional or Occupational Group]
   770   C1705285:Mutated [Cell or Molecular Dysfunction]
   770   C2939425:Neonatal [Temporal Concept]
   737 E C1513776:Mutate [Genetic Function]

Phrase: ")."
Processing 00000000.tx.172: Residues are classified as those putatively involved in ATP binding (red and pink) or in regulation of open-state stability (blue and green). 

Phrase: "Residues"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   966   C1709915:Residue [Conceptual Entity]
   966   C1882936:RESIDUE [Phenomenon or Process]
   916 E C1609982:Residual [Qualitative Concept]

Phrase: "are"

Phrase: "classified as those putatively"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0008902:Classified [Classification]

Phrase: "involved in ATP binding"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C1148923:ATP binding [Molecular Function]
   770   C0243122:binding [Functional Concept]
   770   C1145667:Binding [Activity]
   770   C1167622:Binding [Molecular Function]
   770   C1314939:Involved [Functional Concept]

Phrase: "(red"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332575:Red [Finding]
  1000   C1260956:Red [Qualitative Concept]

Phrase: "and"

Phrase: "pink"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332585:Pink [Qualitative Concept]

Phrase: ")"

Phrase: "or in regulation of open-state stability"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   748   C0175566:Open [Spatial Concept]
   748   C0205360:Stability [Qualitative Concept]
   748   C0851285:Regulation [Governmental or Regulatory Activity]
   748   C1301808:State [Geographic Area]
   748   C1327622:Regulation [Biologic Function]
   748   C1442792:State [Functional Concept]
   748   C2347098:Stability [Qualitative Concept]
   748   C3148680:State [Geographic Area]

Phrase: "(blue"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260957:Blue [Qualitative Concept]

Phrase: "and"

Phrase: "green"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332583:Green [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.173: The type 2 diabetesassociated polymorphism E23K is located in the far NH2-terminus, for which a predicted structural location is unavailable.  

Phrase: "The type 2 diabetesassociated polymorphism E23K"

Phrase: "is"

Phrase: "located in the far NH2-terminus,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0002508:NH2 [Organic Chemical]
   753   C0025033:NH2 [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance]
   753   C0205108:far [Spatial Concept]

Phrase: "for which"

Phrase: "a predicted structural location"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0450429:Location [Spatial Concept]
   827   C1515974:Location [Body Location or Region]

Phrase: "is"

Phrase: "unavailable."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0686905:Unavailable [Functional Concept]
Processing 00000000.tx.174: Molecular mechanisms of KATP channelinduced neonatal diabetes. 

Phrase: "Molecular mechanisms of KATP channelinduced neonatal diabetes."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   748   C0441712:Mechanisms [Functional Concept]
   714 E C1706376:Mechanism [Manufactured Object]
Processing 00000000.tx.175: Multiple permanent neonatal diabetes mutations have now been identified in Kir6.2 (Fig. 3C). 

Phrase: "Multiple permanent neonatal diabetes mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   804   C0026882:Mutations [Genetic Function]
   771 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "have"

Phrase: "now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948052:Now [Temporal Concept]

Phrase: "been"

Phrase: "identified in Kir6.2"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C1416578:Kir6.2 [Gene or Genome]
   770   C0205396:Identified [Qualitative Concept]
   770   C1550043:Identified [Finding]
   770   C1551388:Identified [Functional Concept]

Phrase: "(Fig. 3C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450366:3c [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.176: To date, the most frequently mutated residues are R201 and V59; 

Phrase: "To date,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011008:Date [Temporal Concept]
  1000   C2348077:Date [Food]

Phrase: "the most frequently mutated residues"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   779   C1709915:Residue [Conceptual Entity]
   779   C1882936:RESIDUE [Phenomenon or Process]
   729 E C1609982:Residual [Qualitative Concept]

Phrase: "are"

Phrase: "R201"

Phrase: "and"

Phrase: "V59"

Phrase: ";"
Processing 00000000.tx.177: heterozygous mutations of these residues have been detected in multiple probands (27,29,30). 

Phrase: "heterozygous mutations of these residues"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0026882:Mutations [Genetic Function]
   726 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "have"

Phrase: "been"

Phrase: "detected in multiple probands"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   770   C0439064:Multiple [Quantitative Concept]
   770   C0442726:Detected [Finding]
   770   C0702111:probands [Organism Attribute]
   770   C1511790:Detected [Therapeutic or Preventive Procedure]
   737 E C1948021:Proband [Family Group]

Phrase: "(27,"

Phrase: "29,"

Phrase: "30"

Phrase: ")."
Processing 00000000.tx.178: Y330C accounted for three cases of permanent neonatal diabetes (28,30), whereas K170 substitutions accounted for two permanent neonatal diabetes cases (K170N and K170R) (29). 

Phrase: "Y330C"

Phrase: "accounted for three cases of permanent neonatal diabetes"
Meta Candidates (Total=15; Excluded=2; Pruned=0; Remaining=13)
   770   C0158981:Neonatal diabetes [Disease or Syndrome]
   744   C0011847:Diabetes [Disease or Syndrome]
   744   C0011849:Diabetes [Disease or Syndrome]
   744   C0205355:Permanent [Temporal Concept]
   744   C0205449:Three [Quantitative Concept]
   744   C0868928:Cases [Functional Concept]
   744   C1533148:Cases [Quantitative Concept]
   744   C1552240:Neonatal [Professional or Occupational Group]
   744   C1552264:Neonatal [Professional or Occupational Group]
   744   C2939425:Neonatal [Temporal Concept]
   711   C1551359:account [Idea or Concept]
   711 E C1706255:CASE [Medical Device]
   711 E C1706256:Case [Conceptual Entity]
   711   C2741673:Account # [Clinical Attribute]
   711   C2981730:Account [Classification]

Phrase: "(28,"

Phrase: "30"

Phrase: ")"

Phrase: ","

Phrase: "whereas"

Phrase: "K170 substitutions"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1555721:Substitution [Idea or Concept]
   827   C1706204:Substitution [Activity]

Phrase: "accounted for two permanent neonatal diabetes cases"
Meta Candidates (Total=15; Excluded=2; Pruned=0; Remaining=13)
   778   C0158981:Neonatal diabetes [Disease or Syndrome]
   748   C0011847:Diabetes [Disease or Syndrome]
   748   C0011849:Diabetes [Disease or Syndrome]
   748   C0205355:Permanent [Temporal Concept]
   748   C0205448:Two [Quantitative Concept]
   748   C0868928:Cases [Functional Concept]
   748   C1533148:Cases [Quantitative Concept]
   748   C1552240:Neonatal [Professional or Occupational Group]
   748   C1552264:Neonatal [Professional or Occupational Group]
   748   C2939425:Neonatal [Temporal Concept]
   714   C1551359:account [Idea or Concept]
   714 E C1706255:CASE [Medical Device]
   714 E C1706256:Case [Conceptual Entity]
   714   C2741673:Account # [Clinical Attribute]
   714   C2981730:Account [Classification]

Phrase: "(K170N"

Phrase: "and"

Phrase: "K170R"

Phrase: ")"

Phrase: "(29"

Phrase: ")."
Processing 00000000.tx.179: Q52R, I296L, R50P, F33I, and E322K have all been found in one proband each (28,29,31). 

Phrase: "Q52R,"

Phrase: "I296L,"

Phrase: "R50P,"

Phrase: "F33I,"

Phrase: "and"

Phrase: "E322K"

Phrase: "have"

Phrase: "all"

Phrase: "been"

Phrase: "found in one proband"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   770   C0150312:Found [Quantitative Concept]
   770   C0205447:One [Quantitative Concept]
   770   C1948021:Proband [Family Group]
   737 E C0243095:Find [Finding]
   715 E C0702110:Propositus [Organism Attribute]

Phrase: "each"

Phrase: "(28,"

Phrase: "29,"

Phrase: "31"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.180: Kir6.2 mutations causing transient neonatal diabetes include G53, I182, and C42 (32,33). 

Phrase: "Kir6.2 mutations"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]
   734   C1416578:Kir6.2 [Gene or Genome]

Phrase: "causing"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0678227:Causing [Functional Concept]
   966 E C0015127:cause [Functional Concept]
   966 E C1524003:Cause [Conceptual Entity]

Phrase: "transient neonatal diabetes"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   901   C0158981:Neonatal diabetes [Disease or Syndrome]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0040704:Transient [Population Group]
   827   C0205374:Transient [Temporal Concept]
   827   C1552240:Neonatal [Professional or Occupational Group]
   827   C1552264:Neonatal [Professional or Occupational Group]
   827   C2939425:Neonatal [Temporal Concept]

Phrase: "include"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332257:include [Functional Concept]
  1000   C1552866:include [Idea or Concept]
  1000   C2700399:Include [Activity]

Phrase: "G53,"

Phrase: "I182,"

Phrase: "and"

Phrase: "C42"

Phrase: "(32,"

Phrase: "33"

Phrase: ")."
Processing 00000000.tx.181: These mutations could reduce ATP sensitivity 1) directly by decreasing the affinity of the ATP-binding pocket for the nucleotide, 2) indirectly by an increase in the intrinsic stability of the open state of the channel, or 3) indirectly by an increased sensitivity to the counteractivation by MgADP or by phosphatidylinositol-4,5-bisphosphate (PIP2) or other phospholipids. 

Phrase: "These mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "could"

Phrase: "reduce"

Phrase: "ATP sensitivity 1"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   827   C0036667:Sensitivity [Quantitative Concept]
   827   C0312418:Sensitivity [Mental Process]
   827   C0427965:Sensitivity [Finding]
   827   C1511883:Sensitivity [Quantitative Concept]
   827   C1522640:Sensitivity [Qualitative Concept]
   827   C2346484:SENSITIVITY [Phenomenon or Process]
   827   C2349185:Sensitivity [Qualitative Concept]
   755 E C0332324:Sensitive [Functional Concept]
   755 E C1550474:sensitive [Idea or Concept]

Phrase: ")"

Phrase: "directly by decreasing"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0442797:Decreasing [Qualitative Concept]
   790   C1947931:Directly [Qualitative Concept]
   756 E C0392756:Decrease [Qualitative Concept]
   756 E C0547047:Decrease [Quantitative Concept]

Phrase: "the affinity of the ATP-binding pocket"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "for the nucleotide,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0028630:Nucleotide [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ")"

Phrase: "indirectly by an increase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0442805:Increase [Functional Concept]

Phrase: "in the intrinsic stability"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0205360:Stability [Qualitative Concept]
   861   C2347098:Stability [Qualitative Concept]
   789 E C1547311:Stable [Intellectual Product]

Phrase: "of the open state"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   861   C0175566:Open [Spatial Concept]
   861   C1301808:State [Geographic Area]
   861   C1442792:State [Functional Concept]
   861   C3148680:State [Geographic Area]
   789 E C0547049:Openness [Spatial Concept]

Phrase: "of the channel,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439799:Channel [Spatial Concept]
  1000   C1706095:Channel [Conceptual Entity]

Phrase: "or"

Phrase: "3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")"

Phrase: "indirectly by an increased sensitivity"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   806   C1881189:INCREASED SENSITIVITY [Phenomenon or Process]
   806   C2346484:INCREASED SENSITIVITY [Phenomenon or Process]
           SENSITIVITY
   760   C0036667:Sensitivity [Quantitative Concept]
   760   C0205217:Increased [Quantitative Concept]
   760   C0312418:Sensitivity [Mental Process]
   760   C0427965:Sensitivity [Finding]
   760   C0442805:Increased [Functional Concept]
   760   C1511883:Sensitivity [Quantitative Concept]
   760   C1522640:Sensitivity [Qualitative Concept]
   760   C2349185:Sensitivity [Qualitative Concept]

Phrase: "to the counteractivation"

Phrase: "by MgADP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024468:MgADP [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "or by phosphatidylinositol-4,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0031621:Phosphatidyl Inositol [Biologically Active Substance,Lipid]
   770   C2348046:Phosphatidylinositol [Lipid]

Phrase: "5-bisphosphate"

Phrase: "(PIP2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0070798:PIP2 [Biologically Active Substance,Lipid,Organophosphorus Compound]
  1000   C3538724:PIP2 [Body Part, Organ, or Organ Component]

Phrase: ")"

Phrase: "or"

Phrase: "other phospholipids."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0031676:Phospholipids [Biologically Active Substance,Lipid]
   966 E C0202177:Phospholipid [Laboratory Procedure]
Processing 00000000.tx.182: Consistent with a direct effect on binding, R50, I182, Y330, F333, and R201 have all previously been implicated as putative ATP-binding residues in Kir6.2 (27,74,85). 

Phrase: "Consistent with a direct effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C0332290:Consistent with [Idea or Concept]
           Consistent

Phrase: "on binding,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0243122:binding [Functional Concept]
  1000   C1145667:Binding [Activity]
  1000   C1167622:Binding [Molecular Function]

Phrase: "R50,"

Phrase: "I182,"

Phrase: "Y330,"

Phrase: "F333,"

Phrase: "and"

Phrase: "R201"

Phrase: "have"

Phrase: "all previously"

Phrase: "been"

Phrase: "implicated as putative ATP-binding residues"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C1148923:ATP binding [Molecular Function]
   753   C0243122:binding [Functional Concept]
   753   C1145667:Binding [Activity]
   753   C1167622:Binding [Molecular Function]
   719   C1709915:Residue [Conceptual Entity]
   719   C1882936:RESIDUE [Phenomenon or Process]

Phrase: "in Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:Kir6.2 [Gene or Genome]

Phrase: "(27,"

Phrase: "74,"

Phrase: "85"

Phrase: ")."
Processing 00000000.tx.183: Modeling of the COOH-terminus of Kir6.2, based on homology with the crystal structure of the related Kir3.1, predicts that I182 resides in a hydrophobic pocket that coordinates the adenine ring of ATP (75), while positively charged R201 and R50 are predicted to interact electrostatically with the phosphate tail of ATP (75,85,86). 

Phrase: "Modeling of the COOH-terminus of Kir6.2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0870071:Modeling [Intellectual Product,Research Activity]

Phrase: "based on homology"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   790   C1334043:Homology [Gene or Genome]
   790   C1527178:Based [Functional Concept]
   790   C1705938:Based [Idea or Concept]
   790   C2697616:Homology [Qualitative Concept]
   756 E C0002055:base [Inorganic Chemical]
   756 E C0178499:Base [Chemical Viewed Functionally]
   756 E C1880279:Base [Biomedical or Dental Material]

Phrase: "with the crystal structure"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0444626:Crystal Structure [Chemical Viewed Structurally]
           Crystal
   861   C0427896:Crystal [Body Substance]
   861   C0678594:Structure [Spatial Concept]
   861   C1533132:Crystal [Body Substance]
   861   C1704641:Crystal [Manufactured Object]

Phrase: "of the related Kir3.1,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   901   C1416585:Kir3.1 [Gene or Genome]
   827   C0439849:Related [Qualitative Concept]
   827   C0445223:Related [Finding]
   755 E C0080103:Relation [Family Group]
   755 E C0869014:Relations [Social Behavior]

Phrase: "predicts"

Phrase: "that I182"

Phrase: "resides in a hydrophobic pocket"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0598629:Hydrophobic [Qualitative Concept]
   760   C2982691:Reside [Activity]

Phrase: "that"

Phrase: "coordinates"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0427184:coordinate [Finding]
  1000   C0700114:coordinate [Functional Concept]
  1000   C1707511:Coordinate [Spatial Concept]

Phrase: "the adenine ring of ATP"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0521164:Ring [Spatial Concept]
   760   C1260969:Ring [Medical Device]
   760   C1705184:Ring [Medical Device]

Phrase: "(75"

Phrase: ")"

Phrase: ","

Phrase: "while"

Phrase: "positively charged R201"

Phrase: "and"

Phrase: "R50"

Phrase: "are"

Phrase: "predicted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0681842:Predicted [Idea or Concept]
  1000   C1882327:%{Predicted} [Quantitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "interact"

Phrase: "electrostatically with the phosphate tail of ATP"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   748   C0031701:phosphate [Organophosphorus Compound]
   748   C0039259:Tail [Body Part, Organ, or Organ Component]
   748   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]

Phrase: "(75,"

Phrase: "85,"

Phrase: "86"

Phrase: ")."
Processing 00000000.tx.184: Both Y330 and F333 also predicted to lie close to the phosphate tail in the binding pocket (87). 

Phrase: "Both Y330"

Phrase: "and"

Phrase: "F333 also"

Phrase: "predicted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0681842:Predicted [Idea or Concept]
  1000   C1882327:%{Predicted} [Quantitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "lie"

Phrase: "close to the phosphate tail"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0587267:Close [Functional Concept]

Phrase: "in the binding pocket"

Phrase: "(87"

Phrase: ")."
Processing 00000000.tx.185: Fully consistent with the above structural model of the ATP-binding pocket, functional characterization now demonstrates a significant decrease in the ATP sensitivities of these mutants (27,32,38,39). 

Phrase: "Fully consistent with the above structural model of the ATP-binding pocket,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0332290:Consistent with [Idea or Concept]
           Consistent

Phrase: "functional characterization now"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1880022:Characterization [Activity]

Phrase: "demonstrates"

Phrase: "a significant decrease in the ATP sensitivities of these mutants"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0392756:Decrease [Qualitative Concept]
   739   C0547047:Decrease [Quantitative Concept]

Phrase: "(27,"

Phrase: "32,"

Phrase: "38,"

Phrase: "39"

Phrase: ")."
Processing 00000000.tx.186: In the case of I182V, R201C, R201H, and F333I, these mutations do not alter gating of the channel and are, therefore, likely to directly alter ATP affinity at the binding pocket. 

Phrase: "In the case"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0868928:Case [Functional Concept]
  1000   C1706255:CASE [Medical Device]
  1000   C1706256:Case [Conceptual Entity]

Phrase: "of I182V,"

Phrase: "R201C,"

Phrase: "R201H,"

Phrase: "and"

Phrase: "F333I,"

Phrase: "these mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "do"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "gating of the channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0439799:Channel [Spatial Concept]
   770   C1706095:Channel [Conceptual Entity]

Phrase: "and"

Phrase: "are"

Phrase: ","

Phrase: "therefore,"

Phrase: "likely to directly"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0332148:Likely [Qualitative Concept]
   827   C0750492:Likely [Idea or Concept]
   827   C1947931:Directly [Qualitative Concept]

Phrase: "alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "ATP affinity at the binding pocket."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1510827:Affinity [Natural Phenomenon or Process]
Processing 00000000.tx.187: A few additional residues in the NH2- and COOH-terminus are also likely to be involved in ATP binding (71,73,75,76,88,89), and we speculate that substitutions at these residues would also be disease causing. 

Phrase: "A few additional residues in the NH2-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   714   C1709915:Residue [Conceptual Entity]
   714   C1882936:RESIDUE [Phenomenon or Process]

Phrase: "and"

Phrase: "COOH-terminus"

Phrase: "are"

Phrase: "also likely to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0332148:Likely [Qualitative Concept]
   827   C0750492:Likely [Idea or Concept]

Phrase: "be"

Phrase: "involved in ATP binding"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C1148923:ATP binding [Molecular Function]
   770   C0243122:binding [Functional Concept]
   770   C1145667:Binding [Activity]
   770   C1167622:Binding [Molecular Function]
   770   C1314939:Involved [Functional Concept]

Phrase: "(71,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450389:71 [Intellectual Product]

Phrase: "73,"

Phrase: "75,"

Phrase: "76,"

Phrase: "88,"

Phrase: "89"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "we"

Phrase: "speculate"

Phrase: "that substitutions at these residues"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C1555721:Substitution [Idea or Concept]
   726   C1706204:Substitution [Activity]

Phrase: "would"

Phrase: "also"

Phrase: "be"

Phrase: "disease causing."
Meta Candidates (Total=8; Excluded=5; Pruned=0; Remaining=3)
   983   C1314792:disease cause [Functional Concept]
   861   C0012634:Disease [Disease or Syndrome]
   861   C0678227:Causing [Functional Concept]
   827 E C0015127:cause [Functional Concept]
   827 E C1524003:Cause [Conceptual Entity]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.188: With respect to indirect channel mechanisms, mutations that alter channel gating in the absence of ATP can have profound effects on apparent ATP sensitivity (73,76,90). 

Phrase: "With respect to indirect channel mechanisms,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0441712:Mechanisms [Functional Concept]
   793 E C1706376:Mechanism [Manufactured Object]

Phrase: "mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "that"

Phrase: "alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "channel gating in the absence of ATP"

Phrase: "can"

Phrase: "have"

Phrase: "profound effects on apparent ATP sensitivity"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "(73,"

Phrase: "76,"

Phrase: "90"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439083:>90 [Quantitative Concept]
  1000   C0439087:<90 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.189: Such mutations are found throughout the Kir6.2 subunit. 

Phrase: "Such mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "are"

Phrase: "found throughout the Kir6.2 subunit."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C1416578:Kir6.2 [Gene or Genome]
   753   C0150312:Found [Quantitative Concept]
   753   C1711351:Subunit [Quantitative Concept]
   719 E C0243095:Find [Finding]
Processing 00000000.tx.190: In some cases, these "open-state stability" mutations are located in transmembrane segments, a significant distance from the putative ATP-binding domain (86,91). 

Phrase: "In some cases,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0868928:Cases [Functional Concept]
  1000   C1533148:Cases [Quantitative Concept]
   966 E C1706255:CASE [Medical Device]
   966 E C1706256:Case [Conceptual Entity]

Phrase: "these ""open-state stability"" mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0026882:Mutations [Genetic Function]
   779 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "are"

Phrase: "located in transmembrane segments,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C1167322:transmembrane [Cell Component]
   770   C2752508:transmembrane [Cell Component]
   737   C0441635:Segment [Spatial Concept]

Phrase: "a significant distance from the putative ATP-binding domain"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0012751:Distance [Quantitative Concept]

Phrase: "(86,"

Phrase: "91"

Phrase: ")."
Processing 00000000.tx.191: Many, including E23K, stabilize the open state of the channel, thereby increasing the channel opening independently of ATP and indirectly reducing the apparent affinity for ATP (51,54). 

Phrase: "Many,"

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "E23K,"

Phrase: "stabilize"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0184512:stabilize [Qualitative Concept]

Phrase: "the open state of the channel,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0175566:Open [Spatial Concept]
   753   C1301808:State [Geographic Area]
   753   C1442792:State [Functional Concept]
   753   C3148680:State [Geographic Area]

Phrase: "thereby"

Phrase: "increasing"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442808:Increasing [Functional Concept]
   966 E C0442805:Increase [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0205217:Increased [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "the channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439799:Channel [Spatial Concept]
  1000   C1706095:Channel [Conceptual Entity]

Phrase: "opening independently of ATP"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0175566:Opening [Spatial Concept]
   770   C1882151:Opening [Spatial Concept]

Phrase: "and"

Phrase: "indirectly"

Phrase: "reducing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392756:Reducing [Qualitative Concept]

Phrase: "the apparent affinity for ATP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "(51,"

Phrase: "54"

Phrase: ")."
Processing 00000000.tx.192: The reported loss of ATP sensitivity coupled with high open probability in the Q52R, C42R, Y330C, I1296L, and V59G mutations suggests such a mechanism in these disease mutations (38,39). 

Phrase: "The reported loss of ATP sensitivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1517945:Loss [Quantitative Concept]

Phrase: "coupled with high open probability"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   760   C0033204:Probability [Quantitative Concept]
   760   C0175566:Open [Spatial Concept]
   760   C0205250:High [Qualitative Concept]
   760   C1299351:High [Qualitative Concept]
   760   C1948027:Coupled [Functional Concept]
   760   C2700149:HIGH [Intellectual Product]
   726 E C0010222:couple [Family Group]

Phrase: "in the Q52R,"

Phrase: "C42R,"

Phrase: "Y330C,"

Phrase: "I1296L,"

Phrase: "and"

Phrase: "V59G mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0026882:Mutations [Genetic Function]
   827 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "such a mechanism in these disease mutations"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0441712:Mechanism [Functional Concept]
   748   C1706376:Mechanism [Manufactured Object]

Phrase: "(38,"

Phrase: "39"

Phrase: ")."
Processing 00000000.tx.193: Consistent with the functional interpretation, Q52 and V59 are located within the predicted slide helix region of Kir6.2 and may regulate channel gating by coupling the ATP-binding site physically to the gating region (75,86). 

Phrase: "Consistent with the functional interpretation,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C0332290:Consistent with [Idea or Concept]
           Consistent

Phrase: "Q52"

Phrase: "and"

Phrase: "V59"

Phrase: "are"

Phrase: "located within the predicted slide helix region of Kir6.2"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   760   C1416578:Kir6.2 [Gene or Genome]
   739   C0017446:Region [Geographic Area]
   739   C0018882:Helix [Eukaryote]
   739   C0205147:Region [Spatial Concept]
   739   C0229304:Helix [Body Part, Organ, or Organ Component]
   739   C0444330:Slide [Research Device]
   739   C0681842:Predicted [Idea or Concept]
   739   C1704821:Helix [Spatial Concept]
   739   C1705201:Slide [Manufactured Object]
   739   C1705682:Helix [Anatomical Structure]
   739   C1882327:%{Predicted} [Quantitative Concept]

Phrase: "and"

Phrase: "may"

Phrase: "regulate"

Phrase: "channel gating by coupling"

Phrase: "the ATP-binding site physically to the gating region"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   764   C0005456:Binding Site [Receptor]
   764   C0682969:Binding Site [Amino Acid Sequence]
   764   C1148923:ATP binding [Molecular Function]
   742   C0205145:Site [Spatial Concept]
   742   C0243122:binding [Functional Concept]
   742   C1145667:Binding [Activity]
   742   C1167622:Binding [Molecular Function]
   742   C1515974:Site [Body Location or Region]
   742   C2825164:Site [Spatial Concept]

Phrase: "(75,"

Phrase: "86"

Phrase: ")."
Processing 00000000.tx.194: The second transmembrane helices in each of the Kir6.2 subunits converge at the so-called "bundle crossing" and may form the ligand-controlled gate (Fig. 3C) (86,91). 

Phrase: "The second transmembrane helices in each of the Kir6.2 subunits"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   738   C0018882:Helix [Eukaryote]
   738   C0229304:Helix [Body Part, Organ, or Organ Component]
   738   C1017315:helices [Eukaryote]
   738   C1167322:transmembrane [Cell Component]
   738   C1704821:Helix [Spatial Concept]
   738   C1705682:Helix [Anatomical Structure]
   738   C2752508:transmembrane [Cell Component]

Phrase: "converge at the so-called ""bundle crossing"""
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C2700387:Converge [Activity]
   714   C0679006:Call [Mental Process]
   714   C1947967:Call [Functional Concept]

Phrase: "and"

Phrase: "may"

Phrase: "form"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0348078:Form [Qualitative Concept]
  1000   C0376315:Form [Manufactured Object]
  1000   C1522492:Form [Functional Concept]

Phrase: "the ligand-controlled gate"

Phrase: "(Fig. 3C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450366:3c [Intellectual Product]

Phrase: ")"

Phrase: "(86,"

Phrase: "91"

Phrase: ")."
Processing 00000000.tx.195: An effect on the gate region of the channel might then explain the diabetes-causing effects of mutations at residue K170 (K170N and K170R; Fig. 3) within this region (29). 

Phrase: "An effect on the gate region of the channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C1280500:Effect [Qualitative Concept]
   742   C2348382:Effect [Qualitative Concept]

Phrase: "might"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "explain"

Phrase: "the diabetes-causing effects of mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "at residue K170"

Phrase: "(K170N"

Phrase: "and"

Phrase: "K170R"

Phrase: "; Fig. 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")"

Phrase: "within this region"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0017446:Region [Geographic Area]
  1000   C0205147:Region [Spatial Concept]
   928 E C0205276:Regional [Spatial Concept]
   928 E C1947913:Regional [Spatial Concept]

Phrase: "(29"

Phrase: ")."
Processing 00000000.tx.196: Since all proteins are evolutionarily tailored to generate specific functions, it follows that disease-causing mutations are most likely to cause loss of the specific function. 

Phrase: "Since"

Phrase: "all proteins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "are"

Phrase: "evolutionarily"

Phrase: "tailored"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0402883:tailored [Professional or Occupational Group]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "generate"

Phrase: "specific functions,"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   861   C0542341:Functions [Functional Concept]
   827 E C0031843:function [Physiologic Function]
   827 E C0700205:FUNCTION [Classification]
   827 E C1705273:Function [Intellectual Product]
   777 E C0205245:Functional [Functional Concept]
   777 E C2700217:Functional [Conceptual Entity]

Phrase: "it"

Phrase: "follows"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332283:follow [Temporal Concept]
  1000   C1719822:Follow [Intellectual Product]

Phrase: "that disease-causing mutations"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   988   C2985434:Disease-causing Mutation [Cell or Molecular Dysfunction]
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]
   717   C1314792:disease cause [Functional Concept]

Phrase: "are"

Phrase: "most likely to"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   901   C0750501:most likely [Idea or Concept]
   827   C0205393:Most [Quantitative Concept]
   827   C0332148:Likely [Qualitative Concept]
   827   C0750492:Likely [Idea or Concept]
   755 E C0033204:Likelihood [Quantitative Concept]

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "loss of the specific function."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1517945:Loss [Quantitative Concept]
Processing 00000000.tx.197: In the present context, loss of high-affinity inhibition by ATP, either directly or indirectly, is thus the most likely mechanism to underlie the net "gain of function" that underlies neonatal diabetes. 

Phrase: "In the present context,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0449255:Context [Finding]
   861   C0542559:Context [Functional Concept]

Phrase: "loss of high-affinity inhibition"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1517945:Loss [Quantitative Concept]

Phrase: "by ATP,"

Phrase: "either directly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1947931:Directly [Qualitative Concept]

Phrase: "or"

Phrase: "indirectly,"

Phrase: "is"

Phrase: "thus"

Phrase: "the most likely mechanism to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0441712:Mechanism [Functional Concept]
   812   C1706376:Mechanism [Manufactured Object]

Phrase: "underlie"

Phrase: "the net ""gain of function"""
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1517378:Gain [Quantitative Concept]

Phrase: "that underlies neonatal diabetes."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0158981:Neonatal diabetes [Disease or Syndrome]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.198: However, it is conceivable that spontaneous mutations may also cause an increase in an activating function, such as an increase in the MgADP affinity of SUR1. 

Phrase: "However,"

Phrase: "it"

Phrase: "is"

Phrase: "conceivable"

Phrase: "that spontaneous mutations"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   983   C0678939:spontaneous mutation [Genetic Function]
   861   C0026882:Mutations [Genetic Function]
   827 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "may"

Phrase: "also"

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "an increase in an activating function,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0442805:Increase [Functional Concept]

Phrase: "such as an increase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]

Phrase: "in the MgADP affinity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "of SUR1."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   827   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   827   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   827   C3536898:Sulfonylurea [Pharmacologic Substance]
Processing 00000000.tx.199: Alternately, mutations could increase the affinity for PIP2 or other phospholipids, which serve as activators of the channel. 

Phrase: "Alternately,"

Phrase: "mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "could"

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "the affinity for PIP2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "or"

Phrase: "other phospholipids,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0031676:Phospholipids [Biologically Active Substance,Lipid]
   966 E C0202177:Phospholipid [Laboratory Procedure]

Phrase: "which"

Phrase: "serve as activators of the channel."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0439799:Channel [Spatial Concept]
   753   C1706095:Channel [Conceptual Entity]
Processing 00000000.tx.200: In this regard, one or two rare mutations engineered into SUR1 (83,92) increase activation by MgADP, and they could potentially appear spontaneously. 

Phrase: "In this regard,"

Phrase: "one"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205447:One [Quantitative Concept]

Phrase: "or"

Phrase: "two rare mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "engineered into SUR1"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
   806   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   760   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   760   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   760   C0878517:engineered [Professional or Occupational Group]
   760   C3536898:Sulfonylurea [Pharmacologic Substance]

Phrase: "(83,"

Phrase: "92"

Phrase: ")"

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "activation by MgADP,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1879547:Activation [Activity]

Phrase: "and"

Phrase: "they"

Phrase: "could"

Phrase: "potentially"

Phrase: "appear"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700364:APPEAR [Qualitative Concept]

Phrase: "spontaneously."
Processing 00000000.tx.201: Mutations of Kir2.1, a related K channel subunit, underlie Andersens syndrome, which is characterized by dysmorphic facial features, epilepsy, and cardiac arrhythmias (93,94). 

Phrase: "Mutations of Kir2.1,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0026882:Mutations [Genetic Function]
   737 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "a related K channel subunit,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1711351:Subunit [Quantitative Concept]

Phrase: "underlie"

Phrase: "Andersens syndrome,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   983   C1563715:Andersen Syndrome [Disease or Syndrome]
   861   C0039082:Syndrome [Disease or Syndrome]

Phrase: "which"

Phrase: "is"

Phrase: "characterized by dysmorphic facial features,"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   806   C0871976:facial features [Organism Attribute]
   797   C0432072:Dysmorphic features [Congenital Abnormality]
   762   C0266617:Facial dysmorphism [Congenital Abnormality]
   760   C0015450:Facial [Body Location or Region]
   760   C0524465:Facial [Spatial Concept]
   760   C1880022:Characterized [Activity]
   726   C1521970:Feature [Qualitative Concept]
   726   C1706388:Feature [Conceptual Entity]
   726   C2346469:Feature [Qualitative Concept]
   726   C2348519:Feature [Qualitative Concept]

Phrase: "epilepsy,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0014544:Epilepsy [Disease or Syndrome]

Phrase: "and"

Phrase: "cardiac arrhythmias"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0003811:Arrhythmias, Cardiac [Pathologic Function]
           Arrhythmias
   966 E C1560249:CARDIAC ARRHYTHMIA [Finding]
   861   C0018787:Cardiac [Body Part, Organ, or Organ Component]
   861   C1522601:Cardiac [Spatial Concept]

Phrase: "(93,"

Phrase: "94"

Phrase: ")."
Processing 00000000.tx.202: It is argued that these mutations alter Kir2.1 channel function by modulating the phospholipids sensitivity (94). 

Phrase: "It"

Phrase: "is"

Phrase: "argued"

Phrase: "that"

Phrase: "these mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "Kir2.1 channel function by modulating"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0031843:function [Physiologic Function]
   753   C0542341:Function [Functional Concept]
   753   C0700205:FUNCTION [Classification]
   753   C1705273:Function [Intellectual Product]

Phrase: "the phospholipids sensitivity"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   861   C0036667:Sensitivity [Quantitative Concept]
   861   C0312418:Sensitivity [Mental Process]
   861   C0427965:Sensitivity [Finding]
   861   C1511883:Sensitivity [Quantitative Concept]
   861   C1522640:Sensitivity [Qualitative Concept]
   861   C2346484:SENSITIVITY [Phenomenon or Process]
   861   C2349185:Sensitivity [Qualitative Concept]
   789 E C0332324:Sensitive [Functional Concept]
   789 E C1550474:sensitive [Idea or Concept]

Phrase: "(94"

Phrase: ")."
Processing 00000000.tx.203: Similarly, many mutations in KATP are likely to affect apparent PIP2 sensitivity by changes in intrinsic open-state stability (54) or by change in affinity. 

Phrase: "Similarly,"

Phrase: "many mutations in KATP"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0026882:Mutations [Genetic Function]
   737 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "are"

Phrase: "likely to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332148:Likely [Qualitative Concept]
   861   C0750492:Likely [Idea or Concept]

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "apparent PIP2 sensitivity by changes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0036667:Sensitivity [Quantitative Concept]
   760   C0312418:Sensitivity [Mental Process]
   760   C0427965:Sensitivity [Finding]
   760   C1511883:Sensitivity [Quantitative Concept]
   760   C1522640:Sensitivity [Qualitative Concept]
   760   C2346484:SENSITIVITY [Phenomenon or Process]
   760   C2349185:Sensitivity [Qualitative Concept]

Phrase: "in intrinsic open-state stability"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   812   C0175566:Open [Spatial Concept]
   812   C0205360:Stability [Qualitative Concept]
   812   C1301808:State [Geographic Area]
   812   C1442792:State [Functional Concept]
   812   C2347098:Stability [Qualitative Concept]
   812   C3148680:State [Geographic Area]
   741 E C0547049:Openness [Spatial Concept]
   741 E C1547311:Stable [Intellectual Product]

Phrase: "(54"

Phrase: ")"

Phrase: "or by change"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0392747:Change [Functional Concept]
   790   C0443172:change [Quantitative Concept]
   790   C1705241:Change [Quantitative Concept]

Phrase: "in affinity."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1510827:Affinity [Natural Phenomenon or Process]
Processing 00000000.tx.204: Although none have been reported, it remains possible that neonatal diabetes could also result from gain of function due to an increased affinity for PIP2. 

Phrase: "Although"

Phrase: "none"

Phrase: "have"

Phrase: "been"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: ","

Phrase: "it"

Phrase: "remains"

Phrase: "possible"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332149:Possible [Qualitative Concept]
  1000   C1705910:Possible [Qualitative Concept]
  1000   C2362652:Possible [Qualitative Concept]

Phrase: "that neonatal diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0158981:Neonatal diabetes [Disease or Syndrome]
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "could"

Phrase: "also"

Phrase: "result from gain of function"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   760   C0031843:function [Physiologic Function]
   760   C0542341:Function [Functional Concept]
   760   C0700205:FUNCTION [Classification]
   760   C1274040:Result [Functional Concept]
   760   C1517378:Gain [Quantitative Concept]
   760   C1546471:Result [Idea or Concept]
   760   C1705273:Function [Intellectual Product]
   760   C2825142:Result [Finding]

Phrase: "due to an increased affinity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1510827:Affinity [Natural Phenomenon or Process]

Phrase: "for PIP2."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0070798:PIP2 [Biologically Active Substance,Lipid,Organophosphorus Compound]
  1000   C3538724:PIP2 [Body Part, Organ, or Organ Component]
Processing 00000000.tx.205: Perspectives and prospects. 

Phrase: "Perspectives"

Phrase: "and"

Phrase: "prospects."
Processing 00000000.tx.206: The 10-year effort that first yielded the molecular basis of KATP channel activity (77,79) permitted the generation of animal models of channel dysfunction (11) and paved the way to genetic determination of predisposing polymorphisms in type 2 diabetes (41,45,46,95) and disease-causing mutations in both CHI (5) and neonatal diabetes (27,29,33). 

Phrase: "The 10-year effort"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0015264:Effort [Organism Function]

Phrase: "that first"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205435:First [Quantitative Concept]
  1000   C1279901:First [Qualitative Concept]

Phrase: "yielded"

Phrase: "the molecular basis of KATP channel activity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C1853126:MOLECULAR BASIS [Idea or Concept]
   748   C1527178:Basis [Functional Concept]
   748   C1874451:Basis [Pharmacologic Substance]

Phrase: "(77,"

Phrase: "79"

Phrase: ")"

Phrase: "permitted"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0329040:permitted [Fish]
   966 E C0023636:Permit [Regulation or Law]

Phrase: "the generation of animal models of channel dysfunction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0079411:Generation [Temporal Concept]
   744   C3146294:Generation [Activity]

Phrase: "(11"

Phrase: ")"

Phrase: "and"

Phrase: "paved"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0211067:PAVe [Therapeutic or Preventive Procedure]

Phrase: "the way to genetic determination of predisposing polymorphisms"

Phrase: "in type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "(41,"

Phrase: "45,"

Phrase: "46,"

Phrase: "95"

Phrase: ")"

Phrase: "and"

Phrase: "disease-causing mutations in both CHI"
Meta Candidates (Total=13; Excluded=3; Pruned=0; Remaining=10)
   779   C2985434:Disease-causing Mutation [Cell or Molecular Dysfunction]
   764   C2931834:Congenital Hyperinsulinism [Disease or Syndrome]
   762   C0242354:Congenital disease [Congenital Abnormality,Disease or Syndrome]
   748   C1314792:disease cause [Functional Concept]
   742   C0009678:congenital [Qualitative Concept]
   742   C0012634:Disease [Disease or Syndrome]
   742   C0020459:Hyperinsulinism [Disease or Syndrome]
   742   C0026882:Mutations [Genetic Function]
   742   C0678227:Causing [Functional Concept]
   742   C1744681:Congenital [Qualitative Concept]
   708 E C0015127:cause [Functional Concept]
   708 E C1524003:Cause [Conceptual Entity]
   708 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "(5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ")"

Phrase: "and"

Phrase: "neonatal diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0158981:Neonatal diabetes [Disease or Syndrome]
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "(27,"

Phrase: "29,"

Phrase: "33"

Phrase: ")."
Processing 00000000.tx.207: This in turn has led to an immediate understanding of the likely molecular basis of permanent neonatal diabetes and to improved therapy (31,36). 

Phrase: "This in turn"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0541749:turn [Finding]
   861   C1709743:Turn [Spatial Concept]

Phrase: "has"

Phrase: "led to an immediate understanding of the likely molecular basis of permanent neonatal diabetes"
Meta Candidates (Total=22; Excluded=5; Pruned=0; Remaining=17)
   748   C0158981:Neonatal diabetes [Disease or Syndrome]
   748   C1853126:MOLECULAR BASIS [Idea or Concept]
   734   C0011847:Diabetes [Disease or Syndrome]
   734   C0011849:Diabetes [Disease or Syndrome]
   734   C0162340:Understanding [Mental Process]
   734   C0205253:Immediate [Temporal Concept]
   734   C0205355:Permanent [Temporal Concept]
   734   C0205548:Immediate [Temporal Concept]
   734   C0332148:Likely [Qualitative Concept]
   734   C0750492:Likely [Idea or Concept]
   734   C1521991:Molecular [Qualitative Concept]
   734   C1527178:Basis [Functional Concept]
   734   C1552240:Neonatal [Professional or Occupational Group]
   734   C1552264:Neonatal [Professional or Occupational Group]
   734   C1708698:LED [Manufactured Object]
   734   C1874451:Basis [Pharmacologic Substance]
   734   C2939425:Neonatal [Temporal Concept]
   701 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   701 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   701 E C1522538:Lead [Functional Concept]
   701 E C2348269:Lead [Element, Ion, or Isotope]
   701 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "and to improved therapy"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0039798:therapy [Functional Concept]
   770   C0087111:Therapy [Therapeutic or Preventive Procedure]
   770   C0184511:Improved [Qualitative Concept]
   770   C0332272:Improved [Qualitative Concept]
   770   C1363945:Therapy [Finding]
   770   C1515981:And [Idea or Concept]
   770   C1561611:Improved [Intellectual Product]

Phrase: "(31,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: "36"

Phrase: ")."
Processing 00000000.tx.208: This progression is a dramatic demonstration of the power of multidisciplinary biology in disease analysis. 

Phrase: "This progression"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0242656:progression [Pathologic Function]
  1000   C0449258:Progression [Functional Concept]

Phrase: "is"

Phrase: "a dramatic demonstration of the power of multidisciplinary biology"

Phrase: "in disease analysis."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0002778:Analysis [Laboratory Procedure]
   861   C0936012:Analysis [Research Activity]
   861   C1524024:analysis [Functional Concept]
Processing 00000000.tx.209: The current results elucidate the molecular basis of a traumatic neonatal disease and exciting possibilities for improvement in treatment options. 

Phrase: "The current results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]

Phrase: "elucidate"

Phrase: "the molecular basis of a traumatic neonatal disease"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C1853126:MOLECULAR BASIS [Idea or Concept]
   744   C1527178:Basis [Functional Concept]
   744   C1874451:Basis [Pharmacologic Substance]

Phrase: "and"

Phrase: "exciting possibilities for improvement in treatment options."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   732   C1709605:Possible Improvement [Qualitative Concept]
Processing 00000000.tx.210: KATP channel may be involved in a whole spectrum of diabetes. 

Phrase: "KATP channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439799:Channel [Spatial Concept]
   861   C1706095:Channel [Conceptual Entity]

Phrase: "may"

Phrase: "be"

Phrase: "involved in a whole spectrum of diabetes."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   748   C0011847:Diabetes [Disease or Syndrome]
   748   C0011849:Diabetes [Disease or Syndrome]
   748   C0444667:Whole [Quantitative Concept]
   748   C1314939:Involved [Functional Concept]
   748   C1883073:Spectrum [Quantitative Concept]
   748   C2827424:Spectrum [Conceptual Entity]
Processing 00000000.tx.211: For the E23K polymorphism, the effect on nucleotide sensitivity is modest, and only in the proper genetic and environmental background may channel overactivity appreciably influence -cell function. 

Phrase: "For the E23K polymorphism,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0032529:Polymorphism [Genetic Function]
   861   C1882417:Polymorphism [Qualitative Concept]

Phrase: "the effect on nucleotide sensitivity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "is"

Phrase: "modest,"

Phrase: "and"

Phrase: "only in the proper genetic"
Meta Candidates (Total=11; Excluded=7; Pruned=0; Remaining=4)
   760   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   760   C0205171:Only [Quantitative Concept]
   760   C0314603:Genetic [Functional Concept]
   760   C1720467:Only [Intellectual Product]
   704 E C0005615:Birth [Organism Function]
   704 E C0035150:Reproduction [Organism Function]
   704 E C0079946:origin [Classification]
   704 E C0439659:Origin [Temporal Concept]
   704 E C1550512:origin [Intellectual Product]
   704 E C1550722:birth [Idea or Concept]
   704 E C3245487:birth [Intellectual Product]

Phrase: "and"

Phrase: "environmental background"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1706907:Background [Conceptual Entity]

Phrase: "may"

Phrase: "channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439799:Channel [Spatial Concept]
  1000   C1706095:Channel [Conceptual Entity]

Phrase: "overactivity appreciably"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0474395:overactivity [Finding]
   861   C1536696:Overactivity [Finding]
   789 E C0443272:Overactive [Qualitative Concept]

Phrase: "influence -"

Phrase: "cell function."
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
  1000   C0007613:Cell Function [Cell Function]
   861   C0007634:Cell [Cell]
   861   C0031843:function [Physiologic Function]
   861   C0542341:Function [Functional Concept]
   861   C0700205:FUNCTION [Classification]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1705273:Function [Intellectual Product]
   861   C1948049:Cell [Spatial Concept]
   789 E C0205245:Functional [Functional Concept]
   789 E C2700217:Functional [Conceptual Entity]
Processing 00000000.tx.212: Mutations resulting in greater gain of function may still be found to underlie childhood diabetes, while mutations that result in more significant gain of function are likely to give rise to an earlier and more severe form of diabetes, as in permanent neonatal diabetes. 

Phrase: "Mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "resulting in greater gain of function"
Meta Candidates (Total=13; Excluded=4; Pruned=0; Remaining=9)
   790   C0332294:Resulting in [Functional Concept]
   753   C0031843:function [Physiologic Function]
   753   C0443228:greater [Quantitative Concept]
   753   C0542341:Function [Functional Concept]
   753   C0678226:resulting [Functional Concept]
   753   C0700205:FUNCTION [Classification]
   753   C1517378:Gain [Quantitative Concept]
   753   C1704243:Greater [Quantitative Concept]
   753   C1705273:Function [Intellectual Product]
   719 E C0549177:Great [Quantitative Concept]
   719 E C1274040:Result [Functional Concept]
   719 E C1546471:Result [Idea or Concept]
   719 E C2825142:Result [Finding]

Phrase: "may"

Phrase: "still"

Phrase: "be"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "underlie"

Phrase: "childhood diabetes,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "while"

Phrase: "mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "that"

Phrase: "result in more significant gain of function"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   748   C0031843:function [Physiologic Function]
   748   C0237881:significant [Quantitative Concept]
   748   C0542341:Function [Functional Concept]
   748   C0700205:FUNCTION [Classification]
   748   C0750502:Significant [Idea or Concept]
   748   C1274040:Result [Functional Concept]
   748   C1517378:Gain [Quantitative Concept]
   748   C1546471:Result [Idea or Concept]
   748   C1546944:Significant [Qualitative Concept]
   748   C1705273:Function [Intellectual Product]
   748   C2825142:Result [Finding]

Phrase: "are"

Phrase: "likely to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332148:Likely [Qualitative Concept]
   861   C0750492:Likely [Idea or Concept]

Phrase: "give"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1947971:Give [Functional Concept]

Phrase: "rise to an earlier"

Phrase: "and"

Phrase: "more severe form of diabetes,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0348078:Form [Qualitative Concept]
   760   C0376315:Form [Manufactured Object]
   760   C1522492:Form [Functional Concept]

Phrase: "as in permanent neonatal diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   806   C0158981:Neonatal diabetes [Disease or Syndrome]
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0205355:Permanent [Temporal Concept]
   760   C1552240:Neonatal [Professional or Occupational Group]
   760   C1552264:Neonatal [Professional or Occupational Group]
   760   C2939425:Neonatal [Temporal Concept]
Processing 00000000.tx.213: In the most severe cases, KATP channel overactivity in extrapancreatic tissue likely contributes to multiorgan syndromic permanent neonatal diabetes. 

Phrase: "In the most severe cases,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0868928:Cases [Functional Concept]
   827   C1533148:Cases [Quantitative Concept]
   793 E C1706255:CASE [Medical Device]
   793 E C1706256:Case [Conceptual Entity]

Phrase: "KATP channel overactivity in extrapancreatic tissue likely"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0474395:overactivity [Finding]
   748   C1536696:Overactivity [Finding]

Phrase: "contributes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1880177:Contribute [Activity]

Phrase: "to multiorgan syndromic permanent neonatal diabetes."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0158981:Neonatal diabetes [Disease or Syndrome]
   799   C0011847:Diabetes [Disease or Syndrome]
   799   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.214: Sulfonylureas may provide dramatic improvement in therapeutic options for neonatal diabetes (27,31,33), but the sulfonylurea-desensitizing effect of open-statestabilizing mutations (39,56,96) and the possibility of secondary nonelectrical consequences heed caution regarding whether this is a panacea.  

Phrase: "Sulfonylureas"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0038766:SULFONYLUREAS [Organic Chemical,Pharmacologic Substance]
   966 E C3536898:Sulfonylurea [Pharmacologic Substance]

Phrase: "may"

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "dramatic improvement in therapeutic options"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C2986411:Improvement [Conceptual Entity]

Phrase: "for neonatal diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0158981:Neonatal diabetes [Disease or Syndrome]
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "(27,"

Phrase: "31,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: "33"

Phrase: ")"

Phrase: ","

Phrase: "but"

Phrase: "the sulfonylurea-desensitizing effect of open-statestabilizing mutations"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "(39,"

Phrase: "56,"

Phrase: "96"

Phrase: ")"

Phrase: "and"

Phrase: "the possibility of secondary nonelectrical consequences"

Phrase: "heed"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1414269:HEED [Gene or Genome]
  1000   C3537344:hEED [Amino Acid, Peptide, or Protein]
  1000   C3538900:HEED [Gene or Genome]

Phrase: "caution"

Phrase: "regarding"

Phrase: "whether"

Phrase: "this"

Phrase: "is"

Phrase: "a panacea."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1061387:Panacea [Eukaryote]
  1000   C1521944:panacea [Idea or Concept]
Processing 00000000.tx.215: ACKNOWLEDGMENTS  The authors experimental work has been supported by National Institutes of Health Grant DK69445 (to C.G.N.) and Washington University Diabetes Research and Training Center Pilot and Feasibility Award DK20579 (to J.C.K.). 

Phrase: "ACKNOWLEDGMENTS"

Phrase: "The authors experimental work"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0043227:Work [Occupational Activity]

Phrase: "has"

Phrase: "been"

Phrase: "supported by National Institutes of Health Grant DK69445"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   833   C0027468:National Institutes of Health [Health Care Related Organization]
           national health institutes
   744   C0018173:Grant [Quantitative Concept]
   744   C0018684:Health [Idea or Concept]
   744   C0021622:Institutes [Organization]
   744   C1521721:Supported [Conceptual Entity]
   744   C1548284:Grant [Idea or Concept]
   744   C3245503:national [Intellectual Product]
   711 E C0183683:Support [Medical Device]
   711 E C1272753:Institute [Idea or Concept]

Phrase: "("

Phrase: "to C.G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "N.)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "and"

Phrase: "Washington University Diabetes Research"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0035168:research [Research Activity]
   812   C0242481:Research [Research Activity]

Phrase: "and"

Phrase: "Training Center Pilot"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0473169:Pilot [Professional or Occupational Group]
   827   C1414316:PILOT [Gene or Genome]
   734   C0557814:Training center [Manufactured Object]

Phrase: "and"

Phrase: "Feasibility Award DK20579"

Phrase: "("

Phrase: "to J.C.K."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C2346601:J/K [Quantitative Concept]
   827   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1708601:K' [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.216: Received for publication December 29, 2004 and accepted in revised form July 7, 2005  REFERENCES TOP ABSTRACT Part 1: -cell KATP... 

Phrase: "Received for publication December 29,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0034036:Publication [Intellectual Product,Manufactured Object]
   760   C0034037:Publication [Occupational Activity]
   760   C1514756:Received [Qualitative Concept]
   760   C1704324:Publication [Intellectual Product]

Phrase: "2004"

Phrase: "and"

Phrase: "accepted in revised form July 7,"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   753   C0348078:Form [Qualitative Concept]
   753   C0376315:Form [Manufactured Object]
   753   C1272684:Accepted [Qualitative Concept]
   753   C1522492:Form [Functional Concept]
   753   C1527075:Revised [Therapeutic or Preventive Procedure]
   753   C1548435:Accepted [Idea or Concept]
   719 E C1548601:Accept [Idea or Concept]

Phrase: "2005"

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "TOP ABSTRACT Part 1"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0000857:Abstract [Occupational Activity]
   812   C0449719:Part [Spatial Concept]
   812   C0600678:Abstract [Intellectual Product]
   812   C1552863:Abstract [Idea or Concept]
   812   C1704458:Top [Spatial Concept]
   812   C1709471:Part [Quantitative Concept]

Phrase: ": -"

Phrase: "cell KATP..."
Processing 00000000.tx.217: Part 2: KATP channel-dependent... 

Phrase: "Part 2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0449719:Part [Spatial Concept]
   861   C1709471:Part [Quantitative Concept]

Phrase: ":"

Phrase: "KATP channel-dependent..."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0851827:Dependent [Qualitative Concept]
   827   C1701901:Dependent [Qualitative Concept]
   827   C3244310:dependent [Functional Concept]
Processing 00000000.tx.218: REFERENCES  Ashcroft FM, Rorsman P: ATP-sensitive K+ channels: a link between B-cell metabolism and insulin secretion. 

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Ashcroft FM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: "Rorsman P"

Phrase: ":"

Phrase: "ATP-sensitive K+ channels"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0332324:Sensitive [Functional Concept]
   812   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   812   C1550474:sensitive [Idea or Concept]
   812   C1708601:K' [Quantitative Concept]
   779   C0439799:Channel [Spatial Concept]
   779   C1706095:Channel [Conceptual Entity]

Phrase: ":"

Phrase: "a link between B-cell metabolism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1517892:Link [Intellectual Product]
   753   C1704666:Link [Intellectual Product]

Phrase: "and"

Phrase: "insulin secretion."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.219: Biochem Soc Trans18 :109 111,1990[Medline] Aguilar-Bryan L, Bryan J: Molecular biology of adenosine triphosphate-sensitive potassium channels. 

Phrase: "Biochem Soc Trans18"

Phrase: ":"

Phrase: "109 111,"

Phrase: "1990"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Aguilar-Bryan L,"

Phrase: "Bryan J"

Phrase: ":"

Phrase: "Molecular biology of adenosine triphosphate-sensitive potassium channels."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0026376:Molecular Biology [Biomedical Occupation or Discipline]
   744   C0005532:Biology [Biomedical Occupation or Discipline]
   744   C1521991:Molecular [Qualitative Concept]
Processing 00000000.tx.220: Endocr Rev20 :101 135,1999[Abstract/Free FullText] Aizawa T, Komatsu M, Asanuma N, Sato Y, Sharp GW: Glucose action beyond ionic events in the pancreatic beta cell. 

Phrase: "Endocr Rev20"

Phrase: ":"

Phrase: "101 135,"

Phrase: "1999"

Phrase: "[Abstract/Free FullText"

Phrase: "] Aizawa T,"

Phrase: "Komatsu M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Asanuma N,"

Phrase: "Sato Y,"

Phrase: "Sharp GW"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0018387:GW [Geographic Area]

Phrase: ":"

Phrase: "Glucose action beyond ionic events"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0441472:Action [Functional Concept]
   760   C3266814:Action [Activity]

Phrase: "in the pancreatic beta cell."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
  1000   C0030281:Pancreatic beta cell [Cell]
           Beta cell
   827   C0007634:Cell [Cell]
   827   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
   827   C0330390:Beta [Plant]
   827   C0439096:Beta [Intellectual Product]
   827   C1269647:Cell [Cell]
   827   C1704653:Cell [Medical Device]
   827   C1948049:Cell [Spatial Concept]
   827   C2004068:Beta [Qualitative Concept]
Processing 00000000.tx.221: Trends Pharmacol Sci19 :496 499,1998 [erratum in Trends Pharmacol Sci20:124, 1999] Komatsu M, Sato Y, Aizawa T, Hashizume K: KATP channel-independent glucose action: an elusive pathway in stimulus-secretion coupling of pancreatic beta-cell (Review). 

Phrase: "Trends"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0040833:trends [Temporal Concept]
  1000   C1521798:Trends [Temporal Concept]

Phrase: "Pharmacol Sci19"

Phrase: ":"

Phrase: "496 499,"

Phrase: "1998"

Phrase: "[erratum in Trends Pharmacol Sci20"

Phrase: ":"

Phrase: "124,"

Phrase: "1999"

Phrase: "] Komatsu M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Sato Y,"

Phrase: "Aizawa T,"

Phrase: "Hashizume K"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: ":"

Phrase: "KATP channel-independent glucose action"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0441472:Action [Functional Concept]
   804   C3266814:Action [Activity]

Phrase: ":"

Phrase: "an elusive pathway in stimulus-secretion coupling of pancreatic beta-cell"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   754   C1159342:Secretion Pathway [Cell Function]
   738   C1704259:Pathway [Molecular Function]
   738   C1705987:Pathway [Conceptual Entity]

Phrase: "(Review"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282443:Review [Intellectual Product]
  1000   C1552617:Review [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.222: Endocr J48 :275 288,2001[Medline] Huopio H, Shyng SL, Otonkoski T, Nichols CG: K(ATP) channels and insulin secretion disorders (Review). 

Phrase: "Endocr J48"

Phrase: ":"

Phrase: "275 288,"

Phrase: "2001"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Huopio H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Shyng SL,"

Phrase: "Otonkoski T,"

Phrase: "Nichols CG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: ":"

Phrase: "K(ATP) channels"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1708601:K' [Quantitative Concept]
   793   C0439799:Channel [Spatial Concept]
   793   C1706095:Channel [Conceptual Entity]

Phrase: "and"

Phrase: "insulin secretion disorders"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0012634:Disorders [Disease or Syndrome]
   734   C1256369:insulin secretion [Cell Function]

Phrase: "(Review"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282443:Review [Intellectual Product]
  1000   C1552617:Review [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.223: Am J Physiol Endocrinol Metab283 :E207 E216,2002[Abstract/Free FullText] Thomas PM, Cote GJ, Wohllk N, Haddad B, Mathew PM, Rabl W, Aguilar-Bryan L, Gagel RF, Bryan J: Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. 

Phrase: "Am"

Phrase: "J Physiol Endocrinol Metab283"

Phrase: ":"

Phrase: "E207 E216,"

Phrase: "2002"

Phrase: "[Abstract/Free FullText"

Phrase: "] Thomas PM, Cote GJ,"

Phrase: "Wohllk N,"

Phrase: "Haddad B,"

Phrase: "Mathew PM, Rabl W,"

Phrase: "Aguilar-Bryan L,"

Phrase: "Gagel RF,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0035448:RF [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0201660:RF [Laboratory Procedure]
   861   C0748398:RF [Finding]

Phrase: "Bryan J"

Phrase: ":"

Phrase: "Mutations in the sulfonylurea receptor gene"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   783   C0596611:gene mutations [Genetic Function]
   753   C0026882:Mutations [Genetic Function]
   719 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "in familial persistent hyperinsulinemic hypoglycemia"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   923   C2931833:HYPERINSULINEMIC HYPOGLYCEMIA, PERSISTENT [Disease or Syndrome]
   923   C2931834:Persistent Hyperinsulinemic Hypoglycemia [Disease or Syndrome]
   861   C1864903:Hyperinsulinemic hypoglycemia [Finding]
   812   C0020615:Hypoglycaemia [Disease or Syndrome]
   741 E C0020616:Hypoglycaemic [Pharmacologic Substance]

Phrase: "of infancy."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231330:Infancy [Temporal Concept]
Processing 00000000.tx.224: Science268 :426 429,1995[Medline] Nestorowicz A, Glaser B, Wilson BA, Shyng SL, Nichols CG, Stanley CA, Thornton PS, Permutt MA: Genetic heterogeneity in familial hyperinsulinism. 

Phrase: "Science268"

Phrase: ":"

Phrase: "426 429,"

Phrase: "1995"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Nestorowicz A,"

Phrase: "Glaser B,"

Phrase: "Wilson BA,"

Phrase: "Shyng SL,"

Phrase: "Nichols CG,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: "Stanley CA,"

Phrase: "Thornton PS,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1418867:Ps [Gene or Genome]
   861   C1518860:PS [Geographic Area]
   861   C1552158:Ps [Body Part, Organ, or Organ Component]

Phrase: "Permutt MA"

Phrase: ":"

Phrase: "Genetic heterogeneity in familial hyperinsulinism."
Meta Candidates (Total=12; Excluded=7; Pruned=0; Remaining=5)
   806   C0242960:Genetic Heterogeneity [Organism Attribute]
   760   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   760   C0019409:Heterogeneity [Qualitative Concept]
   760   C0314603:Genetic [Functional Concept]
   734   C0870545:family origins [Family Group]
   704 E C0005615:Birth [Organism Function]
   704 E C0035150:Reproduction [Organism Function]
   704 E C0079946:origin [Classification]
   704 E C0439659:Origin [Temporal Concept]
   704 E C1550512:origin [Intellectual Product]
   704 E C1550722:birth [Idea or Concept]
   704 E C3245487:birth [Intellectual Product]
Processing 00000000.tx.225: Hum Mol Genet7 :1119 1128,1998 [erratum in Hum Mol Genet7:1527, 1998] Nichols CG, Shyng SL, Nestorowicz A, Glaser B, Clement JP 4th, Gonzalez G, Aguilar-Bryan L, Permutt MA, Bryan J: Adenosine diphosphate as an intracellular regulator of insulin secretion. 

Phrase: "Hum Mol Genet7"

Phrase: ":"

Phrase: "1119 1128,"

Phrase: "1998"

Phrase: "[erratum in Hum Mol Genet7"

Phrase: ":"

Phrase: "1527,"

Phrase: "1998"

Phrase: "] Nichols CG,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: "Shyng SL,"

Phrase: "Nestorowicz A,"

Phrase: "Glaser B,"

Phrase: "Clement JP 4th,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0205438:4th [Quantitative Concept]

Phrase: "Gonzalez G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Aguilar-Bryan L,"

Phrase: "Permutt MA,"

Phrase: "Bryan J"

Phrase: ":"

Phrase: "Adenosine diphosphate as an intracellular regulator of insulin secretion."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   764   C0001459:Adenosine Diphosphate [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   764   C0523452:Adenosine Diphosphate [Laboratory Procedure]
   742   C0001443:Adenosine [Nucleic Acid, Nucleoside, or Nucleotide,Neuroreactive Substance or Biogenic Amine,Pharmacologic Substance]
   742   C0034320:diphosphate [Inorganic Chemical,Pharmacologic Substance]
Processing 00000000.tx.226: Science272 :1785 1787,1996[Abstract] Cartier EA, Conti LR, Vandenberg CA, Shyng SL: Defective trafficking and function of KATP channels caused by a sulfonylurea receptor 1 mutation associated with persistent hyperinsulinemic hypoglycemia of infancy. 

Phrase: "Science272"

Phrase: ":"

Phrase: "1785 1787,"

Phrase: "1996"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Cartier EA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0014963:EA [Organic Chemical,Pharmacologic Substance]
   861   C1457900:EA [Quantitative Concept]

Phrase: "Conti LR,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0023617:LR [Geographic Area]
   861   C2986899:LR [Idea or Concept]

Phrase: "Vandenberg CA,"

Phrase: "Shyng SL"

Phrase: ":"

Phrase: "Defective"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332452:Defective [Functional Concept]

Phrase: "trafficking"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0599896:trafficking [Cell Function]

Phrase: "and"

Phrase: "function of KATP channels"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0031843:function [Physiologic Function]
   770   C0542341:Function [Functional Concept]
   770   C0700205:FUNCTION [Classification]
   770   C1705273:Function [Intellectual Product]

Phrase: "caused by a sulfonylurea receptor 1 mutation"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   778   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
   778   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   748   C0026882:Mutation [Genetic Function]
   748   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   748   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   748   C1705285:Mutation [Cell or Molecular Dysfunction]
   748   C3536898:Sulfonylurea [Pharmacologic Substance]
   714   C0015127:cause [Functional Concept]
   714   C1524003:Cause [Conceptual Entity]

Phrase: "associated with persistent hyperinsulinemic hypoglycemia of infancy."
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   897   C0027773:Persistent Hyperinsulinemic Hypoglycemia of Infancy [Disease or Syndrome]
   897   C2931834:Persistent hyperinsulinaemic hypoglycaemia of infancy [Disease or Syndrome]
           Persistent Hyperinsulinemic Hypoglycemia
   814   C1456352:Hypoglycaemia of infancy [Pathologic Function]
   814   C2931833:HYPERINSULINEMIC HYPOGLYCEMIA, PERSISTENT [Disease or Syndrome]
   778   C0332281:Associated with [Qualitative Concept]
           Associated
   778   C1864903:Hyperinsulinemic hypoglycemia [Finding]
   748   C0020615:Hypoglycaemia [Disease or Syndrome]
   748   C0205322:Persistent [Temporal Concept]
   748   C0231330:Infancy [Temporal Concept]
   714 E C0750490:Associate [Idea or Concept]
   714 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.227: Proc Natl Acad Sci U S A98 :2882 2887,2001[Abstract/Free FullText] Terauchi Y, Sakura H, Yasuda K, Iwamoto K, Takahashi N, Ito K, Kasai H, Suzuki H, Ueda O, Kamada N, et al.: 

Phrase: "Proc Natl Acad Sci U S A98"

Phrase: ":"

Phrase: "2882 2887,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Terauchi Y,"

Phrase: "Sakura H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Yasuda K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Iwamoto K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Takahashi N,"

Phrase: "Ito K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Kasai H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Suzuki H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Ueda O,"

Phrase: "Kamada N,"

Phrase: "et al."

Phrase: ":"
Processing 00000000.tx.228: Pancreatic beta-cell-specific targeted disruption of glucokinase gene: diabetes mellitus due to defective insulin secretion to glucose. 

Phrase: "Pancreatic beta-cell-specific targeted disruption of glucokinase gene"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0332453:Disruption [Functional Concept]

Phrase: ":"

Phrase: "diabetes mellitus due to defective insulin secretion"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   748   C0011847:Diabetes [Disease or Syndrome]

Phrase: "to glucose."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
Processing 00000000.tx.229: J Biol Chem270 :30253 30256,1995[Abstract/Free FullText] Koster JC, Marshall BA, Ensor N, Corbett JA, Nichols CG: Targeted overactivity of beta cell K(ATP) channels induces profound neonatal diabetes. 

Phrase: "J Biol Chem270"

Phrase: ":"

Phrase: "30253 30256,"

Phrase: "1995"

Phrase: "[Abstract/Free FullText"

Phrase: "] Koster JC,"

Phrase: "Marshall BA,"

Phrase: "Ensor N,"

Phrase: "Corbett JA,"

Phrase: "Nichols CG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: ":"

Phrase: "Targeted overactivity of beta cell K(ATP) channels"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0474395:overactivity [Finding]
   744   C1536696:Overactivity [Finding]

Phrase: "induces"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induce [Functional Concept]

Phrase: "profound neonatal diabetes."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0158981:Neonatal diabetes [Disease or Syndrome]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.230: Cell100 :645 654,2000[Medline] Sakura H, Ashcroft SJ, Terauchi Y, Kadowaki T, Ashcroft FM: Glucose modulation of ATP-sensitive K-currents in wild-type, homozygous and heterozygous glucokinase knock-out mice. 

Phrase: "Cell100"

Phrase: ":"

Phrase: "645 654,"

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Sakura H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Ashcroft SJ,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1515101:SJ [Geographic Area]
   861   C2986905:SJ [Idea or Concept]

Phrase: "Terauchi Y,"

Phrase: "Kadowaki T,"

Phrase: "Ashcroft FM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: ":"

Phrase: "Glucose modulation of ATP-sensitive K-currents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0443264:Modulation [Spatial Concept]

Phrase: "in wild-type, homozygous"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0019904:Homozygous [Organism Attribute]
   734   C1883559:Wild Type [Organism Attribute]

Phrase: "and"

Phrase: "heterozygous glucokinase knock-out mice."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   884   C0206745:Knock-out Mice [Mammal]
   804   C0025914:Mice [Mammal]
   804   C0025929:mice [Mammal]
   804   C0026809:Mice [Mammal]
Processing 00000000.tx.231: Diabetologia41 :654 659,1998[Medline] Ashcroft FM, Rorsman P: Type 2 diabetes mellitus: not quite exciting enough? 

Phrase: "Diabetologia41"

Phrase: ":"

Phrase: "654 659,"

Phrase: "1998"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Ashcroft FM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: "Rorsman P"

Phrase: ":"

Phrase: "Type 2 diabetes mellitus"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
  1000   C0011860:Diabetes Mellitus, Type 2 [Disease or Syndrome]
           Type 2 Diabetes
  1000   C2984301:Type II diabetes mellitus [Functional Concept]
   875   C1320657:type diabetes [Finding]
   861   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   861   C0441730:Type 2 [Classification]
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0332307:Type [Qualitative Concept]
   812   C1547052:*Type [Quantitative Concept]

Phrase: ":"

Phrase: "not quite"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "exciting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0549255:Excite [Activity]

Phrase: "enough?"
Processing 00000000.tx.232: (Review). 

Phrase: "(Review"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282443:Review [Intellectual Product]
  1000   C1552617:Review [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.233: Hum Mol Genet13 :R21 R31,2004[Abstract/Free FullText] Nichols CG, Koster JC: Diabetes and insulin secretion: whither KATP? 

Phrase: "Hum Mol Genet13"

Phrase: ":"

Phrase: "R21 R31,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1549840:R31 [Intellectual Product]

Phrase: "2004"

Phrase: "[Abstract/Free FullText"

Phrase: "] Nichols CG,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: "Koster JC"

Phrase: ":"

Phrase: "Diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "and"

Phrase: "insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]

Phrase: ":"

Phrase: "whither KATP?"
Processing 00000000.tx.234: (Review). 

Phrase: "(Review"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282443:Review [Intellectual Product]
  1000   C1552617:Review [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.235: Am J Physiol Endocrinol Metab283 :E403 E412,2002[Abstract/Free FullText] Polak M, Shield J: Neonatal and very-early-onset diabetes mellitus. 

Phrase: "Am"

Phrase: "J Physiol Endocrinol Metab283"

Phrase: ":"

Phrase: "E403 E412,"

Phrase: "2002"

Phrase: "[Abstract/Free FullText"

Phrase: "] Polak M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Shield J"

Phrase: ":"

Phrase: "Neonatal"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1552240:Neonatal [Professional or Occupational Group]
  1000   C1552264:Neonatal [Professional or Occupational Group]
  1000   C2939425:Neonatal [Temporal Concept]

Phrase: "and"

Phrase: "very-early-onset diabetes mellitus."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   840   C0011849:Diabetes Mellitus [Disease or Syndrome]
Processing 00000000.tx.236: Semin Neonatol9 :59 65,2004[Medline] Njolstad PR, Sovik O, Cuesta-Munoz A, Bjorkhaug L, Massa O, Barbetti F, Undlien DE, Shiota C, Magnuson MA, Molven A, Matschinsky FM, Bell GI: Neonatal diabetes mellitus due to complete glucokinase deficiency. 

Phrase: "Semin Neonatol9"

Phrase: ":"

Phrase: "59 65,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450385:65 [Intellectual Product]

Phrase: "2004"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Njolstad PR,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0279759:PR+ [Laboratory or Test Result]
   861   C0279766:PR- [Laboratory or Test Result]
   861   C1418864:PR@ [Gene or Genome]
   861   C3538934:PR [Intellectual Product]
   861   C3538935:PR [Idea or Concept]

Phrase: "Sovik O,"

Phrase: "Cuesta-Munoz A,"

Phrase: "Bjorkhaug L,"

Phrase: "Massa O,"

Phrase: "Barbetti F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Undlien DE,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0011198:DE [Geographic Area]
   861   C0017480:DE [Geographic Area]
   861   C3541240:DE [Idea or Concept]

Phrase: "Shiota C,"

Phrase: "Magnuson MA,"

Phrase: "Molven A,"

Phrase: "Matschinsky FM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: "Bell GI"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3539617:GI [Idea or Concept]

Phrase: ":"

Phrase: "Neonatal diabetes mellitus due to complete glucokinase deficiency."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   800   C0158981:Neonatal diabetes mellitus [Disease or Syndrome]
           Neonatal diabetes
   770   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   744   C0011847:Diabetes [Disease or Syndrome]
Processing 00000000.tx.237: N Engl J Med344 :1588 1592,2001[Free FullText] Njolstad PR, Sagen JV, Bjorkhaug L, Odili S, Shehadeh N, Bakry D, Sarici SU, Alpay F, Molnes J, Molven A, Sovik O, Matschinsky FM: Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. 

Phrase: "N Engl J Med344"

Phrase: ":"

Phrase: "1588 1592,"

Phrase: "2001"

Phrase: "[Free FullText"

Phrase: "] Njolstad PR,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0279759:PR+ [Laboratory or Test Result]
   861   C0279766:PR- [Laboratory or Test Result]
   861   C1418864:PR@ [Gene or Genome]
   861   C3538934:PR [Intellectual Product]
   861   C3538935:PR [Idea or Concept]

Phrase: "Sagen JV,"

Phrase: "Bjorkhaug L,"

Phrase: "Odili S,"

Phrase: "Shehadeh N,"

Phrase: "Bakry D,"

Phrase: "Sarici SU,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1705534:SU [Idea or Concept]

Phrase: "Alpay F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Molnes J,"

Phrase: "Molven A,"

Phrase: "Sovik O,"

Phrase: "Matschinsky FM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: ":"

Phrase: "Permanent neonatal diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0158981:Neonatal diabetes [Disease or Syndrome]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]

Phrase: "caused by glucokinase deficiency"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0011155:Deficiency [Functional Concept]
   770   C0017713:Glucokinase [Amino Acid, Peptide, or Protein,Enzyme]
   770   C0162429:Deficiency [Disease or Syndrome]
   770   C1415014:GLUCOKINASE [Gene or Genome]
   770   C1623416:deficiency [Qualitative Concept]
   737   C0015127:cause [Functional Concept]
   737   C1524003:Cause [Conceptual Entity]

Phrase: ":"

Phrase: "inborn error of the glucose-insulin signaling pathway."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0743559:error [Qualitative Concept]
   744   C1608199:Error [Functional Concept]
Processing 00000000.tx.238: Diabetes52 :2854 2860,2003[Abstract/Free FullText] Stoffers DA, Zinkin NT, Stanojevic V, Clarke WL, Habener JF: Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. 

Phrase: "Diabetes52"

Phrase: ":"

Phrase: "2854 2860,"

Phrase: "2003"

Phrase: "[Abstract/Free FullText"

Phrase: "] Stoffers DA,"

Phrase: "Zinkin NT,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332126:NT [Qualitative Concept]
   861   C1449832:NT [Diagnostic Procedure]

Phrase: "Stanojevic V,"

Phrase: "Clarke WL,"

Phrase: "Habener JF"

Phrase: ":"

Phrase: "Pancreatic agenesis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0000846:Agenesis [Functional Concept]
   861   C0332907:Agenesis [Congenital Abnormality]

Phrase: "attributable to a single nucleotide deletion"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0596130:Attributable [Mental Process]

Phrase: "in the human IPF1 gene coding sequence."
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   840   C0079941:Coding Sequence [Gene or Genome]
   804   C0004793:Sequence [Nucleotide Sequence]
   804   C0009219:Coding [Occupational Activity]
   804   C0162326:Sequence [Nucleotide Sequence]
   804   C0162327:Sequence [Nucleotide Sequence]
   804   C1519249:Sequence [Functional Concept]
   771 E C0805701:Code [Intellectual Product]
   733 E C1548958:Sequential [Idea or Concept]
   733 E C1705294:Sequential [Qualitative Concept]
Processing 00000000.tx.239: Nat Genet15 :106 110,1997[Medline] Schwitzgebel VM, Mamin A, Brun T, Ritz-Laser B, Zaiko M, Maret A, Jornayvaz FR, Theintz GE, Michielin O, Melloul D, Philippe J: Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. 

Phrase: "Nat Genet15"

Phrase: ":"

Phrase: "106 110,"

Phrase: "1997"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Schwitzgebel VM,"

Phrase: "Mamin A,"

Phrase: "Brun T,"

Phrase: "Ritz-Laser B,"

Phrase: "Zaiko M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Maret A,"

Phrase: "Jornayvaz FR,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2348513:Fr. [Conceptual Entity]
   861   C3538902:FR [Gene or Genome]

Phrase: "Theintz GE,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538705:GE [Gene or Genome]

Phrase: "Michielin O,"

Phrase: "Melloul D,"

Phrase: "Philippe J"

Phrase: ":"

Phrase: "Agenesis of human pancreas"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   881   C0266266:Agenesis of pancreas [Congenital Abnormality]
   770   C0000846:Agenesis [Functional Concept]
   770   C0332907:Agenesis [Congenital Abnormality]

Phrase: "due to decreased half-life"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   901   C0018517:Half-Life [Temporal Concept]
   827   C0376558:Life [Idea or Concept]
   827   C2825407:Half [Quantitative Concept]
   743 E C0595998:lives [Finding]

Phrase: "of insulin promoter factor 1."
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
  1000   C0248419:insulin promoter factor 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1826562:INSULIN PROMOTER FACTOR 1 [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   812   C1521761:Factor [Functional Concept]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C2827422:Factor [Conceptual Entity]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.240: J Clin Endocrinol Metab88 :4398 4406,2003[Abstract/Free FullText] Biason-Lauber A, Lang-Muritano M, Vaccaro T, Schoenle EJ: Loss of kinase activity in a patient with Wolcott-Rallison syndrome caused by a novel mutation in the EIF2AK3 gene. 

Phrase: "J Clin Endocrinol Metab88"

Phrase: ":"

Phrase: "4398 4406,"

Phrase: "2003"

Phrase: "[Abstract/Free FullText"

Phrase: "] Biason-Lauber A,"

Phrase: "Lang-Muritano M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "Vaccaro T,"

Phrase: "Schoenle EJ"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1718783:Ej [Immunologic Factor]

Phrase: ":"

Phrase: "Loss of kinase activity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1517945:Loss [Quantitative Concept]

Phrase: "in a patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:*^patient [Patient or Disabled Group]

Phrase: "with Wolcott-Rallison syndrome"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0432217:Wolcott-Rallison syndrome [Congenital Abnormality,Disease or Syndrome]
   827   C0039082:Syndrome [Disease or Syndrome]

Phrase: "caused by a novel mutation"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   806   C2985438:Novel Mutation [Cell or Molecular Dysfunction]
   760   C0026882:Mutation [Genetic Function]
   760   C0205314:Novel [Temporal Concept]
   760   C0679622:novel [Intellectual Product]
   760   C1705285:Mutation [Cell or Molecular Dysfunction]
   726   C0015127:cause [Functional Concept]
   726   C1524003:Cause [Conceptual Entity]

Phrase: "in the EIF2AK3 gene."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1414326:EIF2AK3 gene [Gene or Genome]
   861   C0017337:Gene [Gene or Genome]
Processing 00000000.tx.241: Diabetes51 :2301 2305,2002[Abstract/Free FullText] Delepine M, Nicolino M, Barrett T, Golamaully M, Lathrop GM, Julier C: EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. 

Phrase: "Diabetes51"

Phrase: ":"

Phrase: "2301 2305,"

Phrase: "2002"

Phrase: "[Abstract/Free FullText"

Phrase: "] Delepine M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Nicolino M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Barrett T,"

Phrase: "Golamaully M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Lathrop GM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0546866:GM [Antibiotic,Carbohydrate]

Phrase: "Julier C"

Phrase: ":"

Phrase: "EIF2AK3,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1414326:EIF2AK3 [Gene or Genome]

Phrase: "encoding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1547699:Encoding [Idea or Concept]
  1000   C2700640:Encoding [Activity]

Phrase: "translation initiation factor 2-alpha kinase 3,"
Meta Candidates (Total=20; Excluded=0; Pruned=0; Remaining=20)
   911   C0070348:Translation Initiation Factor 3 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   845   C0030943:Translation Initiation Factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
           Initiation Factor
   845   C0083982:Initiation Factor-2 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
           Translational Initiation Factor 2
   845   C1538267:alpha-kinase 3 [Gene or Genome]
   829   C0597603:translation factor [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   818   C1519613:Translation Initiation [Genetic Function]
   795   C0031727:Kinase [Amino Acid, Peptide, or Protein,Enzyme]
   795   C0040712:Translation [Intellectual Product]
   795   C0439095:Alpha [Intellectual Product]
   795   C0589507:Initiation [Mental Process]
   795   C0597295:translation [Molecular Function]
   795   C1158830:Initiation [Genetic Function]
   795   C1519614:Translation [Genetic Function]
   795   C1521761:Factor [Functional Concept]
   795   C1704686:Initiation [Functional Concept]
   795   C2003941:Alpha [Intellectual Product]
   795   C2350010:Alpha [Qualitative Concept]
   795   C2827422:Factor [Conceptual Entity]

Phrase: "is"

Phrase: "mutated in patients"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C1705285:Mutated [Cell or Molecular Dysfunction]
   756 E C1513776:Mutate [Genetic Function]

Phrase: "with Wolcott-Rallison syndrome."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0432217:Wolcott-Rallison syndrome [Congenital Abnormality,Disease or Syndrome]
   827   C0039082:Syndrome [Disease or Syndrome]
Processing 00000000.tx.242: Nat Genet25 :406 409,2000[Medline] Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD: The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. 

Phrase: "Nat Genet25"

Phrase: ":"

Phrase: "406 409,"

Phrase: "2000"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Bennett CL,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596019:Cl - [Element, Ion, or Isotope]

Phrase: "Christie J,"

Phrase: "Ramsdell F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Brunkow"

Phrase: "ME,"

Phrase: "Ferguson PJ,"

Phrase: "Whitesell L,"

Phrase: "Kelly TE,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0039462:Te [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   861   C1705540:TE [Conceptual Entity]

Phrase: "Saulsbury FT,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1881534:ft. [Functional Concept]

Phrase: "Chance PF,"

Phrase: "Ochs HD"

Phrase: ":"

Phrase: "The immune dysregulation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1844666:Immune dysregulation [Finding]

Phrase: "polyendocrinopathy,"

Phrase: "enteropathy,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021831:Enteropathy [Disease or Syndrome]

Phrase: "X-linked syndrome"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0039082:Syndrome [Disease or Syndrome]
   734   C0241764:X-linked [Genetic Function]

Phrase: "(IPEX"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0342288:IPEX [Congenital Abnormality]
  1000   C3539774:IPEX [Gene or Genome]

Phrase: ")"

Phrase: "is"

Phrase: "caused by mutations of FOXP3."
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   814   C1416467:FORKHEAD BOX P3 [Gene or Genome]
   778   C3273493:Fork Head Box [Amino Acid Sequence]
   748   C0026882:Mutations [Genetic Function]
   748   C0179400:Box [Manufactured Object]
   748   C1412751:P3 [Gene or Genome]
   748   C1427831:P3 [Gene or Genome]
   748   C1533124:Box [Medical Device]
   748   C1539372:p3 [Gene or Genome]
   714   C0015127:cause [Functional Concept]
   714   C1524003:Cause [Conceptual Entity]
   714 E C1705285:Mutation [Cell or Molecular Dysfunction]
Processing 00000000.tx.243: Nat Genet27 :20 21,2001[Medline] Roberts J, Searle J: Neonatal diabetes mellitus associated with severe diarrhea, hyperimmunoglobulin E syndrome, and absence of islets of Langerhans. 

Phrase: "Nat Genet27"

Phrase: ":"

Phrase: "20 21,"

Phrase: "2001"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Roberts J,"

Phrase: "Searle J"

Phrase: ":"

Phrase: "Neonatal diabetes mellitus"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0158981:Neonatal diabetes mellitus [Disease or Syndrome]
           Neonatal diabetes
   901   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   827   C0011847:Diabetes [Disease or Syndrome]

Phrase: "associated with severe diarrhea,"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   833   C1443924:Severe diarrhea [Sign or Symptom]
   770   C0011991:Diarrhea [Sign or Symptom]
   770   C0205082:Severe [Qualitative Concept]
   770   C1963091:Diarrhea [Finding]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "hyperimmunoglobulin E syndrome,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0022398:Hyperimmunoglobulin E syndrome [Disease or Syndrome]
   913   C1334069:Hyperimmunoglobulin Syndrome [Disease or Syndrome]
   827   C0039082:Syndrome [Disease or Syndrome]

Phrase: "and"

Phrase: "absence of islets of Langerhans."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0332197:absence [Quantitative Concept]
   760   C1689985:Absence [Anatomical Abnormality]
Processing 00000000.tx.244: Pediatr Pathol Lab Med15 :477 483,1995[Medline] Jonsson J, Carlsson L, Edlund T, Edlund H: Insulin-promoter-factor 1 is required for pancreas development in mice. 

Phrase: "Pediatr Pathol Lab Med15"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0378666:MED15 [Organic Chemical,Pharmacologic Substance]
   812   C1422509:MED15 [Gene or Genome]

Phrase: ":"

Phrase: "477 483,"

Phrase: "1995"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Jonsson J,"

Phrase: "Carlsson L,"

Phrase: "Edlund T,"

Phrase: "Edlund H"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: ":"

Phrase: "Insulin-promoter-factor 1"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
  1000   C0248419:insulin promoter factor 1 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1826562:INSULIN PROMOTER FACTOR 1 [Gene or Genome]
   812   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   812   C1521761:Factor [Functional Concept]
   812   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   812   C1579433:Insulin [Pharmacologic Substance]
   812   C2827422:Factor [Conceptual Entity]
   756 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   729 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "is"

Phrase: "required for pancreas development"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C1523495:pancreas development [Biologic Function]
   770   C0030274:Pancreas [Body Part, Organ, or Organ Component]
   770   C0243107:development [Physiologic Function]
   770   C0678723:Development [Organism Function]
   770   C1278931:Pancreas [Body Part, Organ, or Organ Component]
   770   C1514873:Required [Functional Concept]
   770   C1527148:Development [Functional Concept]

Phrase: "in mice."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025914:Mice [Mammal]
  1000   C0025929:mice [Mammal]
  1000   C0026809:Mice [Mammal]
Processing 00000000.tx.245: Nature371 :606 609,1994[Medline] Gardner RJ, Mackay DJ, Mungall AJ, Polychronakos C, Siebert R, Shield JP, Temple IK, Robinson DO: An imprinted locus associated with transient neonatal diabetes mellitus. 

Phrase: "Nature371"

Phrase: ":"

Phrase: "606 609,"

Phrase: "1994"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Gardner RJ,"

Phrase: "Mackay DJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012836:DJ [Geographic Area]

Phrase: "Mungall AJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0230613:AJ [Cell Component]

Phrase: "Polychronakos C,"

Phrase: "Siebert R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Shield JP,"

Phrase: "Temple IK,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1416378:IK [Gene or Genome]

Phrase: "Robinson"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443050:Robinson [Intellectual Product]

Phrase: "DO"

Phrase: ":"

Phrase: "An imprinted locus"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1708726:Locus [Gene or Genome]

Phrase: "associated with transient neonatal diabetes mellitus."
Meta Candidates (Total=15; Excluded=2; Pruned=0; Remaining=13)
   882   C0342273:Transient neonatal diabetes mellitus [Disease or Syndrome]
   833   C0158981:Neonatal diabetes mellitus [Disease or Syndrome]
           Neonatal diabetes
   790   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   790   C0332281:Associated with [Qualitative Concept]
           Associated
   753   C0011847:Diabetes [Disease or Syndrome]
   753   C0040704:Transient [Population Group]
   753   C0205374:Transient [Temporal Concept]
   753   C1552240:Neonatal [Professional or Occupational Group]
   753   C1552264:Neonatal [Professional or Occupational Group]
   753   C2939425:Neonatal [Temporal Concept]
   719 E C0750490:Associate [Idea or Concept]
   719 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.246: Hum Mol Genet9 :589 596,2000[Abstract/Free FullText] Gloyn AL, Cummings EA, Edghill EL, Harries LW, Scott R, Costa T, Temple IK, Hattersley AT, Ellard S: Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. 

Phrase: "Hum Mol Genet9"

Phrase: ":"

Phrase: "589 596,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "] Gloyn AL,"

Phrase: "Cummings EA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0014963:EA [Organic Chemical,Pharmacologic Substance]
   861   C1457900:EA [Quantitative Concept]

Phrase: "Edghill EL,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1416870:EL [Gene or Genome]
   861   C1823249:EL [Gene or Genome]

Phrase: "Harries"

Phrase: "LW,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1415842:LW [Gene or Genome]

Phrase: "Scott R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Costa T,"

Phrase: "Temple IK,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1416378:IK [Gene or Genome]

Phrase: "Hattersley AT,"

Phrase: "Ellard S"

Phrase: ":"

Phrase: "Permanent neonatal diabetes due to paternal germline mosaicism"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0158981:Neonatal diabetes [Disease or Syndrome]
   744   C0011847:Diabetes [Disease or Syndrome]
   744   C0011849:Diabetes [Disease or Syndrome]

Phrase: "for an activating mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0026882:Mutation [Genetic Function]
   861   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "of the KCNJ11 gene"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1416578:KCNJ11 gene [Gene or Genome]
   861   C0017337:Gene [Gene or Genome]

Phrase: "encoding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1547699:Encoding [Idea or Concept]
  1000   C2700640:Encoding [Activity]

Phrase: "the Kir6.2 subunit"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1711351:Subunit [Quantitative Concept]
   734   C1416578:Kir6.2 [Gene or Genome]

Phrase: "of the beta-cell potassium adenosine triphosphate channel."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   858   C0032824:Potassium Channel [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   799   C0439799:Channel [Spatial Concept]
   799   C1706095:Channel [Conceptual Entity]
Processing 00000000.tx.247: J Clin Endocrinol Metab89 :3932 3935,2004[Abstract/Free FullText] Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njolstad PR, Ashcroft FM, Hattersley AT: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. 

Phrase: "J Clin Endocrinol Metab89"

Phrase: ":"

Phrase: "3932 3935,"

Phrase: "2004"

Phrase: "[Abstract/Free FullText"

Phrase: "] Gloyn AL,"

Phrase: "Pearson ER,"

Phrase: "Antcliff JF,"

Phrase: "Proks P,"

Phrase: "Bruining GJ,"

Phrase: "Slingerland AS,"

Phrase: "Howard N,"

Phrase: "Srinivasan S,"

Phrase: "Silva JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Molnes J,"

Phrase: "Edghill EL,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1416870:EL [Gene or Genome]
   861   C1823249:EL [Gene or Genome]

Phrase: "Frayling TM,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0145779:TM [Amino Acid, Peptide, or Protein,Receptor]
   861   C3540468:TM [Gene or Genome]

Phrase: "Temple IK,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1416378:IK [Gene or Genome]

Phrase: "Mackay D,"

Phrase: "Shield JP,"

Phrase: "Sumnik Z,"

Phrase: "van Rhijn A,"

Phrase: "Wales JK,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1420098:JK [Gene or Genome]

Phrase: "Clark P,"

Phrase: "Gorman S,"

Phrase: "Aisenberg J,"

Phrase: "Ellard S,"

Phrase: "Njolstad PR,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0279759:PR+ [Laboratory or Test Result]
   861   C0279766:PR- [Laboratory or Test Result]
   861   C1418864:PR@ [Gene or Genome]
   861   C3538934:PR [Intellectual Product]
   861   C3538935:PR [Idea or Concept]

Phrase: "Ashcroft FM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: "Hattersley AT"

Phrase: ":"

Phrase: "Activating mutations in the gene"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   797   C0596611:gene mutations [Genetic Function]
   760   C0026882:Mutations [Genetic Function]
   726 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "encoding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1547699:Encoding [Idea or Concept]
  1000   C2700640:Encoding [Activity]

Phrase: "the ATP-sensitive potassium-channel subunit Kir6.2"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   868   C1416547:POTASSIUM CHANNEL 2 [Gene or Genome]
   818   C0032824:Potassium Channel [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   818   C1416578:Kir6.2 [Gene or Genome]
   795   C0032821:Potassium [Element, Ion, or Isotope]
   795   C0332324:Sensitive [Functional Concept]
   795   C0439799:Channel [Spatial Concept]
   795   C0597277:Potassium+ [Element, Ion, or Isotope,Pharmacologic Substance]
   795   C1550474:sensitive [Idea or Concept]
   795   C1706095:Channel [Conceptual Entity]
   795   C1711351:Subunit [Quantitative Concept]

Phrase: "and"

Phrase: "permanent neonatal diabetes."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0158981:Neonatal diabetes [Disease or Syndrome]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.248: N Engl J Med350 :1838 1849,2004[Abstract/Free FullText] Edghill EL, Gloyn AL, Gillespie KM, Lambert AP, Raymond NT, Swift PG, Ellard S, Gale EA, Hattersley AT: Activating mutations in the KCNJ11 gene encoding the ATP-sensitivie K+ channel subunit Kir6.2 are rare in clinically defined type 1 diabetes diagnosed before 2 years. 

Phrase: "N Engl J Med350"

Phrase: ":"

Phrase: "1838 1849,"

Phrase: "2004"

Phrase: "[Abstract/Free FullText"

Phrase: "] Edghill EL,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1416870:EL [Gene or Genome]
   861   C1823249:EL [Gene or Genome]

Phrase: "Gloyn AL,"

Phrase: "Gillespie KM,"

Phrase: "Lambert AP,"

Phrase: "Raymond NT,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332126:NT [Qualitative Concept]
   861   C1449832:NT [Diagnostic Procedure]

Phrase: "Swift PG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1266240:PG [Laboratory Procedure]

Phrase: "Ellard S,"

Phrase: "Gale EA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0014963:EA [Organic Chemical,Pharmacologic Substance]
   861   C1457900:EA [Quantitative Concept]

Phrase: "Hattersley AT"

Phrase: ":"

Phrase: "Activating mutations in the KCNJ11 gene"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   783   C0596611:gene mutations [Genetic Function]
   753   C0026882:Mutations [Genetic Function]
   719 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "encoding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1547699:Encoding [Idea or Concept]
  1000   C2700640:Encoding [Activity]

Phrase: "the ATP-sensitivie K+ channel subunit Kir6.2"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   818   C1416578:Kir6.2 [Gene or Genome]
   795   C0439799:Channel [Spatial Concept]
   795   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   795   C1706095:Channel [Conceptual Entity]
   795   C1708601:K' [Quantitative Concept]
   795   C1711351:Subunit [Quantitative Concept]

Phrase: "are"

Phrase: "rare in clinically defined type 1 diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0521114:Rare [Temporal Concept]
   748   C0522498:Rare [Qualitative Concept]
   748   C1514917:RARE [Gene or Genome]

Phrase: "diagnosed before 2 years."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0011900:Diagnosed [Finding]
   770   C0439234:years [Temporal Concept]
   737 E C0439508:/year [Temporal Concept]
Processing 00000000.tx.249: Diabetes53 :2998 3001,2004[Abstract/Free FullText] Massa O, Iafusco D, DAmato E, Gloyn AL, Hattersley AT, Pasquino B, Tonini G, Dammacco F, Zanette G, Meschi F, Porzio O, Bottazzo G, Crino A, Lorini R, Cerutti F, Vanelli M, Barbetti F, the Early Onset Diabetes Study Group of the Italian Society of Pediatric Endocrinology and Diabetology: KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. 

Phrase: "Diabetes53"

Phrase: ":"

Phrase: "2998 3001,"

Phrase: "2004"

Phrase: "[Abstract/Free FullText"

Phrase: "] Massa O,"

Phrase: "Iafusco D,"

Phrase: "DAmato E,"

Phrase: "Gloyn AL,"

Phrase: "Hattersley AT,"

Phrase: "Pasquino B,"

Phrase: "Tonini G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Dammacco F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Zanette G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Meschi F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Porzio O,"

Phrase: "Bottazzo G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Crino A,"

Phrase: "Lorini R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Cerutti F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Vanelli M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Barbetti F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "the Early Onset Diabetes Study Group of the Italian Society of Pediatric Endocrinology"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   735   C0441833:Group [Idea or Concept]
   735   C0557651:Study [Manufactured Object]
   735   C0687744:group [Population Group]
   735   C1257890:Group [Population Group]
   735   C1552516:Group [Health Care Related Organization]
   735   C1705428:Group [Conceptual Entity]
   735   C1705429:Group [Population Group]
   735   C2603343:Study [Research Activity]

Phrase: "and"

Phrase: "Diabetology"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441552:Diabetology [Diagnostic Procedure]

Phrase: ":"

Phrase: "KCNJ11 activating mutations in Italian patients"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0026882:Mutations [Genetic Function]
   719 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "with permanent neonatal diabetes."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0158981:Neonatal diabetes [Disease or Syndrome]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.250: Hum Mutat25 :22 27,2005[Medline] Vaxillaire M, Populaire C, Busiah K, Cave H, Gloyn AL, Hattersley AT, Czernichow P, Froguel P, Polak M: Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. 

Phrase: "Hum Mutat25"

Phrase: ":"

Phrase: "22 27,"

Phrase: "2005"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Vaxillaire M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Populaire C,"

Phrase: "Busiah K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Cave H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Gloyn AL,"

Phrase: "Hattersley AT,"

Phrase: "Czernichow P,"

Phrase: "Froguel P,"

Phrase: "Polak M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "Kir6.2 mutations"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]
   734   C1416578:Kir6.2 [Gene or Genome]

Phrase: "are"

Phrase: "a common cause of permanent neonatal diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0015127:cause [Functional Concept]
   748   C1524003:Cause [Conceptual Entity]

Phrase: "in a large cohort"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0599755:Cohort [Population Group]

Phrase: "of French patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.251: Diabetes53 :2719 2722,2004[Abstract/Free FullText] Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H, Abuelo D, Phornphutkul C, Molnes J, Bell GI, Gloyn AL, Hattersley AT, Molven A, Sovik O, Njolstad PR: Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. 

Phrase: "Diabetes53"

Phrase: ":"

Phrase: "2719 2722,"

Phrase: "2004"

Phrase: "[Abstract/Free FullText"

Phrase: "] Sagen JV,"

Phrase: "Raeder H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Hathout E,"

Phrase: "Shehadeh N,"

Phrase: "Gudmundsson K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Baevre H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Abuelo D,"

Phrase: "Phornphutkul C,"

Phrase: "Molnes J,"

Phrase: "Bell GI,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3539617:GI [Idea or Concept]

Phrase: "Gloyn AL,"

Phrase: "Hattersley AT,"

Phrase: "Molven A,"

Phrase: "Sovik O,"

Phrase: "Njolstad PR"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0279759:PR+ [Laboratory or Test Result]
   861   C0279766:PR- [Laboratory or Test Result]
   861   C1418864:PR@ [Gene or Genome]
   861   C3538934:PR [Intellectual Product]
   861   C3538935:PR [Idea or Concept]

Phrase: ":"

Phrase: "Permanent neonatal diabetes due to mutations"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0158981:Neonatal diabetes [Disease or Syndrome]
   753   C0011847:Diabetes [Disease or Syndrome]
   753   C0011849:Diabetes [Disease or Syndrome]

Phrase: "in KCNJ11 encoding Kir6.2"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C1416578:Kir6.2 [Gene or Genome]
           KCNJ11
   812   C1547699:Encoding [Idea or Concept]
   812   C2700640:Encoding [Activity]

Phrase: ":"

Phrase: "patient characteristics"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0815172:patient characteristics [Clinical Attribute]
   861   C1521970:Characteristics [Qualitative Concept]

Phrase: "and"

Phrase: "initial response to sulfonylurea therapy."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0871261:Response [Organism Attribute]
   760   C1704632:Response [Finding]
   760   C1706817:Response [Intellectual Product]
   760   C2911692:Response [Mental Process]
Processing 00000000.tx.252: Diabetes53 :2713 2718,2004[Abstract/Free FullText] Gloyn AL, Reimann F, Girard C, Edghill EL, Proks P, Pearson ER, Temple IK, Mackay DJ, Shield JP, Freedenberg D, Noyes K, Ellard S, Ashcroft FM, Gribble FM, Hattersley AT: Relapsing diabetes can result from moderately activating mutations in KCNJ11. 

Phrase: "Diabetes53"

Phrase: ":"

Phrase: "2713 2718,"

Phrase: "2004"

Phrase: "[Abstract/Free FullText"

Phrase: "] Gloyn AL,"

Phrase: "Reimann F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Girard C,"

Phrase: "Edghill EL,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1416870:EL [Gene or Genome]
   861   C1823249:EL [Gene or Genome]

Phrase: "Proks P,"

Phrase: "Pearson ER,"

Phrase: "Temple IK,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1416378:IK [Gene or Genome]

Phrase: "Mackay DJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012836:DJ [Geographic Area]

Phrase: "Shield JP,"

Phrase: "Freedenberg D,"

Phrase: "Noyes K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Ellard S,"

Phrase: "Ashcroft FM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: "Gribble FM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: "Hattersley AT"

Phrase: ":"

Phrase: "Relapsing"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0035020:Relapsing [Phenomenon or Process]
  1000   C0205336:relapsing [Temporal Concept]
   966 E C0277556:Relapse [Disease or Syndrome]

Phrase: "diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "can"

Phrase: "result from moderately activating mutations"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   760   C0026882:Mutations [Genetic Function]
   760   C1274040:Result [Functional Concept]
   760   C1546471:Result [Idea or Concept]
   760   C1879547:activating [Activity]
   760   C1881878:Moderately [Qualitative Concept]
   760   C2825142:Result [Finding]
   726 E C1515877:Activate [Functional Concept]
   726 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "in KCNJ11."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:KCNJ11 [Gene or Genome]
Processing 00000000.tx.253: Hum Mol Genet14 :925 934,2005[Abstract/Free FullText] Yorifuji T, Nagashima K, Kurokawa K, Kawai M, Oishi M, Akazawa Y, Hosokawa M, Yamada Y, Inagaki N, Nakahata T: The C42R mutation in the Kir6.2 (KCNJ11) gene as a cause of transient neonatal diabetes, childhood diabetes, or later-onset, apparently type 2 diabetes mellitus. 

Phrase: "Hum Mol Genet14"

Phrase: ":"

Phrase: "925 934,"

Phrase: "2005"

Phrase: "[Abstract/Free FullText"

Phrase: "] Yorifuji T,"

Phrase: "Nagashima K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Kurokawa K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Kawai M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Oishi M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Akazawa Y,"

Phrase: "Hosokawa M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Yamada Y,"

Phrase: "Inagaki N,"

Phrase: "Nakahata T"

Phrase: ":"

Phrase: "The C42R mutation in the Kir6.2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0026882:Mutation [Genetic Function]
   748   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "(KCNJ11"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:KCNJ11 [Gene or Genome]

Phrase: ")"

Phrase: "gene as a cause of transient neonatal diabetes,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0017337:Gene [Gene or Genome]

Phrase: "childhood diabetes,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: "or"

Phrase: "later-onset,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0332162:Onset [Qualitative Concept]

Phrase: "apparently type 2 diabetes mellitus."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   937   C0011860:Diabetes Mellitus, Type 2 [Disease or Syndrome]
           Type 2 Diabetes
   937   C2984301:Type II diabetes mellitus [Functional Concept]
   853   C1320657:type diabetes [Finding]
   840   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   840   C0441730:Type 2 [Classification]
   804   C0011847:Diabetes [Disease or Syndrome]
   804   C0332307:Type [Qualitative Concept]
   804   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.254: J Clin Endocrinol Metab90 :3174 3178,2005[Abstract/Free FullText] Seino S, Iwanaga T, Nagashima K, Miki T: Diverse roles of KATP channels learned from Kir6.2 genetically engineered mice. 

Phrase: "J Clin Endocrinol Metab90"

Phrase: ":"

Phrase: "3174 3178,"

Phrase: "2005"

Phrase: "[Abstract/Free FullText"

Phrase: "] Seino S,"

Phrase: "Iwanaga T,"

Phrase: "Nagashima K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Miki T"

Phrase: ":"

Phrase: "Diverse roles of KATP channels"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0035820:Roles [Social Behavior]
   726 E C1705810:Role [Conceptual Entity]

Phrase: "learned from Kir6.2 genetically engineered mice."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   802   C1522222:Genetically Engineered Mouse [Experimental Model of Disease]
   778   C0017387:Genetically Engineered [Molecular Biology Research Technique]
   778   C1416578:Kir6.2 [Gene or Genome]
   748   C0023185:learned [Mental Process]
   748   C0025914:Mice [Mammal]
   748   C0025929:mice [Mammal]
   748   C0026809:Mice [Mammal]
   748   C0878517:engineered [Professional or Occupational Group]
Processing 00000000.tx.255: Diabetes49 :311 318,2000[Abstract] Yamada K, Ji JJ, Yuan H, Miki T, Sato S, Horimoto N, Shimizu T, Seino S, Inagaki N: Protective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizure. 

Phrase: "Diabetes49"

Phrase: ":"

Phrase: "311 318,"

Phrase: "2000"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Yamada K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Ji JJ,"

Phrase: "Yuan H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Miki T,"

Phrase: "Sato S,"

Phrase: "Horimoto N,"

Phrase: "Shimizu T,"

Phrase: "Seino S,"

Phrase: "Inagaki N"

Phrase: ":"

Phrase: "Protective role of ATP-sensitive potassium channels"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0035820:Role [Social Behavior]
   748   C1705810:Role [Conceptual Entity]

Phrase: "in hypoxia-"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0242184:Hypoxia [Pathologic Function]
  1000   C1963140:HYPOXIA [Finding]

Phrase: "induced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]

Phrase: "generalized seizure."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0234533:Generalized seizure [Disease or Syndrome]
   861   C0036572:Seizure [Sign or Symptom]
   861   C1959629:Seizure [Finding]
Processing 00000000.tx.256: Science292 :1543 1546,2001[Abstract/Free FullText] Zung A, Glaser B, Nimri R, Zadik Z: Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. 

Phrase: "Science292"

Phrase: ":"

Phrase: "1543 1546,"

Phrase: "2001"

Phrase: "[Abstract/Free FullText"

Phrase: "] Zung"

Phrase: "A,"

Phrase: "Glaser B,"

Phrase: "Nimri R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Zadik Z"

Phrase: ":"

Phrase: "Glibenclamide treatment in permanent neonatal diabetes mellitus"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   748   C0039798:treatment [Functional Concept]
   748   C0087111:Treatment [Therapeutic or Preventive Procedure]
   748   C1522326:Treatment [Functional Concept]
   748   C1533734:Treatment [Therapeutic or Preventive Procedure]
   748   C1705169:Treatment [Conceptual Entity]
   748   C3538994:TREATMENT [Research Activity]

Phrase: "due to an activating mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0026882:Mutation [Genetic Function]
   861   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "in Kir6.2."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:Kir6.2 [Gene or Genome]
Processing 00000000.tx.257: J Clin Endocrinol Metab89 :5504 5507,2004[Abstract/Free FullText] Codner E, Flanagan S, Ellard S, Garcia H, Hattersley AT: High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation (Letter). 

Phrase: "J Clin Endocrinol Metab89"

Phrase: ":"

Phrase: "5504 5507,"

Phrase: "2004"

Phrase: "[Abstract/Free FullText"

Phrase: "] Codner E,"

Phrase: "Flanagan S,"

Phrase: "Ellard S,"

Phrase: "Garcia H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Hattersley AT"

Phrase: ":"

Phrase: "High-dose glibenclamide"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0017628:Glibenclamide [Organic Chemical,Pharmacologic Substance]
   734   C0444956:High dose [Quantitative Concept]

Phrase: "can"

Phrase: "replace"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1554078:Replace [Idea or Concept]

Phrase: "insulin therapy despite transitory diarrhea"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   760   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C0039798:therapy [Functional Concept]
   760   C0087111:Therapy [Therapeutic or Preventive Procedure]
   760   C1363945:Therapy [Finding]
   760   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   760   C1579433:Insulin [Pharmacologic Substance]
   704 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]

Phrase: "in early-onset diabetes"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C1833334:Early-onset [Finding]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332162:Onset [Qualitative Concept]
   827   C1279919:Early [Temporal Concept]

Phrase: "caused by a novel R201L Kir6.2 mutation"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   770   C1416578:Kir6.2 [Gene or Genome]
   767   C2985438:Novel Mutation [Cell or Molecular Dysfunction]
   744   C0026882:Mutation [Genetic Function]
   744   C0205314:Novel [Temporal Concept]
   744   C0679622:novel [Intellectual Product]
   744   C1705285:Mutation [Cell or Molecular Dysfunction]
   711   C0015127:cause [Functional Concept]
   711   C1524003:Cause [Conceptual Entity]

Phrase: "(Letter"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C1096774:Letter [Intellectual Product]
  1000   C2360551:Letter [Clinical Attribute]
   944 E C0079691:Levothyroxine Sodium [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C0282413:letters [Intellectual Product]
   916 E C0728762:Synthroid [Amino Acid, Peptide, or Protein,Pharmacologic Substance]

Phrase: ")."
Processing 00000000.tx.258: Diabetes Care28 :758 759,2005[Free FullText] Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM: Molecular basis of Kir6.2 mutations associated with neonatal diabetes plus neurological features. 

Phrase: "Diabetes Care28"

Phrase: ":"

Phrase: "758 759,"

Phrase: "2005"

Phrase: "[Free FullText"

Phrase: "] Proks P,"

Phrase: "Antcliff JF,"

Phrase: "Lippiat J,"

Phrase: "Gloyn AL,"

Phrase: "Hattersley AT,"

Phrase: "Ashcroft FM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: ":"

Phrase: "Molecular basis of Kir6.2 mutations"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1853126:MOLECULAR BASIS [Idea or Concept]
   753   C1527178:Basis [Functional Concept]
   753   C1874451:Basis [Pharmacologic Substance]

Phrase: "associated with neonatal diabetes"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   833   C0158981:Neonatal diabetes [Disease or Syndrome]
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0011847:Diabetes [Disease or Syndrome]
   770   C0011849:Diabetes [Disease or Syndrome]
   770   C1552240:Neonatal [Professional or Occupational Group]
   770   C1552264:Neonatal [Professional or Occupational Group]
   770   C2939425:Neonatal [Temporal Concept]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "plus neurological features."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C1521970:Feature [Qualitative Concept]
   827   C1706388:Feature [Conceptual Entity]
   827   C2346469:Feature [Qualitative Concept]
   827   C2348519:Feature [Qualitative Concept]
Processing 00000000.tx.259: Proc Natl Acad Sci U S A101 :17539 17544,2004[Abstract/Free FullText] Koster JC, Remedi MS, Dao C, Nichols CG: ATP and sulfonylurea sensitivity of mutant ATP-sensitive K+ channels in neonatal diabetes: implications for pharmacogenomic therapy. 

Phrase: "Proc Natl Acad Sci U S A101"

Phrase: ":"

Phrase: "17539 17544,"

Phrase: "2004"

Phrase: "[Abstract/Free FullText"

Phrase: "] Koster JC,"

Phrase: "Remedi MS,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039676:MS [Amino Acid, Peptide, or Protein,Enzyme]
   861   C2349943:Ms. [Conceptual Entity]
   861   C3539704:MS [Gene or Genome]

Phrase: "Dao C,"

Phrase: "Nichols CG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: ":"

Phrase: "ATP"

Phrase: "and"

Phrase: "sulfonylurea sensitivity of mutant ATP-sensitive K+ channels"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   750   C1547341:Channel sensitivity [Idea or Concept]
   744   C0036667:Sensitivity [Quantitative Concept]
   744   C0312418:Sensitivity [Mental Process]
   744   C0427965:Sensitivity [Finding]
   744   C1511883:Sensitivity [Quantitative Concept]
   744   C1522640:Sensitivity [Qualitative Concept]
   744   C2346484:SENSITIVITY [Phenomenon or Process]
   744   C2349185:Sensitivity [Qualitative Concept]

Phrase: "in neonatal diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0158981:Neonatal diabetes [Disease or Syndrome]
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "implications for pharmacogenomic therapy."
Processing 00000000.tx.260: Diabetes54 :2645 2654,2005[Abstract/Free FullText] Inoue H, Ferrer J, Welling CM, Elbein SC, Hoffman M, Mayorga R, Warren-Perry M, Zhang Y, Millns H, Turner R, Province M, Bryan J, Permutt MA, Aguilar-Bryan L: Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. 

Phrase: "Diabetes54"

Phrase: ":"

Phrase: "2645 2654,"

Phrase: "2005"

Phrase: "[Abstract/Free FullText"

Phrase: "] Inoue H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Ferrer J,"

Phrase: "Welling"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0205170:Well [Qualitative Concept]
   966   C3146287:Well [Manufactured Object]

Phrase: "CM,"

Phrase: "Elbein SC,"

Phrase: "Hoffman M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Mayorga R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Warren-Perry M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "Zhang Y,"

Phrase: "Millns H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Turner R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Province M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Bryan J,"

Phrase: "Permutt MA,"

Phrase: "Aguilar-Bryan L"

Phrase: ":"

Phrase: "Sequence variants in the sulfonylurea receptor (SUR) gene"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0205419:variants [Qualitative Concept]

Phrase: "are"

Phrase: "associated with NIDDM"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   882   C0332281:Associated with [Qualitative Concept]
           Associated
   790   C0011860:NIDDM [Disease or Syndrome]
   790   C3273872:NIDDM [Gene or Genome]
   756 E C0750490:Associate [Idea or Concept]
   756 E C1706221:Associate [Professional or Occupational Group]

Phrase: "in Caucasians."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0007457:Caucasians [Population Group]
  1000   C0043157:Caucasians [Population Group]
Processing 00000000.tx.261: Diabetes45 :825 831,1996[Abstract] Hani EH, Boutin P, Durand E, Inoue H, Permutt MA, Velho G, Froguel P: Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of type II diabetes mellitus in Caucasians. 

Phrase: "Diabetes45"

Phrase: ":"

Phrase: "825 831,"

Phrase: "1996"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Hani EH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1520135:EH [Geographic Area]

Phrase: "Boutin P,"

Phrase: "Durand E,"

Phrase: "Inoue H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Permutt MA,"

Phrase: "Velho G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Froguel P"

Phrase: ":"

Phrase: "Missense mutations in the pancreatic islet beta cell inwardly"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   764   C0599155:Mutations, Missense [Genetic Function]
   742   C0026882:Mutations [Genetic Function]
   708 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "rectifying"

Phrase: "K+ channel gene"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017337:Gene [Gene or Genome]

Phrase: "(KIR6.2/BIR"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1416578:BIR [Gene or Genome]
           Kir6.2
   827   C3272365:BIR [Genetic Function]

Phrase: ")"

Phrase: ":"

Phrase: "a meta-analysis"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0282458:Meta-Analysis [Intellectual Product]
  1000   C0920317:Meta-Analysis [Research Activity]
   861   C0002778:Analysis [Laboratory Procedure]
   861   C0936012:Analysis [Research Activity]
   861   C1042496:Meta [Eukaryote]
   861   C1524024:analysis [Functional Concept]

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "a role in the polygenic basis of type II diabetes mellitus"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   738   C0035820:Role [Social Behavior]
   738   C1705810:Role [Conceptual Entity]

Phrase: "in Caucasians."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0007457:Caucasians [Population Group]
  1000   C0043157:Caucasians [Population Group]
Processing 00000000.tx.262: Diabetologia41 :1511 1515,1998[Medline] Gloyn AL, Weedon MN, Owen KR, Turner MJ, Knight BA, Hitman G, Walker M, Levy JC, Sampson M, Halford S, McCarthy MI, Hattersley AT, Frayling TM: Large-scale association studies of variants in genes encoding the pancreatic -cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. 

Phrase: "Diabetologia41"

Phrase: ":"

Phrase: "1511 1515,"

Phrase: "1998"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Gloyn AL,"

Phrase: "Weedon MN,"

Phrase: "Owen KR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022773:KR [Geographic Area]

Phrase: "Turner MJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439254:MJ [Medical Device]

Phrase: "Knight BA,"

Phrase: "Hitman G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Walker M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Levy JC,"

Phrase: "Sampson M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Halford S,"

Phrase: "McCarthy MI,"

Phrase: "Hattersley AT,"

Phrase: "Frayling TM"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0145779:TM [Amino Acid, Peptide, or Protein,Receptor]
   861   C3540468:TM [Gene or Genome]

Phrase: ":"

Phrase: "Large-scale association"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0004083:Association [Mental Process]
   827   C0439849:Association [Qualitative Concept]
   827   C0596306:Association [Phenomenon or Process]
   827   C0699792:association [Social Behavior]

Phrase: "studies of variants"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0205419:variants [Qualitative Concept]
   790   C0557651:Study [Manufactured Object]
   790   C0947630:studies [Laboratory Procedure]
   790   C2603343:Study [Research Activity]

Phrase: "in genes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017337:Genes [Gene or Genome]

Phrase: "encoding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1547699:Encoding [Idea or Concept]
  1000   C2700640:Encoding [Activity]

Phrase: "the pancreatic -cell KATP channel subunits Kir6.2"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   818   C1416578:Kir6.2 [Gene or Genome]
   795   C0007634:Cell [Cell]
   795   C0030274:Pancreatic [Body Part, Organ, or Organ Component]
   795   C0439799:Channel [Spatial Concept]
   795   C1269647:Cell [Cell]
   795   C1704653:Cell [Medical Device]
   795   C1706095:Channel [Conceptual Entity]
   795   C1948049:Cell [Spatial Concept]
   762   C1711351:Subunit [Quantitative Concept]

Phrase: "(KCNJ11"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:KCNJ11 [Gene or Genome]

Phrase: ")"

Phrase: "and"

Phrase: "SUR1"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   827   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   827   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   827   C3536898:Sulfonylurea [Pharmacologic Substance]

Phrase: "(ABCC8"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1412082:ABCC8 [Gene or Genome]

Phrase: ")"

Phrase: "confirm"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0521093:confirm [Qualitative Concept]
  1000   C0750484:confirm [Idea or Concept]
  1000   C1456348:Confirm [Qualitative Concept]

Phrase: "that"

Phrase: "the KCNJ11 E23K variant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0205419:Variant [Qualitative Concept]

Phrase: "is"

Phrase: "associated with type 2 diabetes."
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   862   C0011860:Type 2 Diabetes [Disease or Syndrome]
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   806   C0441730:Type 2 [Classification]
   797   C1320657:Diabetes type [Finding]
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0332307:Type [Qualitative Concept]
   760   C1547052:*Type [Quantitative Concept]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.263: Diabetes52 :568 572,2003[Abstract/Free FullText] t Hart LM, van Haeften TW, Dekker JM, Bot M, Heine RJ, Maassen JA: Variations in insulin secretion in carriers of the E23K variant in the KIR6.2 subunit of the ATP-sensitive K+ channel in the -cell. 

Phrase: "Diabetes52"

Phrase: ":"

Phrase: "568 572,"

Phrase: "2003"

Phrase: "[Abstract/Free FullText"

Phrase: "] t Hart LM,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1261082:LM [Body Part, Organ, or Organ Component]
   827   C1551056:lm [Quantitative Concept]
   827   C2981682:LM [Quantitative Concept]

Phrase: "van Haeften TW,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0039260:TW [Geographic Area]
   827   C0332293:TW [Therapeutic or Preventive Procedure]

Phrase: "Dekker JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Bot M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Heine RJ,"

Phrase: "Maassen JA"

Phrase: ":"

Phrase: "Variations in insulin secretion"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0205419:variations [Qualitative Concept]

Phrase: "in carriers"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0007294:carriers [Finding]
   966 E C0560175:Carrier [Finding]
   966 E C1706209:Carrier [Medical Device]
   966 E C3273162:Carrier [Intellectual Product]

Phrase: "of the E23K variant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205419:Variant [Qualitative Concept]

Phrase: "in the KIR6.2 subunit"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1711351:Subunit [Quantitative Concept]
   734   C1416578:Kir6.2 [Gene or Genome]

Phrase: "of the ATP-sensitive K+ channel"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0332324:Sensitive [Functional Concept]
   812   C0439799:Channel [Spatial Concept]
   812   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   812   C1550474:sensitive [Idea or Concept]
   812   C1706095:Channel [Conceptual Entity]
   812   C1708601:K' [Quantitative Concept]

Phrase: "in the -cell."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0007634:Cell [Cell]
  1000   C1269647:Cell [Cell]
  1000   C1704653:Cell [Medical Device]
  1000   C1948049:Cell [Spatial Concept]
Processing 00000000.tx.264: Diabetes51 :3135 3138,2002[Abstract/Free FullText] Barroso I, Luan J, Middelberg RP, Harding AH, Franks PW, Jakes RW, Clayton D, Schafer AJ, ORahilly S, Wareham NJ: Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action. 

Phrase: "Diabetes51"

Phrase: ":"

Phrase: "3135 3138,"

Phrase: "2002"

Phrase: "[Abstract/Free FullText"

Phrase: "] Barroso I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Luan J,"

Phrase: "Middelberg RP,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1538326:RP [Gene or Genome]
   861   C3541325:RP [Idea or Concept]

Phrase: "Harding AH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1836672:AH [Disease or Syndrome]

Phrase: "Franks PW,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0242397:PW [Geographic Area]

Phrase: "Jakes RW,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0035978:RW [Geographic Area]
   861   C2700310:RW [Fish]

Phrase: "Clayton D,"

Phrase: "Schafer AJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0230613:AJ [Cell Component]

Phrase: "ORahilly S,"

Phrase: "Wareham NJ"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0027971:NJ [Geographic Area]

Phrase: ":"

Phrase: "Candidate gene association study in type 2 diabetes"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C2717881:Candidate Gene Association Study [Molecular Biology Research Technique]
   767   C0035171:Study Type [Research Activity]
   767   C2985227:Study Type [Research Activity]
   744   C0557651:Study [Manufactured Object]
   744   C2603343:Study [Research Activity]

Phrase: "indicates"

Phrase: "a role for genes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0035820:Role [Social Behavior]
   770   C1705810:Role [Conceptual Entity]

Phrase: "involved in beta-cell function"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   806   C0007613:Cell Function [Cell Function]
   806   C0030281:Beta cell [Cell]
   760   C0007634:Cell [Cell]
   760   C0031843:function [Physiologic Function]
   760   C0330390:Beta [Plant]
   760   C0439096:Beta [Intellectual Product]
   760   C0542341:Function [Functional Concept]
   760   C0700205:FUNCTION [Classification]
   760   C1269647:Cell [Cell]
   760   C1314939:Involved [Functional Concept]
   760   C1704653:Cell [Medical Device]
   760   C1705273:Function [Intellectual Product]
   760   C1948049:Cell [Spatial Concept]
   760   C2004068:Beta [Qualitative Concept]

Phrase: "as well as"

Phrase: "insulin action."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0441472:Action [Functional Concept]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   861   C3266814:Action [Activity]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.265: PLoS Biology1 :E20 ,2003[Medline] Sakura H, Wat N, Horton V, Millns H, Turner RC, Ashcroft FM: Sequence variations in the human Kir6.2 gene, a subunit of the beta-cell ATP-sensitive K-channel: no association with NIDDM in while Caucasian subjects or evidence of abnormal function when expressed in vitro. 

Phrase: "PLoS Biology1"

Phrase: ":"

Phrase: "E20 ,"

Phrase: "2003"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Sakura H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Wat N,"

Phrase: "Horton V,"

Phrase: "Millns H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Turner RC,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1419366:RC [Gene or Genome]

Phrase: "Ashcroft FM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: ":"

Phrase: "Sequence variations in the human Kir6.2 gene,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   744   C0004793:Sequence [Nucleotide Sequence]
   744   C0162326:Sequence [Nucleotide Sequence]
   744   C0162327:Sequence [Nucleotide Sequence]
   744   C0205419:variations [Qualitative Concept]
   744   C1519249:Sequence [Functional Concept]
   737   C0042333:Sequence Variation [Natural Phenomenon or Process]

Phrase: "a subunit of the beta-cell ATP-sensitive K-channel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   757   C1264631:Beta subunit [Qualitative Concept]
   739   C1711351:Subunit [Quantitative Concept]

Phrase: ":"

Phrase: "no association with NIDDM"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0004083:Association [Mental Process]
   770   C0439849:Association [Qualitative Concept]
   770   C0596306:Association [Phenomenon or Process]
   770   C0699792:association [Social Behavior]

Phrase: "in"

Phrase: "while"

Phrase: "Caucasian subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0681850:Subject [Group]
   827   C1550501:{Subject} [Idea or Concept]
   827   C1706203:Subject [Idea or Concept]
   827   C2349001:Subject [Human]
   827   C2697811:Subject [Functional Concept]

Phrase: "or"

Phrase: "evidence of abnormal function"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: "when"

Phrase: "expressed"

Phrase: "in vitro."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0021135:In Vitro [Intellectual Product]
  1000   C1533691:in vitro [Qualitative Concept]
           vitro
  1000   C2827718:In Vitro [Functional Concept]
Processing 00000000.tx.266: Diabetologia39 :1233 1236,1996[Medline] Inoue H, Ferrer J, Warren-Perry M, Zhang Y, Millns H, Turner RC, Elbein SC, Hampe CL, Suarez BK, Inagaki N, Seino S, Permutt MA: Sequence variants in the pancreatic islet -cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM. 

Phrase: "Diabetologia39"

Phrase: ":"

Phrase: "1233 1236,"

Phrase: "1996"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Inoue H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Ferrer J,"

Phrase: "Warren-Perry M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "Zhang Y,"

Phrase: "Millns H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Turner RC,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1419366:RC [Gene or Genome]

Phrase: "Elbein SC,"

Phrase: "Hampe CL,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596019:Cl - [Element, Ion, or Isotope]

Phrase: "Suarez BK,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0006100:BK [Amino Acid, Peptide, or Protein,Hormone,Neuroreactive Substance or Biogenic Amine]
   861   C1537501:BK [Gene or Genome]

Phrase: "Inagaki N,"

Phrase: "Seino S,"

Phrase: "Permutt MA"

Phrase: ":"

Phrase: "Sequence variants in the pancreatic islet -cell inwardly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0205419:variants [Qualitative Concept]

Phrase: "rectifying"

Phrase: "K+ channel Kir6.2"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C1416578:Kir6.2 [Gene or Genome]
   812   C0439799:Channel [Spatial Concept]
   812   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   812   C1706095:Channel [Conceptual Entity]
   812   C1708601:K' [Quantitative Concept]

Phrase: "(Bir"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1416578:BIR [Gene or Genome]
  1000   C3272365:BIR [Genetic Function]

Phrase: ")"

Phrase: "gene"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017337:Gene [Gene or Genome]

Phrase: ":"

Phrase: "identification"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0020792:Identification [Mental Process]
  1000   C0205396:Identification [Qualitative Concept]

Phrase: "and"

Phrase: "lack of role"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0332268:lack [Qualitative Concept]

Phrase: "in Caucasian patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "with NIDDM."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011860:NIDDM [Disease or Syndrome]
  1000   C3273872:NIDDM [Gene or Genome]
Processing 00000000.tx.267: Diabetes46 :502 507,1997[Abstract] Laukkanen O, Pihlajamaki J, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M, the Finnish Diabetes Prevention Study Group: Polymorphisms of the SUR1 (ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. 

Phrase: "Diabetes46"

Phrase: ":"

Phrase: "502 507,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450381:507 [Intellectual Product]

Phrase: "1997"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Laukkanen O,"

Phrase: "Pihlajamaki J,"

Phrase: "Lindstrom J,"

Phrase: "Eriksson J,"

Phrase: "Valle TT,"

Phrase: "Hamalainen H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Ilanne-Parikka P,"

Phrase: "Keinanen-Kiukaanniemi S,"

Phrase: "Tuomilehto J,"

Phrase: "Uusitupa M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Laakso M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "the Finnish Diabetes Prevention Study Group"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   804   C0441833:Group [Idea or Concept]
   804   C0687744:group [Population Group]
   804   C1257890:Group [Population Group]
   804   C1552516:Group [Health Care Related Organization]
   804   C1705428:Group [Conceptual Entity]
   804   C1705429:Group [Population Group]

Phrase: ":"

Phrase: "Polymorphisms of the SUR1"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0032529:polymorphisms [Genetic Function]
   719 E C1882417:Polymorphism [Qualitative Concept]

Phrase: "(ABCC8"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1412082:ABCC8 [Gene or Genome]

Phrase: ")"

Phrase: "and"

Phrase: "Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:Kir6.2 [Gene or Genome]

Phrase: "(KCNJ11"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:KCNJ11 [Gene or Genome]

Phrase: ")"

Phrase: "genes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017337:Genes [Gene or Genome]

Phrase: "predict"

Phrase: "the conversion from impaired glucose tolerance"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0439836:Conversion [Functional Concept]

Phrase: "to type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: ":"

Phrase: "the Finnish Diabetes Prevention Study."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   861   C1659987:diabetes prevention [Educational Activity]
   861   C1706420:Prevention Study [Research Activity]
           PREVENTION
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0011849:Diabetes [Disease or Syndrome]
   812   C0199176:Prevention [Therapeutic or Preventive Procedure]
   812   C0557651:Study [Manufactured Object]
   812   C2603343:Study [Research Activity]
   812   C2700409:prevention [Qualitative Concept]
Processing 00000000.tx.268: J Clin Endocrinol Metab89 :6286 6290,2004[Abstract/Free FullText] Love-Gregory L, Wasson J, Lin J, Skolnick G, Suarez B, Permutt MA: E23K single nucleotide polymorphism in the islet ATP-sensitive potassium channel gene (Kir6.2) contributes as much to the risk of type II diabetes in Caucasians as the PPARgamma Pro12Ala variant (Letter). 

Phrase: "J Clin Endocrinol Metab89"

Phrase: ":"

Phrase: "6286 6290,"

Phrase: "2004"

Phrase: "[Abstract/Free FullText"

Phrase: "] Love-Gregory L,"

Phrase: "Wasson J,"

Phrase: "Lin J,"

Phrase: "Skolnick G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Suarez B,"

Phrase: "Permutt MA"

Phrase: ":"

Phrase: "E23K single nucleotide polymorphism in the islet ATP-sensitive potassium channel gene"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   770   C0752046:Single Nucleotide Polymorphism [Nucleotide Sequence]
   751   C0678951:gene polymorphism [Genetic Function]
   736   C0028630:Nucleotide [Nucleic Acid, Nucleoside, or Nucleotide]
   736   C0032529:Polymorphism [Genetic Function]
   736   C0037179:Single [Population Group]
   736   C0087136:single [Finding]
   736   C0205171:Single [Quantitative Concept]
   736   C1882417:Polymorphism [Qualitative Concept]

Phrase: "(Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:Kir6.2 [Gene or Genome]

Phrase: ")"

Phrase: "contributes as much"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1880177:Contribute [Activity]

Phrase: "to the risk"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035647:Risk [Qualitative Concept]

Phrase: "of type II diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type II [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]

Phrase: "in Caucasians"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0007457:Caucasians [Population Group]
  1000   C0043157:Caucasians [Population Group]

Phrase: "as the PPARgamma Pro12Ala variant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0205419:Variant [Qualitative Concept]

Phrase: "(Letter"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C1096774:Letter [Intellectual Product]
  1000   C2360551:Letter [Clinical Attribute]
   944 E C0079691:Levothyroxine Sodium [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   916 E C0282413:letters [Intellectual Product]
   916 E C0728762:Synthroid [Amino Acid, Peptide, or Protein,Pharmacologic Substance]

Phrase: ")."
Processing 00000000.tx.269: Diabetologia46 :136 137,2003[Medline] Florez JC, Burtt N, de Bakker PI, Almgren P, Tuomi T, Holmkvist J, Gaudet D, Hudson TJ, Schaffner SF, Daly MJ, Hirschhorn JN, Groop L, Altshuler D: Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. 

Phrase: "Diabetologia46"

Phrase: ":"

Phrase: "136 137,"

Phrase: "2003"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Florez JC,"

Phrase: "Burtt N,"

Phrase: "de Bakker PI,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0429863:PI [Clinical Attribute]
   827   C3537219:PI [Gene or Genome]
   827   C3539772:PI [Intellectual Product]

Phrase: "Almgren P,"

Phrase: "Tuomi T,"

Phrase: "Holmkvist J,"

Phrase: "Gaudet D,"

Phrase: "Hudson TJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0039247:TJ [Geographic Area]

Phrase: "Schaffner SF,"

Phrase: "Daly MJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439254:MJ [Medical Device]

Phrase: "Hirschhorn JN,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1428813:JN [Gene or Genome]

Phrase: "Groop L,"

Phrase: "Altshuler D"

Phrase: ":"

Phrase: "Haplotype structure"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0678594:Structure [Spatial Concept]

Phrase: "and"

Phrase: "genotype-phenotype correlations of the sulfonylurea receptor"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   814   C2717879:Genotype-Phenotype Correlations [Finding]
   714   C1707520:Correlation [Qualitative Concept]

Phrase: "and"

Phrase: "the islet ATP-sensitive potassium channel gene region."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   795   C0017446:Region [Geographic Area]
   795   C0205147:Region [Spatial Concept]
   724 E C0205276:Regional [Spatial Concept]
   724 E C1947913:Regional [Spatial Concept]
Processing 00000000.tx.270: Diabetes53 :1360 1368,2004[Abstract/Free FullText] Riedel MJ, Steckley DC, Light PE: Current status of the E23K Kir6.2 polymorphism: implications for type-2 diabetes (Review). 

Phrase: "Diabetes53"

Phrase: ":"

Phrase: "1360 1368,"

Phrase: "2004"

Phrase: "[Abstract/Free FullText"

Phrase: "] Riedel MJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439254:MJ [Medical Device]

Phrase: "Steckley DC,"

Phrase: "Light PE"

Phrase: ":"

Phrase: "Current status of the E23K Kir6.2 polymorphism"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0449438:Status [Qualitative Concept]

Phrase: ":"

Phrase: "implications for type-2 diabetes"

Phrase: "(Review"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282443:Review [Intellectual Product]
  1000   C1552617:Review [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.271: Hum Genet116 :133 145,2005[Medline] Schwanstecher C, Meyer U, Schwanstecher M: KIR6.2 polymorphism predisposes to type 2 diabetes by inducing overactivity of pancreatic -cell ATP-sensitive K+ channels. 

Phrase: "Hum Genet116"

Phrase: ":"

Phrase: "133 145,"

Phrase: "2005"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Schwanstecher C,"

Phrase: "Meyer U,"

Phrase: "Schwanstecher M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "KIR6.2 polymorphism"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0032529:Polymorphism [Genetic Function]
   827   C1882417:Polymorphism [Qualitative Concept]
   734   C1416578:Kir6.2 [Gene or Genome]

Phrase: "predisposes to type 2 diabetes"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   862   C0011860:Type 2 Diabetes [Disease or Syndrome]
   806   C0441730:Type 2 [Classification]
   797   C1320657:Diabetes type [Finding]
   760   C0011847:Diabetes [Disease or Syndrome]
   760   C0011849:Diabetes [Disease or Syndrome]
   760   C0332307:Type [Qualitative Concept]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "by inducing overactivity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0474395:overactivity [Finding]
   861   C1536696:Overactivity [Finding]
   789 E C0443272:Overactive [Qualitative Concept]

Phrase: "of pancreatic -cell ATP-sensitive K+ channels."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   799   C0332324:Sensitive [Functional Concept]
   799   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   799   C1550474:sensitive [Idea or Concept]
   799   C1708601:K' [Quantitative Concept]
   766   C0439799:Channel [Spatial Concept]
   766   C1706095:Channel [Conceptual Entity]
Processing 00000000.tx.272: Diabetes51 :875 879,2002[Abstract/Free FullText] Schwanstecher C, Schwanstecher M: Nucleotide sensitivity of pancreatic ATP-sensitive potassium channels and type 2 diabetes. 

Phrase: "Diabetes51"

Phrase: ":"

Phrase: "875 879,"

Phrase: "2002"

Phrase: "[Abstract/Free FullText"

Phrase: "] Schwanstecher C,"

Phrase: "Schwanstecher M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "Nucleotide sensitivity of pancreatic ATP-sensitive potassium channels"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   792   C1955862:ATP-Sensitive Potassium Channels [Amino Acid, Peptide, or Protein]
   750   C1547341:Channel sensitivity [Idea or Concept]
   744   C0036667:Sensitivity [Quantitative Concept]
   744   C0312418:Sensitivity [Mental Process]
   744   C0427965:Sensitivity [Finding]
   744   C1511883:Sensitivity [Quantitative Concept]
   744   C1522640:Sensitivity [Qualitative Concept]
   744   C2346484:SENSITIVITY [Phenomenon or Process]
   744   C2349185:Sensitivity [Qualitative Concept]

Phrase: "and"

Phrase: "type 2 diabetes."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.273: Diabetes51 (Suppl. 3) :S358 S362,2002 Schwanstecher C, Neugebauer B, Schulz M, Schwanstecher M: The common single nucleotide polymorphism E23K in KIR6.2 sensitizes pancreatic -cell ATP-sensitive potassium channels toward activation through nucleoside diphosphates. 

Phrase: "Diabetes51"

Phrase: "(Suppl. 3"

Phrase: ")"

Phrase: ":"

Phrase: "S358 S362,"

Phrase: "2002 Schwanstecher C,"

Phrase: "Neugebauer B,"

Phrase: "Schulz M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Schwanstecher M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "The common single nucleotide polymorphism E23K in KIR6.2"

Phrase: "sensitizes"

Phrase: "pancreatic -cell ATP-sensitive potassium channels toward activation"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   833   C1955862:ATP-Sensitive Potassium Channels [Amino Acid, Peptide, or Protein]
   770   C0032824:Potassium Channels [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   744   C0032821:Potassium [Element, Ion, or Isotope]
   744   C0332324:Sensitive [Functional Concept]
   744   C0597277:Potassium+ [Element, Ion, or Isotope,Pharmacologic Substance]
   744   C1550474:sensitive [Idea or Concept]
   711   C0439799:Channel [Spatial Concept]
   711   C1706095:Channel [Conceptual Entity]

Phrase: "through nucleoside diphosphates."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0599002:nucleoside diphosphate [Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0028621:Nucleoside [Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0034320:Diphosphates [Inorganic Chemical,Pharmacologic Substance]
Processing 00000000.tx.274: Diabetes51 (Suppl. 3) :S363 S367,2002 Enkvetchakul D, Nichols CG: Gating mechanism of KATP channels: function fits form. 

Phrase: "Diabetes51"

Phrase: "(Suppl. 3"

Phrase: ")"

Phrase: ":"

Phrase: "S363 S367,"

Phrase: "2002 Enkvetchakul D,"

Phrase: "Nichols CG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: ":"

Phrase: "Gating"

Phrase: "mechanism of KATP channels"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0441712:Mechanism [Functional Concept]
   770   C1706376:Mechanism [Manufactured Object]

Phrase: ":"

Phrase: "function"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0031843:function [Physiologic Function]
  1000   C0542341:Function [Functional Concept]
  1000   C0700205:FUNCTION [Classification]
  1000   C1705273:Function [Intellectual Product]
   928 E C0205245:Functional [Functional Concept]
   928 E C2700217:Functional [Conceptual Entity]

Phrase: "fits"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0036572:Fit [Sign or Symptom]
  1000   C0424576:Fit [Finding]
  1000   C2349186:Fit [Activity]

Phrase: "form."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0348078:Form [Qualitative Concept]
  1000   C0376315:Form [Manufactured Object]
  1000   C1522492:Form [Functional Concept]
Processing 00000000.tx.275: J Gen Physiol122 :471 480,2003[Free FullText] Riedel MJ, Boora P, Steckley D, de Vries G, Light PE: Kir6.2 polymorphisms sensitize -cell ATP-sensitive potassium channels to activation by acyl CoAs: a possible cellular mechanism for increased susceptibility to type 2 diabetes? 

Phrase: "J Gen Physiol122"

Phrase: ":"

Phrase: "471 480,"

Phrase: "2003"

Phrase: "[Free FullText"

Phrase: "] Riedel MJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439254:MJ [Medical Device]

Phrase: "Boora P,"

Phrase: "Steckley D,"

Phrase: "de Vries G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0439267:g% [Quantitative Concept]

Phrase: "Light PE"

Phrase: ":"

Phrase: "Kir6.2 polymorphisms"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0032529:polymorphisms [Genetic Function]
   793 E C1882417:Polymorphism [Qualitative Concept]
   734   C1416578:Kir6.2 [Gene or Genome]

Phrase: "sensitize -"

Phrase: "cell ATP-sensitive potassium channels to activation"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   853   C1955862:ATP-Sensitive Potassium Channels [Amino Acid, Peptide, or Protein]
   778   C0032824:Potassium Channels [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   774   C0332324:Sensitive to [Functional Concept]
           Sensitive
   748   C0032821:Potassium [Element, Ion, or Isotope]
   748   C0597277:Potassium+ [Element, Ion, or Isotope,Pharmacologic Substance]
   748   C1550474:sensitive [Idea or Concept]
   714   C0439799:Channel [Spatial Concept]
   714   C1706095:Channel [Conceptual Entity]

Phrase: "by acyl CoAs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0001374:Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: ":"

Phrase: "a possible cellular mechanism for increased susceptibility"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0441712:Mechanism [Functional Concept]
   748   C1706376:Mechanism [Manufactured Object]

Phrase: "to type 2 diabetes?"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0011860:Type 2 Diabetes [Disease or Syndrome]
   913   C1320657:type diabetes [Finding]
   901   C0441730:Type 2 [Classification]
   827   C0011847:Diabetes [Disease or Syndrome]
   827   C0011849:Diabetes [Disease or Syndrome]
   827   C0332307:Type [Qualitative Concept]
   827   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.276: Diabetes52 :2630 2635,2003[Abstract/Free FullText] Koster JC, Sha Q, Nichols CG: Sulfonylurea and K(+)-channel opener sensitivity of K(ATP) channels: functional coupling of Kir6.2 and SUR1 subunits. 

Phrase: "Diabetes52"

Phrase: ":"

Phrase: "2630 2635,"

Phrase: "2003"

Phrase: "[Abstract/Free FullText"

Phrase: "] Koster JC,"

Phrase: "Sha Q,"

Phrase: "Nichols CG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: ":"

Phrase: "Sulfonylurea"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
  1000   C3536898:Sulfonylurea [Pharmacologic Substance]

Phrase: "and"

Phrase: "K(+)-channel opener sensitivity of K(ATP) channels"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   767   C1547341:Channel sensitivity [Idea or Concept]
   744   C0036667:Sensitivity [Quantitative Concept]
   744   C0312418:Sensitivity [Mental Process]
   744   C0427965:Sensitivity [Finding]
   744   C1511883:Sensitivity [Quantitative Concept]
   744   C1522640:Sensitivity [Qualitative Concept]
   744   C2346484:SENSITIVITY [Phenomenon or Process]
   744   C2349185:Sensitivity [Qualitative Concept]

Phrase: ":"

Phrase: "functional coupling of Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1948027:Coupling [Functional Concept]

Phrase: "and"

Phrase: "SUR1 subunits."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   779   C1711351:Subunit [Quantitative Concept]
Processing 00000000.tx.277: J Gen Physiol114 :203 213,1999[Abstract/Free FullText] Tschritter O, Stumvoll M, Machicao F, Holzwarth M, Weisser M, Maerker E, Teigeler A, Haring H, Fritsche A: The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. 

Phrase: "J Gen Physiol114"

Phrase: ":"

Phrase: "203 213,"

Phrase: "1999"

Phrase: "[Abstract/Free FullText"

Phrase: "] Tschritter O,"

Phrase: "Stumvoll M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Machicao F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Holzwarth M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Weisser M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Maerker E,"

Phrase: "Teigeler A,"

Phrase: "Haring"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0242372:haring [Mammal]
   966 E C1425660:HARE [Gene or Genome]

Phrase: "H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "Fritsche A"

Phrase: ":"

Phrase: "The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   738   C0032529:Polymorphism [Genetic Function]
   738   C1882417:Polymorphism [Qualitative Concept]

Phrase: "(KIR6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1416578:Kir6.2 [Gene or Genome]

Phrase: ")"

Phrase: "gene"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017337:Gene [Gene or Genome]

Phrase: "is"

Phrase: "associated with impaired glucagon suppression"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   760   C0017687:Glucagon [Amino Acid, Peptide, or Protein,Hormone,Neuroreactive Substance or Biogenic Amine,Pharmacologic Substance]
   760   C0221099:Impaired [Functional Concept]
   760   C0221103:Suppression [Pathologic Function]
   760   C0301625:Suppression [Organism Function]
   760   C0439181:% suppression [Quantitative Concept]
   760   C0684336:Impaired [Pathologic Function]
   760   C0728721:suppression [Mental Process]
   760   C0876232:Glucagon [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]

Phrase: "in response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0871261:Response [Organism Attribute]
  1000   C1704632:Response [Finding]
  1000   C1706817:Response [Intellectual Product]
  1000   C2911692:Response [Mental Process]

Phrase: "to hyperglycemia."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0020456:Hyperglycaemia [Disease or Syndrome]
Processing 00000000.tx.278: Diabetes51 :2854 2860,2002[Abstract/Free FullText] Nielsen EM, Hansen L, Carstensen B, Echwald SM, Drivsholm T, Glumer C, Thorsteinsson B, Borch-Johnsen K, Hansen T, Pedersen O: The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes. 

Phrase: "Diabetes51"

Phrase: ":"

Phrase: "2854 2860,"

Phrase: "2002"

Phrase: "[Abstract/Free FullText"

Phrase: "] Nielsen EM,"

Phrase: "Hansen L,"

Phrase: "Carstensen B,"

Phrase: "Echwald SM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0036154:SM [Geographic Area]

Phrase: "Drivsholm T,"

Phrase: "Glumer C,"

Phrase: "Thorsteinsson B,"

Phrase: "Borch-Johnsen K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1708601:K' [Quantitative Concept]

Phrase: "Hansen T,"

Phrase: "Pedersen O"

Phrase: ":"

Phrase: "The E23K variant of Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0205419:Variant [Qualitative Concept]

Phrase: "associates with"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0750490:Associate [Idea or Concept]
   833   C1706221:Associate [Professional or Occupational Group]

Phrase: "impaired"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0221099:Impaired [Functional Concept]
  1000   C0684336:Impaired [Pathologic Function]

Phrase: "post-OGTT serum insulin response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0871261:Response [Organism Attribute]
   804   C1704632:Response [Finding]
   804   C1706817:Response [Intellectual Product]
   804   C2911692:Response [Mental Process]

Phrase: "and"

Phrase: "increased risk of type 2 diabetes."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   783   C1171304:diabetes risk [Quantitative Concept]
   753   C0035647:Risk [Qualitative Concept]
   753   C0205217:Increased [Quantitative Concept]
   753   C0442805:Increased [Functional Concept]
Processing 00000000.tx.279: Diabetes52 :573 577,2003[Abstract/Free FullText] Shyng S, Nichols CG: Octameric stoichiometry of the KATP channel complex. 

Phrase: "Diabetes52"

Phrase: ":"

Phrase: "573 577,"

Phrase: "2003"

Phrase: "[Abstract/Free FullText"

Phrase: "] Shyng S,"

Phrase: "Nichols CG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: ":"

Phrase: "Octameric stoichiometry of the KATP channel complex."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0597526:Stoichiometry [Quantitative Concept]
Processing 00000000.tx.280: J Gen Physiol110 :655 664,1997[Abstract/Free FullText] Babenko AP, GC Gonzalez, Bryan J: Hetero-concatemeric KIR6.X4/SUR14 channels display distinct conductivities but uniform ATP inhibition. 

Phrase: "J Gen Physiol110"

Phrase: ":"

Phrase: "655 664,"

Phrase: "1997"

Phrase: "[Abstract/Free FullText"

Phrase: "] Babenko AP,"

Phrase: "GC Gonzalez,"

Phrase: "Bryan J"

Phrase: ":"

Phrase: "Hetero-concatemeric KIR6.X4/SUR14 channels"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   766   C0439799:Channel [Spatial Concept]
   766   C1706095:Channel [Conceptual Entity]

Phrase: "display"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705417:Display [Manufactured Object]

Phrase: "distinct conductivities"

Phrase: "but"

Phrase: "uniform ATP inhibition."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   827   C0021467:Inhibition [Mental Process]
   827   C0021469:Inhibition [Molecular Function]
   827   C1628982:% inhibition [Quantitative Concept]
   827   C3463820:Inhibition [Activity]
   755 E C0311403:Inhibited [Qualitative Concept]
Processing 00000000.tx.281: J Biol Chem275 :31563 31566,2000[Abstract/Free FullText] Ma D, Shield JP, Dean W, Leclerc I, Knauf C, Burcelin R R, Rutter GA, Kelsey G: Impaired glucose homeostasis in transgenic mice expressing the human transient neonatal diabetes mellitus locus, TNDM. 

Phrase: "J Biol Chem275"

Phrase: ":"

Phrase: "31563 31566,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "] Ma D,"

Phrase: "Shield JP,"

Phrase: "Dean W,"

Phrase: "Leclerc I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Knauf C,"

Phrase: "Burcelin R R,"

Phrase: "Rutter GA,"

Phrase: "Kelsey G"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: ":"

Phrase: "Impaired glucose homeostasis in transgenic mice"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1326961:glucose homeostasis [Physiologic Function]
   753   C0019868:Homeostasis [Biologic Function]

Phrase: "expressing"

Phrase: "the human transient neonatal diabetes mellitus locus,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C1708726:Locus [Gene or Genome]
   734   C0342273:Transient neonatal diabetes mellitus [Disease or Syndrome]

Phrase: "TNDM."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1832386:TNDM [Disease or Syndrome]
Processing 00000000.tx.282: J Clin Invest114 :339 348,2004[Abstract/Free FullText] Miki T, Nagashima K, Tashiro F, Kotake K, Yoshitomi H, Tamamoto A, Gonoi T, Iwanaga T, Miyazaki J, Seino S: Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice. 

Phrase: "J Clin Invest114"

Phrase: ":"

Phrase: "339 348,"

Phrase: "2004"

Phrase: "[Abstract/Free FullText"

Phrase: "] Miki T,"

Phrase: "Nagashima K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Tashiro F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Kotake K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Yoshitomi H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Tamamoto A,"

Phrase: "Gonoi T,"

Phrase: "Iwanaga T,"

Phrase: "Miyazaki J,"

Phrase: "Seino S"

Phrase: ":"

Phrase: "Defective insulin secretion"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   901   C1256369:insulin secretion [Cell Function]
   827   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C0036536:secretion [Biologic Function]
   827   C0036537:Secretion [Body Substance]
   827   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   827   C1579433:Insulin [Pharmacologic Substance]
   771 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   743 E C3537244:Insulins [Pharmacologic Substance]

Phrase: "and"

Phrase: "enhanced insulin action in KATP channel-deficient mice."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0441472:Action [Functional Concept]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]
   744   C3266814:Action [Activity]
Processing 00000000.tx.283: Proc Natl Acad Sci U S A95 :10402 10406,1998[Abstract/Free FullText] Seghers V, Nakazaki M, DeMayo F, Aguilar-Bryan L, Bryan J: Sur1 knockout mice. 

Phrase: "Proc Natl Acad Sci U S A95"

Phrase: ":"

Phrase: "10402 10406,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "] Seghers V,"

Phrase: "Nakazaki M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "DeMayo F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Aguilar-Bryan L,"

Phrase: "Bryan J"

Phrase: ":"

Phrase: "Sur1 knockout mice."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0206745:Knock-out Mice [Mammal]
   827   C0025914:Mice [Mammal]
   827   C0025929:mice [Mammal]
   827   C0026809:Mice [Mammal]
Processing 00000000.tx.284: A model for K(ATP) channel-independent regulation of insulin secretion. 

Phrase: "A model for K(ATP) channel-independent regulation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C0814675:model regulation [Regulation or Law]
   744   C3161035:Model [Intellectual Product]

Phrase: "of insulin secretion."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C1256369:insulin secretion [Cell Function]
   861   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C0036536:secretion [Biologic Function]
   861   C0036537:Secretion [Body Substance]
   861   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   861   C1579433:Insulin [Pharmacologic Substance]
   805 E C0020884:Iletin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   777 E C3537244:Insulins [Pharmacologic Substance]
Processing 00000000.tx.285: J Biol Chem275 :9270 9277,2000[Abstract/Free FullText] Shiota C, Larsson O, Shelton KD, Shiota M, Efanov AM, Hoy M, Lindner J, Kooptiwut S, Juntti-Berggren L, Gromada J, Berggren PO, Magnuson MA: Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose. 

Phrase: "J Biol Chem275"

Phrase: ":"

Phrase: "9270 9277,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "] Shiota C,"

Phrase: "Larsson O,"

Phrase: "Shelton KD,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0026691:KD [Disease or Syndrome]
   861   C1705240:KD [Gene or Genome]
   861   C1839259:KD [Disease or Syndrome]

Phrase: "Shiota M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Efanov"

Phrase: "AM"

Phrase: ","

Phrase: "Hoy M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Lindner J,"

Phrase: "Kooptiwut S,"

Phrase: "Juntti-Berggren L,"

Phrase: "Gromada J,"

Phrase: "Berggren PO,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0442027:PO [Spatial Concept]

Phrase: "Magnuson MA"

Phrase: ":"

Phrase: "Sulfonylurea receptor type 1 knock-out mice"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   845   C0206745:Knock-out Mice [Mammal]
   795   C0025914:Mice [Mammal]
   795   C0025929:mice [Mammal]
   795   C0026809:Mice [Mammal]

Phrase: "have"

Phrase: "intact feeding-stimulated insulin secretion despite marked impairment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C1256369:insulin secretion [Cell Function]
   744   C0021641:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C0036536:secretion [Biologic Function]
   744   C0036537:Secretion [Body Substance]
   744   C1533581:Insulin [Amino Acid, Peptide, or Protein,Hormone,Pharmacologic Substance]
   744   C1579433:Insulin [Pharmacologic Substance]

Phrase: "in their response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0871261:Response [Organism Attribute]
  1000   C1704632:Response [Finding]
  1000   C1706817:Response [Intellectual Product]
  1000   C2911692:Response [Mental Process]

Phrase: "to glucose."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
Processing 00000000.tx.286: J Biol Chem277 :37176 37183,2002[Abstract/Free FullText] Remedi M-S, Koster JC, Markova KP, Seino S, Miki T, Patton BL, McDaniel ML, Nichols CG: Diet-induced glucose intolerance in mice with decreased -cell KATP channels. 

Phrase: "J Biol Chem277"

Phrase: ":"

Phrase: "37176 37183,"

Phrase: "2002"

Phrase: "[Abstract/Free FullText"

Phrase: "] Remedi M-S,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0439493:m/s [Quantitative Concept]
   901   C1513009:M.S. [Intellectual Product]
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "Koster JC,"

Phrase: "Markova KP,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0022772:KP [Geographic Area]
   861   C1881334:kp [Quantitative Concept]

Phrase: "Seino S,"

Phrase: "Miki T,"

Phrase: "Patton BL,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0006413:BL [Neoplastic Process]
   861   C1552663:BL [Idea or Concept]
   861   C2827109:BL [Geographic Area]

Phrase: "McDaniel ML,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439526:/mL [Quantitative Concept]

Phrase: "Nichols CG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: ":"

Phrase: "Diet-induced glucose intolerance in mice"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0271650:Glucose Intolerance [Disease or Syndrome]
   783   C0151955:INTOLERANCE INDUCED [Finding]
   753   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   753   C0231199:Intolerance [Organism Function]
   753   C1744706:intolerance [Intellectual Product]
   753   C2355652:Intolerance [Organism Attribute]

Phrase: "with decreased -cell KATP channels."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   779   C0439799:Channel [Spatial Concept]
   779   C1706095:Channel [Conceptual Entity]
Processing 00000000.tx.287: Diabetes53 :3159 3167,2004[Abstract/Free FullText] Huopio H, Otonkoski T, Vauhkonen I, Reimann F, Ashcroft FM, Laakso M: A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. 

Phrase: "Diabetes53"

Phrase: ":"

Phrase: "3159 3167,"

Phrase: "2004"

Phrase: "[Abstract/Free FullText"

Phrase: "] Huopio H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Otonkoski T,"

Phrase: "Vauhkonen I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Reimann F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Ashcroft FM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: "Laakso M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "A new subtype of autosomal dominant diabetes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0449560:Subtype [Classification]

Phrase: "attributable to a mutation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0596130:Attributable [Mental Process]

Phrase: "in the gene"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017337:Gene [Gene or Genome]

Phrase: "for sulfonylurea receptor 1."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   827   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   827   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   827   C3536898:Sulfonylurea [Pharmacologic Substance]
Processing 00000000.tx.288: [see comment]. 

Phrase: "["

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "comment"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282411:Comment [Intellectual Product]
  1000   C0947611:Comment [Intellectual Product]

Phrase: "]."
Processing 00000000.tx.289: Lancet361 :301 307,2003[Medline] Miki T, Minami K, Zhang L, Morita M, Gonoi T, Shiuchi T, Minokoshi Y, Renaud JM, Seino S: ATP-sensitive potassium channels participate in glucose uptake in skeletal muscle and adipose tissue. 

Phrase: "Lancet361"

Phrase: ":"

Phrase: "301 307,"

Phrase: "2003"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Miki T,"

Phrase: "Minami K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Zhang L,"

Phrase: "Morita M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Gonoi T,"

Phrase: "Shiuchi T,"

Phrase: "Minokoshi Y,"

Phrase: "Renaud JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Seino S"

Phrase: ":"

Phrase: "ATP-sensitive potassium channels"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C1955862:ATP-Sensitive Potassium Channels [Amino Acid, Peptide, or Protein]
   861   C0032824:Potassium Channels [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   812   C0032821:Potassium [Element, Ion, or Isotope]
   812   C0332324:Sensitive [Functional Concept]
   812   C0597277:Potassium+ [Element, Ion, or Isotope,Pharmacologic Substance]
   812   C1550474:sensitive [Idea or Concept]
   779   C0439799:Channel [Spatial Concept]
   779   C1706095:Channel [Conceptual Entity]

Phrase: "participate in glucose uptake"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C1159527:glucose uptake [Cell Function]
   770   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   770   C0243144:Uptake [Physiologic Function]
   770   C0347980:% uptake [Quantitative Concept]

Phrase: "in skeletal muscle"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0242692:Muscle, Skeletal [Tissue]
  1000   C1280260:Skeletal muscle [Body Part, Organ, or Organ Component]
   861   C0026845:Muscle [Tissue]
   861   C0037253:skeletal [Body System]
   861   C0521324:Skeletal [Spatial Concept]
   789 E C0442025:Muscular [Spatial Concept]

Phrase: "and"

Phrase: "adipose tissue."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0001527:Adipose tissue [Tissue]
   861   C0040300:Tissue [Tissue]
   861   C1547928:Tissue [Intellectual Product]
   789   C0028754:Adiposity [Disease or Syndrome]
   789   C1563743:adiposity [Organism Attribute]
Processing 00000000.tx.290: Am J Physiol Endocrinol Metab283 :E1178 E1184,2002[Abstract/Free FullText] Munoz A, Nakazaki M, Goodman JC, Barrios R, Onetti CG, Bryan J, Aguilar-Bryan L: Ischemic preconditioning in the hippocampus of a knockout mouse lacking SUR1-based K(ATP) channels. 

Phrase: "Am"

Phrase: "J Physiol Endocrinol Metab283"

Phrase: ":"

Phrase: "E1178 E1184,"

Phrase: "2002"

Phrase: "[Abstract/Free FullText"

Phrase: "] Munoz A,"

Phrase: "Nakazaki M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Goodman JC,"

Phrase: "Barrios R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Onetti CG,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: "Bryan J,"

Phrase: "Aguilar-Bryan L"

Phrase: ":"

Phrase: "Ischemic preconditioning in the hippocampus"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   806   C0376466:Ischemic Pre-Conditioning [Therapeutic or Preventive Procedure]
   760   C0475224:Ischaemic [Functional Concept]
   760   C0871117:Preconditioning [Mental Process]
   726 E C1709632:Precondition [Conceptual Entity]

Phrase: "of a knockout mouse lacking SUR1-based K(ATP) channels."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   790   C1708601:K' [Quantitative Concept]
   756   C0439799:Channel [Spatial Concept]
   756   C1706095:Channel [Conceptual Entity]
Processing 00000000.tx.291: Stroke34 :164 170,2003[Abstract/Free FullText] Inagaki N, Gonoi T, Seino S: Subunit stoichiometry of the pancreatic beta-cell ATP-sensitive K+ channel. 

Phrase: "Stroke34"

Phrase: ":"

Phrase: "164 170,"

Phrase: "2003"

Phrase: "[Abstract/Free FullText"

Phrase: "] Inagaki N,"

Phrase: "Gonoi T,"

Phrase: "Seino S"

Phrase: ":"

Phrase: "Subunit stoichiometry"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597526:Stoichiometry [Quantitative Concept]

Phrase: "of the pancreatic beta-cell ATP-sensitive K+ channel."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   795   C0332324:Sensitive [Functional Concept]
   795   C0439799:Channel [Spatial Concept]
   795   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   795   C1550474:sensitive [Idea or Concept]
   795   C1706095:Channel [Conceptual Entity]
   795   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.292: FEBS Lett409 :232 236,1997[Medline] Clement, JPT, Kunjilwar K, Gonzalez G, Schwanstecher M, Panten U, Aguilar-Bryan L, Bryan J: Association and stoichiometry of K(ATP) channel subunits. 

Phrase: "FEBS Lett409"

Phrase: ":"

Phrase: "232 236,"

Phrase: "1997"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Clement, JPT,"

Phrase: "Kunjilwar K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Gonzalez G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Schwanstecher M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Panten U,"

Phrase: "Aguilar-Bryan L,"

Phrase: "Bryan J"

Phrase: ":"

Phrase: "Association"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0004083:Association [Mental Process]
  1000   C0439849:Association [Qualitative Concept]
  1000   C0596306:Association [Phenomenon or Process]
  1000   C0699792:association [Social Behavior]

Phrase: "and"

Phrase: "stoichiometry of K(ATP) channel subunits."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0597526:Stoichiometry [Quantitative Concept]
Processing 00000000.tx.293: Neuron18 :827 838,1997[Medline] Tucker SJ, Gribble FM, Zhao C, Trapp S, Ashcroft FM: Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor. 

Phrase: "Neuron18"

Phrase: ":"

Phrase: "827 838,"

Phrase: "1997"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Tucker SJ,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1515101:SJ [Geographic Area]
   861   C2986905:SJ [Idea or Concept]

Phrase: "Gribble FM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: "Zhao C,"

Phrase: "Trapp S,"

Phrase: "Ashcroft FM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: ":"

Phrase: "Truncation of Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1706395:Truncation [Cell or Molecular Dysfunction]

Phrase: "produces"

Phrase: "ATP-sensitive K+ channels in the absence of the sulphonylurea receptor."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   754   C0004204:ATP Receptor [Amino Acid, Peptide, or Protein,Receptor]
   738   C0332324:Sensitive [Functional Concept]
   738   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   738   C1550474:sensitive [Idea or Concept]
   738   C1708601:K' [Quantitative Concept]
   704   C0439799:Channel [Spatial Concept]
   704   C1706095:Channel [Conceptual Entity]
Processing 00000000.tx.294: Nature387 :179 183,1997[Medline] Tanabe K, Tucker SJ, Matsuo M, Proks P, Ashcroft FM, Seino S, Amachi T, Ueda K: Direct photoaffinity labeling of the Kir6.2 subunit of the ATP-sensitive K+ channel by 8-azido-ATP. 

Phrase: "Nature387"

Phrase: ":"

Phrase: "179 183,"

Phrase: "1997"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Tanabe K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Tucker SJ,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1515101:SJ [Geographic Area]
   861   C2986905:SJ [Idea or Concept]

Phrase: "Matsuo M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Proks P,"

Phrase: "Ashcroft FM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: "Seino S,"

Phrase: "Amachi T,"

Phrase: "Ueda K"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: ":"

Phrase: "Direct photoaffinity labeling of the Kir6.2 subunit"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   744   C1167624:Labeling [Mental Process]
   744   C1947902:Labeling [Manufactured Object]
   744   C2827499:Labeling [Governmental or Regulatory Activity]
   711 E C0181496:Label [Manufactured Object]

Phrase: "of the ATP-sensitive K+ channel"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0332324:Sensitive [Functional Concept]
   812   C0439799:Channel [Spatial Concept]
   812   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   812   C1550474:sensitive [Idea or Concept]
   812   C1706095:Channel [Conceptual Entity]
   812   C1708601:K' [Quantitative Concept]

Phrase: "by 8-azido-ATP."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0050042:8-azido-ATP [Indicator, Reagent, or Diagnostic Aid,Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.295: J Biol Chem274 :3931 3933,1999[Abstract/Free FullText] Drain P, Li L, Wang J: KATP channel inhibition by ATP requires distinct functional domains of the cytoplasmic C terminus of the pore-forming subunit. 

Phrase: "J Biol Chem274"

Phrase: ":"

Phrase: "3931 3933,"

Phrase: "1999"

Phrase: "[Abstract/Free FullText"

Phrase: "] Drain P,"

Phrase: "Li L,"

Phrase: "Wang J"

Phrase: ":"

Phrase: "KATP channel inhibition by ATP"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0021467:Inhibition [Mental Process]
   760   C0021469:Inhibition [Molecular Function]
   760   C1628982:% inhibition [Quantitative Concept]
   760   C3463820:Inhibition [Activity]

Phrase: "requires"

Phrase: "distinct functional domains of the cytoplasmic C terminus"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   750   C1511625:Cytoplasmic Domain [Cell Component]
   711   C1880389:Domain [Functional Concept]
   711   C1883221:Domain [Conceptual Entity]
   711   C3541951:Domain [Intellectual Product]

Phrase: "of the pore-forming subunit."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1711351:Subunit [Quantitative Concept]
Processing 00000000.tx.296: Proc Natl Acad Sci U S A95 :13953 13958,1998[Abstract/Free FullText] Li L, Wang J, Drain P: The I182 region of k(ir)6.2 is closely associated with ligand binding in K(ATP) channel inhibition by ATP. 

Phrase: "Proc Natl Acad Sci U S A95"

Phrase: ":"

Phrase: "13953 13958,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "] Li L,"

Phrase: "Wang J,"

Phrase: "Drain P"

Phrase: ":"

Phrase: "The I182 region of k(ir)6.2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0017446:Region [Geographic Area]
   744   C0205147:Region [Spatial Concept]

Phrase: "is"

Phrase: "closely"

Phrase: "associated with ligand binding"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   833   C1517880:Ligand Binding [Molecular Function]
   770   C0023688:Ligand [Chemical]
   770   C0243122:binding [Functional Concept]
   770   C1145667:Binding [Activity]
   770   C1167622:Binding [Molecular Function]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "in K(ATP) channel inhibition"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   812   C0021467:Inhibition [Mental Process]
   812   C0021469:Inhibition [Molecular Function]
   812   C1628982:% inhibition [Quantitative Concept]
   812   C3463820:Inhibition [Activity]
   741 E C0311403:Inhibited [Qualitative Concept]

Phrase: "by ATP."
Processing 00000000.tx.297: Biophys J79 :841 852,2000[Abstract/Free FullText] Trapp S, Haider S, Jones P, Sansom MS, Ashcroft FM: Identification of residues contributing to the ATP binding site of Kir6.2. 

Phrase: "Biophys J79"

Phrase: ":"

Phrase: "841 852,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "] Trapp S,"

Phrase: "Haider S,"

Phrase: "Jones P,"

Phrase: "Sansom MS,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039676:MS [Amino Acid, Peptide, or Protein,Enzyme]
   861   C2349943:Ms. [Conceptual Entity]
   861   C3539704:MS [Gene or Genome]

Phrase: "Ashcroft FM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: ":"

Phrase: "Identification of residues"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0020792:Identification [Mental Process]
   790   C0205396:Identification [Qualitative Concept]

Phrase: "contributing to the ATP binding site of Kir6.2."
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   764   C0005456:Binding Site [Receptor]
   764   C0682969:Binding Site [Amino Acid Sequence]
   764   C1148923:ATP binding [Molecular Function]
   764   C1416578:Kir6.2 [Gene or Genome]
   764   C2945843:Site of [Qualitative Concept]
   742   C0205145:Site [Spatial Concept]
   742   C0243122:binding [Functional Concept]
   742   C1145667:Binding [Activity]
   742   C1167622:Binding [Molecular Function]
   742   C1515974:Site [Body Location or Region]
   742   C1880177:Contributing [Activity]
   742   C2825164:Site [Spatial Concept]
Processing 00000000.tx.298: EMBO J22 :2903 2912,2003[Abstract/Free FullText] Tucker SJ, Gribble FM, Proks P, Trapp S, Ryder TJ, Haug T, Reimann F, Ashcroft FM: Molecular determinants of KATP channel inhibition by ATP. 

Phrase: "EMBO J22"

Phrase: ":"

Phrase: "2903 2912,"

Phrase: "2003"

Phrase: "[Abstract/Free FullText"

Phrase: "] Tucker SJ,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1515101:SJ [Geographic Area]
   861   C2986905:SJ [Idea or Concept]

Phrase: "Gribble FM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: "Proks P,"

Phrase: "Trapp S,"

Phrase: "Ryder TJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0039247:TJ [Geographic Area]

Phrase: "Haug T,"

Phrase: "Reimann F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Ashcroft FM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: ":"

Phrase: "Molecular determinants of KATP channel inhibition"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   719   C1521761:Determinant [Functional Concept]

Phrase: "by ATP."
Processing 00000000.tx.299: Embo J17 :3290 3296,1998[Abstract/Free FullText] Inagaki N, Gonoi T, Clement JPT, Namba N, Inazawa J, Gonzalez G, Aguilar-Bryan L, Seino S, Bryan J: Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor [see comments]. 

Phrase: "Embo J17"

Phrase: ":"

Phrase: "3290 3296,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "] Inagaki N,"

Phrase: "Gonoi T,"

Phrase: "Clement JPT,"

Phrase: "Namba N,"

Phrase: "Inazawa J,"

Phrase: "Gonzalez G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Aguilar-Bryan L,"

Phrase: "Seino S,"

Phrase: "Bryan J"

Phrase: ":"

Phrase: "Reconstitution of IKATP"

Phrase: ":"

Phrase: "an inward rectifier subunit plus the sulfonylurea receptor"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1711351:Subunit [Quantitative Concept]

Phrase: "["

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "comments"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0282411:Comments [Intellectual Product]
  1000   C0947611:comments [Intellectual Product]
  1000   C1705247:Comments [Conceptual Entity]

Phrase: "]."
Processing 00000000.tx.300: Science270 :1166 1170,1995[Abstract] Kennedy HJ, Pouli AE, Ainscow EK, Jouaville LS, Rizzuto R, Rutter GA: Glucose generates sub-plasma membrane ATP microdomains in single islet beta-cells. 

Phrase: "Science270"

Phrase: ":"

Phrase: "1166 1170,"

Phrase: "1995"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Kennedy HJ,"

Phrase: "Pouli AE,"

Phrase: "Ainscow EK,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0008415:EK [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "Jouaville LS,"

Phrase: "Rizzuto R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Rutter GA"

Phrase: ":"

Phrase: "Glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "generates"

Phrase: "sub-plasma membrane ATP microdomains in single islet beta-cells."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   757   C0887868:Membrane Microdomains [Cell Component]
Processing 00000000.tx.301: Potential role for strategically located mitochondria. 

Phrase: "Potential role for strategically located mitochondria."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]
Processing 00000000.tx.302: J Biol Chem274 :13281 13291,1999[Abstract/Free FullText] Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement JPT, Boyd AER, Gonzalez G, Herrera-Sosa H, Nguy K, Bryan J, Nelson DA: Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. 

Phrase: "J Biol Chem274"

Phrase: ":"

Phrase: "13281 13291,"

Phrase: "1999"

Phrase: "[Abstract/Free FullText"

Phrase: "] Aguilar-Bryan L,"

Phrase: "Nichols CG,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: "Wechsler SW,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1420193:SW [Gene or Genome]
   861   C1832169:SW [Body System]
   861   C3538902:SW [Gene or Genome]

Phrase: "Clement JPT,"

Phrase: "Boyd AER,"

Phrase: "Gonzalez G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Herrera-Sosa H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0033727:H+ [Element, Ion, or Isotope]
   827   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441932:H+ [Classification]
   827   C0564385:/h [Quantitative Concept]

Phrase: "Nguy K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Bryan J,"

Phrase: "Nelson DA"

Phrase: ":"

Phrase: "Cloning of the beta cell high-affinity sulfonylurea receptor"
Meta Candidates (Total=23; Excluded=2; Pruned=0; Remaining=21)
   882   C1412082:SULFONYLUREA RECEPTOR, BETA-CELL HIGH-AFFINITY [Gene or Genome]
           SULFONYLUREA RECEPTOR
   764   C0030281:Beta cell [Cell]
   764   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
   762   C0009013:cell cloning [Cell]
       E   Clone
   762   C1514760:Receptor Cell [Cell]
   742   C0007634:Cell [Cell]
   742   C0009015:Cloning [Research Activity]
   742   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   742   C0205250:High [Qualitative Concept]
   742   C0330390:Beta [Plant]
   742   C0439096:Beta [Intellectual Product]
   742   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   742   C1269647:Cell [Cell]
   742   C1299351:High [Qualitative Concept]
   742   C1510827:Affinity [Natural Phenomenon or Process]
   742   C1704653:Cell [Medical Device]
   742   C1948049:Cell [Spatial Concept]
   742   C2004068:Beta [Qualitative Concept]
   742   C2700149:HIGH [Intellectual Product]
   742   C3536898:Sulfonylurea [Pharmacologic Substance]
   708 E C1522642:Clone [Tissue]

Phrase: ":"

Phrase: "a regulator of insulin secretion."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0182953:REGULATOR [Medical Device]
   760   C1704734:Regulator [Medical Device]
   760   C1704735:Regulator [Conceptual Entity]
Processing 00000000.tx.303: Science268 :423 426,1995[Medline] Inagaki N, Gonoi T, Clement JP, Wang CZ, Aguilar-Bryan L, Bryan J, Seino S: A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. 

Phrase: "Science268"

Phrase: ":"

Phrase: "423 426,"

Phrase: "1995"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Inagaki N,"

Phrase: "Gonoi T,"

Phrase: "Clement JP,"

Phrase: "Wang CZ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0206578:CZ [Geographic Area]

Phrase: "Aguilar-Bryan L,"

Phrase: "Bryan J,"

Phrase: "Seino S"

Phrase: ":"

Phrase: "A family of sulfonylurea receptors"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0015576:Family [Family Group]
   760   C1704727:Family [Conceptual Entity]

Phrase: "determines"

Phrase: "the pharmacological properties of ATP-sensitive K+ channels."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   744   C0871161:properties [Qualitative Concept]
   744   C1292721:properties [Functional Concept]
   711 E C1882134:Property [Conceptual Entity]
   711 E C2347695:Property [Entity]
Processing 00000000.tx.304: Neuron16 :1011 1017,1996[Medline] Schwanstecher M, Sieverding C, Dorschner H, Gross I, Aguilar-Bryan L, Schwanstecher C, Bryan J: Potassium channel openers require ATP to bind to and act through sulfonylurea receptors. 

Phrase: "Neuron16"

Phrase: ":"

Phrase: "1011 1017,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450317:1011 [Intellectual Product]

Phrase: "1996"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Schwanstecher M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Sieverding C,"

Phrase: "Dorschner H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Gross I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Aguilar-Bryan L,"

Phrase: "Schwanstecher C,"

Phrase: "Bryan J"

Phrase: ":"

Phrase: "Potassium channel openers"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
  1000   C3163330:Potassium Channel Openers [Molecular Function]
   966 E C3163331:Potassium Channel Opener [Pharmacologic Substance]
   901   C0032824:Potassium Channel [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0032821:Potassium [Element, Ion, or Isotope]
   827   C0439799:Channel [Spatial Concept]
   827   C0597277:Potassium+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1706095:Channel [Conceptual Entity]

Phrase: "require"

Phrase: "ATP to"

Phrase: "bind to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1145667:Bind [Activity]
   833   C1167622:bind [Molecular Function]

Phrase: "and"

Phrase: "act through sulfonylurea receptors."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   833   C0075586:Sulfonylurea Receptors [Amino Acid, Peptide, or Protein,Receptor]
   799 E C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   770   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   770   C0079613:ACT [Therapeutic or Preventive Procedure]
   770   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   770   C3536898:Sulfonylurea [Pharmacologic Substance]
Processing 00000000.tx.305: EMBO J17 :5529 5535,1998[Abstract/Free FullText] Gribble FM, Tucker SJ, Ashcroft FM: The essential role of the Walker A motifs of SUR1 in K-ATP channel activation by Mg-ADP and diazoxide. 

Phrase: "EMBO J17"

Phrase: ":"

Phrase: "5529 5535,"

Phrase: "1998"

Phrase: "[Abstract/Free FullText"

Phrase: "] Gribble FM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: "Tucker SJ,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1515101:SJ [Geographic Area]
   861   C2986905:SJ [Idea or Concept]

Phrase: "Ashcroft FM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: ":"

Phrase: "The essential role of the Walker"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]

Phrase: "A motifs of SUR1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   719   C1514562:Motif [Amino Acid Sequence]

Phrase: "in K-ATP channel activation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1879547:Activation [Activity]

Phrase: "by Mg-ADP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0523452:ADP [Laboratory Procedure]

Phrase: "and"

Phrase: "diazoxide."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0012022:Diazoxide [Organic Chemical,Pharmacologic Substance]
   944 E C0699324:Hyperstat [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.306: EMBO J16 :1145 1152,1997[Abstract/Free FullText] Shyng S, Ferrigni T, Nichols CG: Regulation of KATP channel activity by diazoxide and MgADP: distinct functions of the two nucleotide binding folds of the sulfonylurea receptor. 

Phrase: "EMBO J16"

Phrase: ":"

Phrase: "1145 1152,"

Phrase: "1997"

Phrase: "[Abstract/Free FullText"

Phrase: "] Shyng S,"

Phrase: "Ferrigni T,"

Phrase: "Nichols CG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: ":"

Phrase: "Regulation of KATP channel activity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0851285:Regulation [Governmental or Regulatory Activity]
   760   C1327622:Regulation [Biologic Function]

Phrase: "by diazoxide"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0012022:Diazoxide [Organic Chemical,Pharmacologic Substance]
   944 E C0699324:Hyperstat [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "MgADP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024468:MgADP [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: ":"

Phrase: "distinct functions of the two nucleotide binding folds of the sulfonylurea receptor."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   736   C0542341:Functions [Functional Concept]
   734   C0920644:function receptor [Molecular Function]
   703 E C0031843:function [Physiologic Function]
   703 E C0700205:FUNCTION [Classification]
   703 E C1705273:Function [Intellectual Product]
Processing 00000000.tx.307: J Gen Physiol110 :643 654,1997[Abstract/Free FullText] Shyng SL, Ferrigni T, Shepard JB, Nestorowicz A, Glaser B, Permutt MA, Nichols CG: Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy. 

Phrase: "J Gen Physiol110"

Phrase: ":"

Phrase: "643 654,"

Phrase: "1997"

Phrase: "[Abstract/Free FullText"

Phrase: "] Shyng SL,"

Phrase: "Ferrigni T,"

Phrase: "Shepard JB,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1550751:JB [Temporal Concept]

Phrase: "Nestorowicz A,"

Phrase: "Glaser B,"

Phrase: "Permutt MA,"

Phrase: "Nichols CG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: ":"

Phrase: "Functional analyses of novel mutations"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0558024:Functional analysis [Health Care Activity]
   764   C0796357:mutation analysis [Laboratory Procedure]
   726   C0002778:Analysis [Laboratory Procedure]
   726   C0936012:Analysis [Research Activity]
   726   C1524024:analysis [Functional Concept]

Phrase: "in the sulfonylurea receptor 1"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
   901   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   827   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   827   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   827   C3536898:Sulfonylurea [Pharmacologic Substance]

Phrase: "associated with persistent hyperinsulinemic hypoglycemia of infancy."
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   897   C0027773:Persistent Hyperinsulinemic Hypoglycemia of Infancy [Disease or Syndrome]
   897   C2931834:Persistent hyperinsulinaemic hypoglycaemia of infancy [Disease or Syndrome]
           Persistent Hyperinsulinemic Hypoglycemia
   814   C1456352:Hypoglycaemia of infancy [Pathologic Function]
   814   C2931833:HYPERINSULINEMIC HYPOGLYCEMIA, PERSISTENT [Disease or Syndrome]
   778   C0332281:Associated with [Qualitative Concept]
           Associated
   778   C1864903:Hyperinsulinemic hypoglycemia [Finding]
   748   C0020615:Hypoglycaemia [Disease or Syndrome]
   748   C0205322:Persistent [Temporal Concept]
   748   C0231330:Infancy [Temporal Concept]
   714 E C0750490:Associate [Idea or Concept]
   714 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.308: Diabetes47 :1145 1151,1998[Abstract] John SA, Weiss JN, Xie LH, Ribalet B: Molecular mechanism for ATP-dependent closure of the K+ channel Kir6.2. 

Phrase: "Diabetes47"

Phrase: ":"

Phrase: "1145 1151,"

Phrase: "1998"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] John SA,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0036243:SA [Geographic Area]
   861   C1539696:SA [Gene or Genome]
   861   C1825840:SA [Gene or Genome]
   861   C3539736:Sa [Spatial Concept]

Phrase: "Weiss JN,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1428813:JN [Gene or Genome]

Phrase: "Xie LH,"

Phrase: "Ribalet B"

Phrase: ":"

Phrase: "Molecular mechanism for ATP-dependent closure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0441712:Mechanism [Functional Concept]
   753   C1706376:Mechanism [Manufactured Object]

Phrase: "of the K+ channel Kir6.2."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C1416578:Kir6.2 [Gene or Genome]
   812   C0439799:Channel [Spatial Concept]
   812   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   812   C1706095:Channel [Conceptual Entity]
   812   C1708601:K' [Quantitative Concept]
Processing 00000000.tx.309: J Physiol552 :23 34,2003[Abstract/Free FullText] Kuo A, Gulbis JM, Antcliff JF, Rahman T, Lowe ED, Zimmer J, Cuthbertson J, Ashcroft FM, Ezaki T, Doyle DA: Crystal structure of the potassium channel KirBac1.1 in the closed state. 

Phrase: "J Physiol552"

Phrase: ":"

Phrase: "23 34,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450348:23 [Quantitative Concept]

Phrase: "2003"

Phrase: "[Abstract/Free FullText"

Phrase: "] Kuo A,"

Phrase: "Gulbis JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Antcliff JF,"

Phrase: "Rahman T,"

Phrase: "Lowe ED,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3538926:ED [Idea or Concept]

Phrase: "Zimmer J,"

Phrase: "Cuthbertson J,"

Phrase: "Ashcroft FM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: "Ezaki T,"

Phrase: "Doyle DA"

Phrase: ":"

Phrase: "Crystal structure of the potassium channel KirBac1.1"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0444626:Crystal Structure [Chemical Viewed Structurally]
           Crystal
   744   C0427896:Crystal [Body Substance]
   744   C0678594:Structure [Spatial Concept]
   744   C1533132:Crystal [Body Substance]
   744   C1704641:Crystal [Manufactured Object]

Phrase: "in the closed state."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0587267:Closed [Functional Concept]
   861   C1301808:State [Geographic Area]
   861   C1442792:State [Functional Concept]
   861   C3148680:State [Geographic Area]
Processing 00000000.tx.310: Science300 :1922 1926,2003[Abstract/Free FullText] Antcliff JF, Haider S, Proks P, Sansom MS, Ashcroft FM: Functional analysis of a structural model of the ATP-binding site of the KATP channel Kir6.2 subunit. 

Phrase: "Science300"

Phrase: ":"

Phrase: "1922 1926,"

Phrase: "2003"

Phrase: "[Abstract/Free FullText"

Phrase: "] Antcliff JF,"

Phrase: "Haider S,"

Phrase: "Proks P,"

Phrase: "Sansom MS,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039676:MS [Amino Acid, Peptide, or Protein,Enzyme]
   861   C2349943:Ms. [Conceptual Entity]
   861   C3539704:MS [Gene or Genome]

Phrase: "Ashcroft FM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: ":"

Phrase: "Functional analysis of a structural model of the ATP-binding site"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   756   C0558024:Functional analysis [Health Care Activity]
   754   C0204514:Structural analysis [Therapeutic or Preventive Procedure]
   738   C0002778:Analysis [Laboratory Procedure]
   738   C0936012:Analysis [Research Activity]
   738   C1524024:analysis [Functional Concept]

Phrase: "of the KATP channel Kir6.2 subunit."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C1711351:Subunit [Quantitative Concept]
Processing 00000000.tx.311: EMBO J24 :229 239,2005[Abstract/Free FullText] Shyng SL, Cukras CA, Harwood J, Nichols CG: Structural determinants of PIP(2) regulation of inward rectifier K(ATP) channels. 

Phrase: "EMBO J24"

Phrase: ":"

Phrase: "229 239,"

Phrase: "2005"

Phrase: "[Abstract/Free FullText"

Phrase: "] Shyng SL,"

Phrase: "Cukras CA,"

Phrase: "Harwood J,"

Phrase: "Nichols CG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: ":"

Phrase: "Structural determinants of PIP(2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   726   C1521761:Determinant [Functional Concept]

Phrase: ")"

Phrase: "regulation of inward rectifier K(ATP) channels."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0851285:Regulation [Governmental or Regulatory Activity]
   748   C1327622:Regulation [Biologic Function]
Processing 00000000.tx.312: J Gen Physiol116 :599 608,2000[Abstract/Free FullText] Cukras CA, Jeliazkova I, Nichols CG: The role of N-terminal positive charges in the activity of inward rectifier KATP channels. 

Phrase: "J Gen Physiol116"

Phrase: ":"

Phrase: "599 608,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "] Cukras CA,"

Phrase: "Jeliazkova I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Nichols CG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: ":"

Phrase: "The role of N-terminal positive charges"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0035820:Role [Social Behavior]
   748   C1705810:Role [Conceptual Entity]

Phrase: "in the activity"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0205177:Activity [Functional Concept]
  1000   C0439167:% activity [Quantitative Concept]
  1000   C0441655:Activity [Activity]
  1000   C1561536:*Activity [Idea or Concept]

Phrase: "of inward rectifier KATP channels."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1955862:KATP Channels [Amino Acid, Peptide, or Protein]
   779   C0439799:Channel [Spatial Concept]
   779   C1706095:Channel [Conceptual Entity]
Processing 00000000.tx.313: J Gen Physiol120 :437 446,2002[Abstract/Free FullText] Enkvetchakul D, Loussouarn G, Makhina E, Shyng SL, Nichols CG: The kinetic and physical basis of K(ATP) channel gating: toward a unified molecular understanding. 

Phrase: "J Gen Physiol120"

Phrase: ":"

Phrase: "437 446,"

Phrase: "2002"

Phrase: "[Abstract/Free FullText"

Phrase: "] Enkvetchakul D,"

Phrase: "Loussouarn G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Makhina E,"

Phrase: "Shyng SL,"

Phrase: "Nichols CG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: ":"

Phrase: "The kinetic"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0022702:kinetic [Natural Phenomenon or Process]
   944 E C0026597:Motion [Natural Phenomenon or Process]
   944 E C0687704:Motions [Functional Concept]
   928 E C0022699:Kineses [Individual Behavior]

Phrase: "and"

Phrase: "physical basis of K(ATP) channel gating"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1527178:Basis [Functional Concept]
   748   C1874451:Basis [Pharmacologic Substance]

Phrase: ":"

Phrase: "toward a unified molecular understanding."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0162340:Understanding [Mental Process]
Processing 00000000.tx.314: Biophys J78 :2334 2348,2000[Abstract/Free FullText] Loussouarn G, Makhina EN, Rose T, Nichols CG: Structure and dynamics of the pore of inwardly rectifying K(ATP) channels. 

Phrase: "Biophys J78"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1453778:J78 [Organic Chemical]

Phrase: ":"

Phrase: "2334 2348,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "] Loussouarn G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Makhina EN,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1417861:eN [Gene or Genome]
   861   C2987294:EN [Qualitative Concept]

Phrase: "Rose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0035853:Rose [Plant]
  1000   C0995005:ROSE [Pharmacologic Substance]

Phrase: "T,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Nichols CG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: ":"

Phrase: "Structure"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678594:Structure [Spatial Concept]

Phrase: "and"

Phrase: "dynamics of the pore of inwardly"

Phrase: "rectifying"

Phrase: "K(ATP) channels."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1708601:K' [Quantitative Concept]
   793   C0439799:Channel [Spatial Concept]
   793   C1706095:Channel [Conceptual Entity]
Processing 00000000.tx.315: J Biol Chem275 :1137 1144,2000[Abstract/Free FullText] Cartier EA, Shen S, Shyng SL: Modulation of the trafficking efficiency and functional properties of ATP-sensitive potassium channels through a single amino acid in the sulfonylurea receptor. 

Phrase: "J Biol Chem275"

Phrase: ":"

Phrase: "1137 1144,"

Phrase: "2000"

Phrase: "[Abstract/Free FullText"

Phrase: "] Cartier EA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0014963:EA [Organic Chemical,Pharmacologic Substance]
   861   C1457900:EA [Quantitative Concept]

Phrase: "Shen S,"

Phrase: "Shyng SL"

Phrase: ":"

Phrase: "Modulation of the"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0443264:Modulation [Spatial Concept]

Phrase: "trafficking"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0599896:trafficking [Cell Function]

Phrase: "efficiency"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0013682:Efficiency [Quantitative Concept]
   928 E C0442799:Efficient [Qualitative Concept]

Phrase: "and"

Phrase: "functional properties of ATP-sensitive potassium channels"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   748   C0871161:properties [Qualitative Concept]
   748   C1292721:properties [Functional Concept]
   714 E C1882134:Property [Conceptual Entity]
   714 E C2347695:Property [Entity]

Phrase: "through a single amino acid"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0002520:Amino acid [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   901   C2917660:Amino Acid [Pharmacologic Substance]
   827   C0001128:Acid [Chemical]
   827   C0202406:Acid [Laboratory Procedure]

Phrase: "in the sulfonylurea receptor."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   861   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   861   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   861   C3536898:Sulfonylurea [Pharmacologic Substance]
Processing 00000000.tx.316: J Biol Chem278 :7081 7090,2003[Abstract/Free FullText] Plaster NM, Tawil R, Tristani-Firouzi M, Canun S, Bendahhou S, Tsunoda A, Donaldson MR, Iannaccone ST, Brunt E, Barohn R, Clark J, Deymeer F, George AL Jr, Fish FA, Hahn A, Nitu A, Ozdemir C, Serdaroglu P, Subramony SH, Wolfe G, Fu YH, Ptacek LJ: Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersens syndrome. 

Phrase: "J Biol Chem278"

Phrase: ":"

Phrase: "7081 7090,"

Phrase: "2003"

Phrase: "[Abstract/Free FullText"

Phrase: "] Plaster NM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0312860:NM [Cell Function]

Phrase: "Tawil R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Tristani-Firouzi M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "Canun S,"

Phrase: "Bendahhou S,"

Phrase: "Tsunoda A,"

Phrase: "Donaldson MR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347167:Mr. [Conceptual Entity]

Phrase: "Iannaccone ST,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3272372:ST [Intellectual Product]

Phrase: "Brunt E,"

Phrase: "Barohn R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Clark J,"

Phrase: "Deymeer F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "George AL Jr,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1708595:Jr [Idea or Concept]
   827   C3280986:JR [Disease or Syndrome]

Phrase: "Fish FA,"

Phrase: "Hahn A,"

Phrase: "Nitu A,"

Phrase: "Ozdemir C,"

Phrase: "Serdaroglu P,"

Phrase: "Subramony SH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0038108:SH [Geographic Area]

Phrase: "Wolfe G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Fu YH,"

Phrase: "Ptacek LJ"

Phrase: ":"

Phrase: "Mutations in Kir2.1"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0026882:Mutations [Genetic Function]
   737 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "the developmental"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0458003:Developmental [Qualitative Concept]
  1000   C0678723:Developmental [Organism Function]
   928 E C0243107:development [Physiologic Function]
   928 E C1527148:Development [Functional Concept]

Phrase: "and"

Phrase: "episodic electrical phenotypes of Andersens syndrome."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0031437:Phenotypes [Organism Attribute]
   719 E C1285572:Phenotype [Laboratory Procedure]
Processing 00000000.tx.317: Cell105 :511 519,2001[Medline] Lopes CM, Zhang H, Rohacs T, Jin T, Yang J, Logothetis DE: Alterations in conserved Kir channel-PIP2 interactions underlie channelopathies. 

Phrase: "Cell105"

Phrase: ":"

Phrase: "511 519,"

Phrase: "2001"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Lopes CM,"

Phrase: "Zhang H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Rohacs T,"

Phrase: "Jin T,"

Phrase: "Yang"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2945617:yang [Idea or Concept]

Phrase: "J,"

Phrase: "Logothetis DE"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0011198:DE [Geographic Area]
   861   C0017480:DE [Geographic Area]
   861   C3541240:DE [Idea or Concept]

Phrase: ":"

Phrase: "Alterations in conserved Kir channel-PIP2 interactions"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   714   C1515926:Alteration [Idea or Concept]

Phrase: "underlie"

Phrase: "channelopathies."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1720983:Channelopathies [Disease or Syndrome]
Processing 00000000.tx.318: Neuron34 :933 944,2002[Medline] Gloyn AL, Hashim Y, Ashcroft SJ, Ashfield R, Wiltshire S, Turner RC, the UK Prospective Diabetes Study (UKPDS 53): Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with type 2 diabetes mellitus (UKPDS 53). 

Phrase: "Neuron34"

Phrase: ":"

Phrase: "933 944,"

Phrase: "2002"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Gloyn AL,"

Phrase: "Hashim Y,"

Phrase: "Ashcroft SJ,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1515101:SJ [Geographic Area]
   861   C2986905:SJ [Idea or Concept]

Phrase: "Ashfield R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Wiltshire S,"

Phrase: "Turner RC,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1419366:RC [Gene or Genome]

Phrase: "the UK Prospective Diabetes Study (UKPDS 53)"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   875   C0033522:prospective study [Research Activity]
   875   C1709709:Prospective Study [Research Activity]
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0011849:Diabetes [Disease or Syndrome]
   812   C0023981:prospective [Research Activity]
   812   C0557651:Study [Manufactured Object]
   812   C2603343:Study [Research Activity]

Phrase: ":"

Phrase: "Association"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0004083:Association [Mental Process]
  1000   C0439849:Association [Qualitative Concept]
  1000   C0596306:Association [Phenomenon or Process]
  1000   C0699792:association [Social Behavior]

Phrase: "studies of variants"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0205419:variants [Qualitative Concept]
   790   C0557651:Study [Manufactured Object]
   790   C0947630:studies [Laboratory Procedure]
   790   C2603343:Study [Research Activity]

Phrase: "in promoter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086860:Promoter [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "and"

Phrase: "coding regions"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   966   C0079941:Coding Region [Gene or Genome]
   861   C0009219:Coding [Occupational Activity]
   827   C0017446:Region [Geographic Area]
   827   C0205147:Region [Spatial Concept]
   827 E C0805701:Code [Intellectual Product]
   777 E C0205276:Regional [Spatial Concept]
   777 E C1947913:Regional [Spatial Concept]

Phrase: "of beta-cell ATP-sensitive K-channel genes SUR1"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   857   C0004204:ATP Receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   790   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   790   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   790   C3536898:Sulfonylurea [Pharmacologic Substance]

Phrase: "and"

Phrase: "Kir6.2 with type 2 diabetes mellitus"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   853   C0011860:Diabetes Mellitus, Type 2 [Disease or Syndrome]
           Diabetes mellitus type 2
           Type 2 Diabetes
           Diabetes Type 2
   853   C2984301:Type II diabetes mellitus [Functional Concept]
   778   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   778   C1416578:Kir6.2 [Gene or Genome]
   774   C0441730:Type 2 [Classification]
   774   C1320657:Diabetes type [Finding]
   748   C0011847:Diabetes [Disease or Syndrome]
   748   C0332307:Type [Qualitative Concept]
   748   C1547052:*Type [Quantitative Concept]

Phrase: "(UKPDS 53"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   875   C0033522:prospective study [Research Activity]
   875   C1709709:Prospective Study [Research Activity]
   812   C0011847:Diabetes [Disease or Syndrome]
   812   C0011849:Diabetes [Disease or Syndrome]
   812   C0023981:prospective [Research Activity]
   812   C0557651:Study [Manufactured Object]
   812   C2603343:Study [Research Activity]

Phrase: ")."
Processing 00000000.tx.319: Diabet Med18 :206 212,2001[Medline] Reimann F, Tucker SJ, Proks P, Ashcroft FM: Involvement of the n-terminus of Kir6.2 in coupling to the sulphonylurea receptor. 

Phrase: "Diabet Med18"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1537679:MED18 [Gene or Genome]

Phrase: ":"

Phrase: "206 212,"

Phrase: "2001"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Reimann F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Tucker SJ,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1515101:SJ [Geographic Area]
   861   C2986905:SJ [Idea or Concept]

Phrase: "Proks P,"

Phrase: "Ashcroft FM"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3540627:FM [Gene or Genome]

Phrase: ":"

Phrase: "Involvement of the n-terminus of Kir6.2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1314939:Involvement [Functional Concept]

Phrase: "in coupling"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948027:Coupling [Functional Concept]

Phrase: "to the sulphonylurea receptor."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0075586:sulfonylurea receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1412082:SULFONYLUREA RECEPTOR [Gene or Genome]
   861   C0038766:Sulfonylurea [Organic Chemical,Pharmacologic Substance]
   861   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   861   C3536898:Sulfonylurea [Pharmacologic Substance]
Processing 00000000.tx.320: J Physiol (Lond)518 :325 336,1999[Abstract/Free FullText] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Koster, J. 

Phrase: "J Physiol"

Phrase: "(Lond)518"

Phrase: ":"

Phrase: "325 336,"

Phrase: "1999"

Phrase: "[Abstract/Free FullText"

Phrase: "]"

Phrase: "This Article Abstract Full Text"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C1527021:Text [Intellectual Product]
   812   C1554111:Text [Idea or Concept]
   812   C1705606:Text [Intellectual Product]
   812   C3541382:Text [Intellectual Product]

Phrase: "(PDF)"

Phrase: "Alert"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0239110:ALERT [Finding]

Phrase: "me"

Phrase: "when"

Phrase: "this article"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1706852:Article [Intellectual Product]

Phrase: "is"

Phrase: "cited"

Phrase: "Alert"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0239110:ALERT [Finding]

Phrase: "me"

Phrase: "if"

Phrase: "a correction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1705565:CORRECTION [Intellectual Product]
  1000   C1947976:Correction [Functional Concept]

Phrase: "is"

Phrase: "posted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0687676:Post [Temporal Concept]
   966   C1704687:Post [Manufactured Object]

Phrase: "Services"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0557854:Services [Occupational Activity]
   966 E C2825316:Service [Manufactured Object]
   966 E C3245478:service [Idea or Concept]

Phrase: "Email"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]

Phrase: "this article to a friend Similar articles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1706852:Article [Intellectual Product]

Phrase: "in this journal Similar articles"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   896   C0282420:Journal Article [Intellectual Product]
   793   C1706852:Article [Intellectual Product]

Phrase: "in PubMed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1138432:PubMed [Intellectual Product]

Phrase: "Alert"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0239110:ALERT [Finding]

Phrase: "me to new issues of the journal Download"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C0162443:Journal [Intellectual Product,Manufactured Object]
   744   C0205314:New [Temporal Concept]
   711   C0033213:Issue [Finding]
   711   C1706387:Issue [Intellectual Product]

Phrase: "to citation manager Request Permissions Google Scholar Articles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   762   C1706852:Article [Intellectual Product]

Phrase: "by Koster,"

Phrase: "J."
Processing 00000000.tx.321: C. 

Phrase: "C."
Processing 00000000.tx.322: Articles by Nichols, C. 

Phrase: "Articles by Nichols,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1706852:Article [Intellectual Product]

Phrase: "C."
Processing 00000000.tx.323: G. 

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.324: PubMed PubMed Citation Articles by Koster, J. 

Phrase: "PubMed PubMed Citation Articles by Koster,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   719   C1706852:Article [Intellectual Product]

Phrase: "J."
Processing 00000000.tx.325: C. 

Phrase: "C."
Processing 00000000.tx.326: Articles by Nichols, C. 

Phrase: "Articles by Nichols,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1706852:Article [Intellectual Product]

Phrase: "C."
Processing 00000000.tx.327: G. 

Phrase: "G."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]
Processing 00000000.tx.328: HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum DOC News

Phrase: "HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS Diabetes Diabetes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   738   C0039224:Table [Manufactured Object]
   738   C1706073:Table [Medical Device]
   738   C1706074:Table [Intellectual Product]

Phrase: "Care"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1947933:Care [Activity]

Phrase: "Clinical Diabetes Diabetes Spectrum DOC News"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0282425:News [Intellectual Product]

